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La cosa migliore che tu possa fare 
è credere in te stessa. 
Non avere paura di tentare. 
Non avere paura di cadere. 
E se capitasse, 
levati la polvere di dosso, 
rialzati e prova ancora. 
 
 
The greatest thing you could ever do, 
is believing in yourself. 
Don’t be afraid of trying. 
Don’t be afraid of falling. 
And if that happens, 
Dust yourself off, 
Raise and try again. 
 
Mother Teresa of Calcutta 
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Sommario 
Le malattie cardiovascolari rappresentano ad oggi una delle principali cause di 
morbidità e mortalità nel mondo, tra le quali la patologia ischemica è responsable 
del maggior numero di decessi negli ultimi 10 anni. L’elevato impatto determinato 
da tali patologie, sia acute che croniche, e gli elevati costi per i sistemi sanitari, 
richiedono lo sviluppo di nuove strategie terapeutiche. 
La questione principale riguardante gli attuali approcci terapeutici, sia 
farmacologici sia interventistici, è rappresentata dalla loro incapacità di 
compensare l’elevata ed irreversibile perdita di cardiomiociti funzionali. A causa 
della limitata capacità rigenerativa dei cardiomiociti post-natali e della difficoltà 
di reperire ed isolare tessuto cardiaco bioptico, scarse sono le fonti di tali cellule 
disponibili per uno studio dedicato. Tra l’altro, anche se i modelli animali ancora 
oggi rappresentano sicuramente lo stumento migliore per studiare e comprendere 
in vivo i meccanismi alla base dello sviluppo di specifiche patologie umane, nel 
constesto di un organismo complesso, essi non sono completamente predittivi e 
rappresentativi della condizione umana analizzata; da un punto di vista 
economico, il mantenimento di tali animali e le relative sperimentazioni, 
richiedono molto tempo e costi elevati. 
In questo scenario, le cellule staminali umane pluripotenti (hPSCs), comprese 
le cellule staminali embrionali (hESCs) e le cellule staminali pluripotenti indotte 
(hiPSCs), rivestono un ruolo importante nella ricerca cardiovascolare perché 
possono essere espanse in coltura indefinitamente, senza perdere la loro 
staminalità, e differenziare nelle cellule che componogono i tre foglietti 
germinativi, come ad esempio i cardiomiociti. Un’importante svolta nella ricerca 
scientifica è avvenuta nel 2007, con la scoperta delle hiPSCs da parte del Premio 
Nobel Shinya Yamanaka. Ciò ha rappresentato il punto di partenza per derivare 
hiPSCs paziente-specifiche attraverso il reprogramming di cellule somatiche 
ottenute con procedure mini- o non-invasive (derivate da biopsie cutanee, sangue, 
urina…), utili per generare tessuti per una riparazione autologa, evitando i prblemi 
etici e politici relativi alla derivazione delle hESCs. Notevoli studi sono stati 
condotti dai ricercatori nel tentativo di sviluppare strategie che efficientemente ed 
in maniera robusta guidino il differenziamento cardiaco delle hPSCs, basate sulla 
perturbazione stadio-specifica di differenti vie di segnalazione, mediante l’uso di 
fattori di crescita e piccole molecole, che ricapitolano i punti essenziali dello 
sviluppo cardiaco osservato in vivo. Tuttavia, questi metodi sono accompagnati da 
 Sommario 
 
VI 
 
alcune limitazioni, quali: elevata variabilità intra ed inter-sperimentale, 
presenza di xeno-contaminanti, componenti indefinite nei medium di coltura e 
differenze nei livelli di espressione di citochine endogene. Altre strategie si 
basano invece sulla conversione diretta di cellule somatiche, specialmente 
fibroblasti, attraverso l’overespressione di una combinazione di fattori di 
trascrizione cardiaci mediante vettori integrativi e non-integrativi; tuttavia, 
anche tali approcci sono caratterizzati da basse efficienze nella generazione di 
cardiomiociti, associate al rischio di integrazioni genomiche e mutagenesi 
inserzionale nel caso dei vettori integrativi, o alla necessità di effettuare diversi 
step di purificazione quando si ultilizzano sistemi non-integrativi. Pertanto, a 
causa delle difficoltà dei sistemi convenzionali di coltura nel dirigere 
specificamente ed in maniera robusta il differenziamento cardiaco delle hPSCs, 
assieme alla scarsa capacità di riprodurre in vitro l’ambiente in cui le cellule 
risiedono in vivo, i cardiomiociti prodotti attualmente sono immaturi e più 
simili allo stadio fetale di sviluppo. 
Nel 2010 Warren L. ed il suo gruppo di ricerca ha sperimentato per la prima 
volta una tecnologia innovativa di tipo non-integrativo basata su trasfezioni 
ripetute con lipidi cationici di RNA messaggeri modificati sinteticamente 
(mmRNA) per evitare la risposta immunitaria innata da parte delle cellule; egli 
ha dimostrato la possibilità sia di riprogrammare cellule somatiche allo stato 
pluripotente, sia di programmare il differenziamento miogenico di hiPSCs. 
Pertanto, lo scopo di questa tesi di dottorato è quello di sviluppare un 
metodo robusto ed efficiente per il differenziamento cardiaco di hPSCs 
combinando gli mmRNA con la tecnologia microfluidica. Ripetute trasfezioni 
di mmRNA codificanti per 6 fattori di trascrizione coinvolti nello sviluppo e nel 
funzionamento cardiaco, vengono impiegate per forzare l’espressione proteica 
endogena delle cellule e per guidare il differenziamento verso la maturazione 
funzionale dei cardiomiociti. L’integrazione del differenziamento cardiaco in 
una piattaforma microfluidica ad hoc, prodotta nel laboratorio BioERA, consente 
un controllo più preciso delle condizioni di coltura garantendo un’elevata 
efficienza di trasfezione degli mmRNA grazie all’elevato rapporto 
superficie/volume e permette la riproduzione in vitro di nicchie fisiologiche. 
Infatti, la miniaturizzazione consente di mimare al meglio le dinamiche cellulari 
che avvengono in vivo nel microambiente solubile. Le tecnologia microfluidica 
offre la possibilità di effettuare esperimenti combinati, multiparametrici e 
paralleli in una sola volta e con elevato rendimento a costi ridotti, non 
realizzabili nei macroscopici e costosi sistemi di coltura convenzionali.  
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Il Capitolo 1 inizia con la definizione di medicina rigenerativa e introduce la 
complessità dello sviluppo cardiaco ed il network di fattori di trascrizione che 
cooperano durante questo processo. Viene poi descritto lo stato dell’arte relativo 
alle strategie per l’ottenimento di cardiomiociti da hPSCs e al 
transdifferenziamento cardiaco di cellule somatiche, insieme alle relative 
limitazioni e alle problematiche attuali da risolvere. Infine viene presentato lo 
scopo generale di questa tesi di dottorato.  
Il Capitolo 2 si focalizzerà sulle hPSCs (sia hES sia hiPS) impiegate durante 
questo progetto, descrivendo le caratterisatiche principali di tali cellule. Verrà 
inoltre presentato un protocollo di differenziamento cardiaco di hPSCs in 
monostrato che attualmente è considerato il gold standard per ottenere 
velocemente un’elevata resa di cardiomiociti contrattili in supporti di coltura 
convenzionali. Tale protocollo si basa sulla modulazione del pathway canonico di 
Wnt attraverso l’applicazione di due piccole molecole. Inoltre, una linea di hES, 
doppio reporter per 2 fattori di trascrizione cardiaci, verrà descritta ed impiegata 
in tutti gli esperimenti come strumento per monitorare l’andamento del 
differenziamento cardiaco delle hPSC. I risultati ottenuti in colture standard 
verranno mostrati. 
Il Capitolo 3 esaminerà lo stato dell’arte della tecnologia microfluidica nelle 
applicazioni di medicina rigenerativa, sottolineando i vantaggi derivanti dalla 
combinazione della microtecnologia con la biologia cellulare. Verrà 
successivamente descritta la fabbricazione della piattaforma microfluidica 
utilizzata, con la successiva ottimizzazione della coltura, espansione e 
differenziamento cardiaco gold standard delle hPSCs conseguenti alla conversione 
dalla macro- alla microscala. 
Il Capitolo 4 introdurrà la nuova strategia degli mmRNA per la 
riprogrammazione e la programmazione cellulare: anche in tal caso verrà discusso 
lo stato dell’arte. In seguito, verranno presentate le strategie sperimentali 
sviluppate per programmare il differenziamento cardiaco delle hPSCs verso un 
fenotipo più maturo dei cardiomiociti, insieme ai risultati ottenuti con le relative 
caratterizzazioni strutturali, funzionali e molecolari. In questo lavoro, per la prima 
volta, è stato possibile ottenere cardiomiociti da hPSCs attraverso ripetute 
trasfezioni di mmRNA per 6 fattori di trascrizione cardiaci in microfluidica, con 
efficienze superiori rispetto ai metodi presenti attualmente in letteratura, svolti in 
sistemi convenzionali. 
Il Capitolo 5 infine presenterà la discussione e le conclusioni generali, assieme 
alle prospettive future riguardanti l’uso degli mmRNA combinati con la 
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microfluidica per ottenere diversi fenotipi di cardiomiociti, variando la 
combinazione di fattori di trascrizione veicolati. In conclusione, gli esperimenti 
sviluppati in questo progetto di dottorato forniscono un proof-of-principle della 
possibilità di programmare con gli mmRNA il destino delle hPSCs verso il 
differenziamento e la maturazione di cardiomiociti funzionali in  microfluidica; 
inoltre, essendo gli mmRNA una strategia non-integrativa , i cardiomiociti 
ottenuti in questo modo possono essere impiegati nel prossimo futuro per 
applicazioni cliniche di ricostruzione tissutale autologa e per screening 
farmacologici personalizzati.  
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Summary  
Cardiovascular disease (CVD) is still one of the major cause of morbidity and 
mortality in the world, with ischemic heart disease representing the majority of 
deaths over the past 10 years. The high burden of the disease, both immediate and 
chronic, associated with the high costs for the healthcare systems, claim for the 
development of novel therapeutic strategies. The main issue of current 
pharmacological and interventional therapeutic approaches is their inability to 
compensate the great and irreversible loss of functional cardiomycytes (CMs). 
Because of the limited regenerative capacity of post-natal CMs and the difficulty 
to obtain and isolate heart bioptic tissue, very limited supplies of these cells are 
available at present for dedicated studies. Moreover, even if animal models are 
surely the best tool to study and understand in vivo the mechanisms of specific 
human pathologies in a complex organism, they are not fully predictive and 
representative of the human condition; from an economic point of view, animal 
maintenance and the related experimentations are time consuming and very 
expensive. 
In this scenario, human pluripotent stem cells (hPSCs), including human 
embryonic (hESCs) and human induced pluripotent stem cells (hiPSCs), play an 
important role in the cardiovascular research field, because they can be indefinitely 
expanded in culture without loosing their stemness, and differentiated into cells 
of the three germ layers, such as CMs. A great breakthrough in science has 
occurred in 2007 with the discovery of hiPSCs by the Nobel Prize Shinya 
Yamanaka. This has been the starting point for deriving patient-specific hiPSCs 
from the reprogramming of somatic cells obtained with less- or non-invasive 
procedures (skin biopsies, blood, urine…), useful for the generation of tissues for 
autologous-repair, bypassing the ethical and political debates surrounding the 
hESCs derivation.  
The researchers have made several efforts to develop strategies to efficiently 
direct hPSCs cardiac differentiation and the existing methods for deriving CMs 
involve stage-specific perturbations of different signaling pathways using growth 
factors (GFs) or small molecules that recapitulate key steps of the cardiac 
development observed in vivo. However, these strategies are accompanied by 
some limitations including: high intra- and inter-experimental variability, low 
efficiencies, presence of xeno-contaminants, undefined medium components and 
differences in the expression of cytokines of endogenous signaling pathways. 
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Other strategies are based on the direct lineage conversion of somatic cells, 
especially fibroblasts, via the overexpression of cardiac transcription factors 
(TFs) combinations through integrating and non-integrating vectors. However, 
also these approaches are characterized by low efficiencies, combined with the 
risk of genomic integration and insertional mutagenesis when using integrating 
vectors or the need for stringent steps of purification when using non-
integrating techniques. Because of the difficulty to specifically direct hPSCs 
cardiac fate in a robust way, combined with the scarce ability of conventional 
culture systems to reproduce in vitro, the environment in which cells reside in 
vivo, the CMs produced to date are immature and more similar to fetal cardiac 
cells.  
In 2010, Warren L. and co-workers pioneered a novel, non-integrating 
strategy based on repeated transfection with cathionic vehicles of synthetic 
modified messenger RNA (mmRNA), specifically designed to avoid innate 
immune response from the cell, demonstrating the possibility to both 
reprogram somatic cells to pluripotency and to programm hPSCs fate into 
terminally differentiated myogenic cells.  
Hence, the aim of this PhD thesis is the development of an efficient and 
robust method for cardiac differentiation of hPSCs by combining the mmRNA 
with the microfluidic technology. Repeated transfections with mmRNA 
encoding 6 cardiac TFs are employed to force the endogenous protein 
expression in the cells and to drive the differentiation toward functional 
maturation of CMs. The integration of cardiac differentiation within an ad hoc 
microfluidic platform, facbricated in BioERA laboratory, allows a more precise 
control of culture conditions, enabling a high mmRNA transfection efficiency, 
thanks to the high volume/surface ratio, and the in vitro reproduction of 
physiological niches. In fact, the small scale offered by microfluidics, best 
mimics the cellular dynamics, which occur in the soluble microenvironment in 
vivo. Moreover, the microfluidic technology offers the possibility to perform 
combinatorial, multiparametric, parallelized and highthroughput experiments 
at one time in a cost-effective manner, not achievable and not economically 
sustainable in macroscopic conventional culture systems. 
Chapter 1 starts with the definition of regenerative medicine and introduces 
the complexity of cardiac development, with the network of TFs that cooperate 
in this process. The state of the art regarding the derivation of CMs from hPSCs 
and from the transdifferentiation of somatic cells is described, together with the 
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current limitations and challenges. Finally, the general aim of this PhD thesis is 
presented. 
Chapter 2 will focus on hPSCs (hES and hiPS) employed during this project, 
describing their most important characteristics. It will be also presented a 
monolayer-based cardiac differentiation protocol of hPSCs that, to date is 
considered the gold standard for the fast generation of a high yield of beating CMs 
in conventional culture systems. This protocol relies on the temporal modulation 
of Wnt pathway via the administration of small molecules. In addition, a hES line, 
dual reporter for 2 cardiac TFs will be described and always adopted as a tool to 
monitor the progression of cardiac differentiation. The results obtained in standard 
cultures will be showed. 
Chapter 3 will review the state of the art of microfluidic technology for cell 
culture in regenerative medicine applications. Then, the microfluidic platform 
fabrication will be described and employed, followed by the optimization of 
culture, expansion and cardiac differentiation of hPSCs with the gold standard 
protocol deriving form the translation from macro- to micro-scale. 
Chapter 4 will introduce the novel mmRNA strategy for reprogramming and 
programming cell fate: also in this case the state of the art will be discussed. Then, 
the experimental strategies developed to program cardiac differentiation of hPSCs 
toward a more mature CM phenotype will be presented, together with the results 
obtained and the related structural, functional and molecular characterizations. In 
this work, for the first time, it has been possible to derive CMs from hPSCs with 
repeated transfections of mmRNA encoding 6 cardiac TFs in microfluidics, with 
efficiencies higher to current methods described in literature, performed in 
standard systems. 
Finally, Chapter 5 will present the general discussion and conclusions, with the 
future perspectives regarding the use of mmRNA combined with microfluidic 
technology for deriving different CMs phenotypes, just varying the combination 
of TFs delivered. 
To conclude, the experiments developed during this project provide proof-of-
principle that it is possible to program hPSCs fate toward cardiac lineage and 
cardiac maturation in microfluidics; moreover, thanks to the non-integrating 
characteristic of mmRNA, the CMs obtained are clinical-grade and could 
potentially be employed in the next future for clinical applications of autologous 
tissue self-repair and for personalized drug screening. 
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This Chapter introduces the concept of Regenerative Medicine, which is the 
curriculum of my PhD School in Biomedicine, focused on the development of 
strategies for cardiac regeneration. The Chapter continues describing the 
complexity of cardiac development and formation, and the network of 
transcription factors (TFs) involved is studied to better understand cardiogenesis. 
Then, the evolution of cardiac regeneration approaches and the current state of the 
art are presented, with the new perspectives offered in this field by the derivation 
of cardiomyocytes (CMs) from human pluripotent stem cells (hPSCs), which 
recapitulate in vitro the cardiac development stages. Finally, the principal 
strategies for the differentiation of hPSCs into CMs are described, highlighting also 
the current limitation and challenges of hPSC-derived CMs for in vitro studies. 
Finally, the aim of this thesis is presented. 
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1.1. Regenerative Medicine 
‘The development of cell lines that may produce almost every tissue of the 
human body is an unprecedented scientific breakthrough. It is not too 
unrealistic to say that stem cell research has the potential to revolutionize the 
practice of medicine and improve the quality and length of life’. 
“Harold Varmus, National Institute of Health and 1989 Nobel Laureate in 
Physiology or Medicine; testimony before the U.S. Senate Appropriations 
Subcommittee on Labor, Health and Human Services, Education and Related 
Agencies, December 2nd, 1998” [1]. 
Human beings have always been fascinated with tissue regeneration, 
especially from the observation of this phenomenon in some species of fishes 
and newts, while they are not able to do the same. In the last decade major 
advances in stem cell biology, created genuine hope for the emerging discipline 
of regenerative medicine [2]. 
Regenerative medicine is a new branch of medicine which studies how to 
regenerate damaged, tired or failing organ caused by age, diseases, injuries, or 
genetic defects. This field aims at stimulating the healing of organs considered 
irreparable and, in order to regenerate tissues suitable for clinical implantation, 
scientists generate and grow them in vitro.  
Organ transplantation and autologous tissue transplantation remain a gold 
standard of treatment in case of severely compromised organ function; 
however, limited availability is one of the major issue, especially for elderly 
patients. In the last two decades, as a response to the requirements of these 
tissues, scientists have made several efforts to grow stem cells for generating 
new tissues using tissue engineering and regenerative medicine techniques for 
restoring tissues of the human body.  
Regenerative medicine can be considered in fact a multidisciplinary field 
that requires exchange of knowledge of a wide variety of scientific disciplines: 
expertise in cell and molecular biology, physiology, chemical engineering, 
biomaterials, nanotechnologies, pharmacology and clinical sciences have to 
collaborate. These approaches will use soluble molecules, stem cells, tissue 
engineering approaches and the reprogramming and programming of cells and 
tissue types [1]. The development rate of new strategies, together with the 
decreasing of costs represent a recurring critical point encountered in 
regenerative medicine. Whitesides G.M. defines microfluidics as “the science 
and technology of systems that process or manipulate small amounts of fluids 
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(10-9 to 10-18 liters), using channels with dimensions of tens to hundreds of 
micrometres”[3][4]; this technology is a useful tool for developing novel, more 
representative in vitro models. Microfluidic devices have found applications in 
cell-based screens to deeply understand fundamental biological processes and for 
drug tests, with advantages over conventional cell culture systems: it allows in 
fact, a spatiotemporal control of fluid dynamycs and physical parameters, 
streamlining the regenerative medicine research, thanks to the ability to provide 
high-throughput  multiplexed platforms, allowing the parallelization of the assays 
as well as automation at the same time [4]. 
Since the heart is one of the last regenerative organs in the body, cardiac 
regenerative medicine applications could bring great benefits [2]; for this reason, 
this work aimed at coupling the potential of pluripotent stem cells field and the 
cell fate programming with the microtechnologies to allow the development of 
functional and mature cardiac tissue on-a-chip, as in vitro disease model or drug 
screening and toxicity assays. 
 
 
1.2. The human heart 
Before starting with the analysis of the strategies for cardiac regeneration, it is 
necessary to have the whole picture of the human heart physiology, 
cardiomyogenesis with the network of signalling pathways and transcription 
factors involved. The human heart has the function of pumping blood in the 
organism in order to provide oxygen and nutrients to tissues and to remove waste 
products. The heart possesses four chambers, two upper atria, and two lower 
ventricles. The heart itself can be divided into right heart, formed by the right 
atrium and right ventricle, and the left heart, constituted by left atrium and 
ventricle, separated by the septum. The pericardium is a double walled sac that 
envelops the heart to protect it. Between the parietal pericardium (outer) and the 
serous pericardium (inner), flows the pericardial fluid, which lubricates the heart 
to soften contractions and movements of the surrounding lungs and diaphragm. 
The external wall of the heart is composed by three layers: the outermost is the 
epicardium (inner face of pericardium); the middle layer is myocardium with its 
contracting muscles and the inner one is the endocardium in contact with blood 
[5] (Figure 1.1).  
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Figure 1.1: Human heart with the four chambers, atria and ventricles. The magnification shows a section of 
the heart wall, composed by three layers: the epicardium (outer), the myocardium (middle), and the 
endocardium (inner (modified from [6]). 
This work focuses on the cardiac muscle, specifically the myocardium, which 
is a three-dimensional arrangement of rod-shaped cardiomyocytes (CMs) [7] 
attached to each other and forming myofibers. Only 20-40% of the cells in the 
heart is represented by CMs but they cover 80-90% of the organ volume [8]. 
Myofibers are in contact with interstitial fibroblasts, blood vessels and the 
extracellular matrix, within a proteoglycan gel matrix [9]. The CMs form a 
three-dimensional syncytium (atrial and ventricular) that enables propagation 
of electrical signals across the gap junctions to coordinate contractions that 
pump blood to the body. The contractile apparatus (Figure 1.2) of each CM is 
the sarcomere that possesses a bundle of myofibrils aligned in parallel in the 
cytoplasm; it contains several contractile proteins such as actin and myosin and 
the accessory proteins, troponin and tropomyosin, which form the thin and 
thick filaments. [10].  
 
Right atrium
Left atrium
Right ventricle
Left ventricle
Septum
Right
Heart
Left
Heart
Chapter 1 
 
Introduction: strategies for cardiac regeneration 
 
5 
 
 
Figure 1.2: Cardiac myofibril cylinder, with single tandem line of sarcomere (banded pattern). At the top of the 
image is represented a section of multi-nucleated striated cardiomyocyte. One sarcomere goes from one Z-band 
to the adjacent one: the thicker myofilaments are composed  of myosin, crossing the A bands, while the thinner 
filaments are mainly represented by of actin, and extends from the Z lines through the I band into the A band 
(modified from [11]).   
 
CMs propagate synchronous contractions of the electrical impulse thanks to 
their connection via intercalated discs. Groups of specialized pacemaker CMs 
generate a wave of electrical excitation from one cell to the adjacent causing a 
coordinated atrial-ventricular rhythmic contraction. The CM excitation is followed 
by an increase of cytoplasmic calcium that triggers mechanical contractions, the 
so-called calcium-induced calcium release (CICR), giving the calcium sparks [12]. 
Precisely, in a resting phase, a myocardial cell has a negative membrane potential; 
after the initiation of the action potential by pacemaker cells, the subsequent 
depolarization determines the extracellular Ca2+ influx via the voltage-gated ion 
channels. The following increase in intracellular Ca2+ leads to the binding of the 
ion with troponin C, moving the tropomyosin complex off the actin binding site. 
The myosin head can now bind to the actin filament [13]. Using ATP hydrolysis, 
the myosin head pulls the actin filament toward the centre of the sarcomere, 
Cardiac muscle
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generating the contraction. Intracellular Ca2+ is re-uptaken into the sarcoplasmic 
reticulum (SR), ready to begin a new cycle. After the absolute refractory period, 
potassium channels reopen, K+ exits from cells which return the resting state 
[14] (Figure 1.3). 
 
Figure 1.3: Scheme of excitation-contraction (EC) coupling in CMs. ECF, Extra-Cellular Fluid; ICF, Intra-
Cellular Fluid (adapted from [15]). 
 
As regards the metabolic requirements of the CMs, during the early phase of 
embryogenesis, the uterine environment in which the fetal heart develops and 
grows is oxygen-poor, with carbohydrates representing the primary source of 
energy[16]. The subsequent maturation determines an oxygen increase and 
oxidative phosphorylation begins to supply additional energy required by the 
growing and maturing heart, with a shift to long-chain fatty acids as the 
primary energy source[16][17][18].  
 
 
1.2.1. Cardiomyogenesis and cardiac Transcription Factors network 
The induction and specification of cardiac progenitor cells within the 
anterior lateral mesoderm is the strating point of the mammalian heart 
development [19]. Around day 15 of human embryonic development [20], the 
cardiac mesoderm gives rise to the endocardium, the First Heart Field (FHF, 
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forming the atria, left ventricle, and the nodal conduction system), the Secondary 
Heart Field (SHF, which forms the right ventricle, outflow tract, and part of the 
atria), and the proepicardial mesenchyme [21][22]. The FHF is composed by cells 
that differentiate, whereas cells of the SHF (expressing the Insulin gene enhancer 
protein 1, ISL1) maintain an undifferentiated state, because of inhibitory Wingless 
integrated (Wnt) signals [21][23]. After approximately 3 weeks of human 
development, a primitive heart tube begins to be formed and undergoes rightward 
looping, with cells from the SHF added to both the inflow and outflow poles. After 
this point, approximately during  the 6th and 7th weeks of human gestation, the 
formation of the outflow tract (OFT) and the atrioventricular canal (AVC) begins 
[19][24]. The early cardiac conduction system also begin to be specified, while 
neural crest and proepicardium give important contributions to the developing 
heart. Proceeding to later stages, the heart undergoes extensive remodelling to 
reach the mature, definitive architecture [19][25]. Figure 1.4 shows the several 
stages of heart development. 
 
 
Figure 1.4: Schematic representation of the stages of mammalian heart development in mouse and human heart 
shown in parallel. Mouse development is indicated in embryonic days (E). Ao, aorta; AVC, atrioventricular 
canal; CM, cardiac mesoderm; LA and LV, left atrium and ventricle respectively; NCC, neural crest cells; OFT, 
outflow tract; PA, pulmonary artery; RA and RV, right atrium and ventricle respectively; SAN, sinoatrial 
node; SV, sinus venosus; V, ventricle (adapted from [19]). 
 
The deep comprehension and knowledge of cardiogenesis in the early embryo 
is of paramount importance for the development of ad hoc differentiation strategies 
for cardiac repair [21]. The study of cardiogenesis in fact allows access to the 
networking and cooperating genes involved in heart development [21]. 
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The first stage of cardiomyogenesis is the generation of mesoderm via the 
process of gastrulation, a process deeply studied in the mouse, as a model for 
human cardiac development [21][22][26]. 
 Three families of extracellular signalling molecules control and orchestrate 
the induction of mesoderm formation and specification into cardiac mesoderm: 
Wingless integrated (Wnt), Fibroblastic Growth factor (FGF) and Transforming 
Growth Factor-beta (TGF-β) superfamily ligands, which include WNT3A, Bone 
Morphogenetic Protein 4 (BMP4), Nodal and Activin A. These ligands are 
expressed in gradients, sending activating as well inhibitory signals to the 
underlying cells, in a spatiotemporal manner [27][28]. Briefly, mesoderm 
induction firstly starts with Nodal signaling in the proximal epiblast, 
approximately on human embryonic day 12, confining BMP4 expression in the 
extraembryonic ectoderm. BMP4 induces the expression of Wnt3a in the 
proximal epiblast. In the anterior visceral endoderm, the expression of the Wnt 
antagonist Dikkopf 1 (DKK1) and the Nodal antagonists Lefty 1 and Cer 1, 
confines Nodal and Wnt signalling to the posterior epiblast. At this 
developmental stage, Wnt induces the expression of mesendodermal markers 
such as Brachyury T (T) and Eomesodermin (EOMES). Subsequently, FGF4 and 
FGF8, which are responsible of mesoderm patterning and epithelial-
mesenchymal transitions (EMTs), are expressed in the developing primitive 
streak. T and EOMES determines the expression of Mesoderm Posterior 1 
(MESP1), which has been identified as the “master regulator” of cardiac 
progenitor specification [21][29][30]. At this point, MESP1 guides cardiac 
differentiation via the DKK1-mediated inhibition of WNT3A signalling [21][31]. 
So, it becomes clear that canonical WNT/β-catenin signaling has a biphasic 
effect and its fine spatiotemporal modulation is essential for these early steps in 
cardiac development[21][32][33]. Downstream of MESP1, cardiogenesis is 
orchestrated by a complex and interacting networking cascade of transcription 
factors (TFs) and genes, including GATA binding protein 4 (GATA4), NK2 
transcription factor related 5 (NKX2.5), Myocyte Enhancer Factor 2C (MEF2C), 
TBX transcription factor 3 and 5 (TBX3, TBX5) and other factors that mark both 
the FHF and the SHF. After the specification of cardiac mesoderm, canonical 
WNT and NOTCH signaling regulate cardiac progenitor cells maintenance and 
differentiation [21] [34][35]. Figure 1.5 shows the signaling pathways and TFs 
guiding heart formation during embryogenesis. 
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Figure 1.5: Signaling pathways and TFs that cooperate for programming a CM during embryonic cardiac 
development. Signaling pathways modulators and TFs work at various stages of cardiac development and 
cardiac cell differentiation in a spatiotemporal context, from mesodermal formation, cardiac specification, 
maintenance of heart field (HF) progenitors to cardiac maturation and patterning. The circular arrows indicates 
the self-renewal process. FHF marker genes is reported in blue and the SHF marker genes in red. CM, 
cardiomyocyte; CS, conduction system and SA, sino-atrial (adapted from [36]). 
 
 
1.3. Cardiovascular Disease and evolution of the strategies for 
human cardiac regeneration 
The heart is one of the first organ formed in the embryo because it is necessary 
for providing oxygen and nutrients to all the tissues of the body, both in 
developing embryo and during the entire life of an individual.  
Given the crucial role of the heart and the CMs, it is clear how diseases or 
injuries affecting the heart function are often compromising or fatal; for this reason, 
scientists are interested in the regenerative medicine of the heart in order to find a 
strategy to better repair the injured organ [27]. Cardiovascular Disease (CVD) is 
currently the leading cause of morbidity and mortality in the world, with ischemic 
heart disease as the principal cause of deaths over the past 10 years. Unfortunately, 
these conditions are projected to rise in the years to come (Figure 1.6) [16]. 
 
 
 
 
 
 
Brachyury T+
EOMES+
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Figure 1.6: A. 2030 projections of global heart disease burden with the diffusion of ischemic heart disease 
worldwide. B. Nearly one-third of deaths worldwide is determined by CVD and ischemic heart disease. The 
number of these fatalities is projected to rise until 2030. C. Over the next 15 years, significant increase in 
deaths from ischemic heart disease and stroke will only be surpassed by cancer (adapted from [37]). 
This is in part due to the lack of a curative treatment for the damage to 
myocardium caused by myocardial infarction, aside from left ventricular assist 
devices (LVADs) and/or organ transplantation, which are an option for a 
limited number of severe cases; furthermore, over 50% of patients are 
nonresponsive to the currently available drug therapies. Therefore, there is a 
huge number of patients experiencing the comprmising and ultimately fatal 
consequences of heart failure, a condition characterized by CMs death by 
apoptosis and/or necrosis [16]. The human left ventricle possesses 2-4 billion 
CMs, and a myocardial infarction can erase 25% of these cells in a few hours 
[38]. Dead CMs are replaced by fibroblasts that migrate into the damaged area 
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to form fibrotic scar tissue, with subsequent thinning of the ventricular wall that 
no longer contracts properly. After the formation of fibroblastic scar, heart failure 
comes with remodelling and hypertrophy, with further cell death. 
The persistence of scar tissue indicates little but insufficient regenerative 
capacity of the heart to compensate cell death. Shortly after birth, a myocardial cell 
transitates from a hyperplastic to a hypertrophic phase, with the formation of 
binucleated CMs that exit from the cell cycle [21]. 
Over the past 15 years, the major goal of cardiac repair is to generate the 
myocardium after injury to prevent or treat heart failure. CMs from laboratory 
animals are currently the most employed tool in the cardiac-related research. 
Although animal models have provided indispensable insights into systemic 
whole-organ function in vivo as well as in vitro disease mechanisms, they are  not 
fully representative of their human counterpart[39][40]. In fact, toxicity studies 
comparing the drug reactions in human and laboratory animals have shown that 
only 43% of the toxic effects on humans can be predicted using rodents[39][41]. 
This suggests the need to use human CMs in drug discovery and cardiovascular 
research. However, it is currently challenging and complex to utilize human CMs 
in regular medical research due to the difficulty in isolation of heart bioptic tissue 
and subsequent primary CMs maintenance, due to their scarce expansion capacity 
in vitro; for these reasons, very limited supplies of these cells are available at 
present. Therefore, it becomes mandatory to develop alternative, most reliable 
sources of human CMs: this will require understanding not only the 
differentiation, but also the physiological maturation of these cells [39]. 
The discovery of first human Embryonic Stem Cells (hESCs) [42], and more 
recently, human induced Pluripotent Stem Cells (hiPSCs) [43][44], provides new 
tools for investigators, who focused their efforts on developing strategies to 
efficiently direct stem cell  to a cardiovascular fate [21]. The majopr exciting 
advantage is represented by the ability to generate patient-specific hiPSCs, 
considered a viable, new and ethically less problematic alternative source for 
studying cardiac diseases, with the unprecedented opportunity to study disease-
specific differences in a patient-specific manner [45]. Substantial efforts has been 
made to improve the efficiency and reproducibility of differentiation, while 
studying new avenues for establishing more differentiation defined conditions 
and producing cells on a clinically relevant scale [21].  
 Directed differentiation approaches of hPSCs into CMs mimic in the 
conventional dish, the steps of embryonic development, from mesoderm 
formation to CM specification, taking into account the sensitivity of hPSCs to their 
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microenvironment, made of signaling pathway and growth factors (GFs) that 
cooperate to drive the cardiac commitment. 
Human Pluripotent Stem Cell-derived CMs (hPSC-CMs) are generally 
differentiated by tuned timed application of cardiomyogenic GFs and/or small 
molecules modulating specific stages of cardiac development, with cells 
cultivated as either Embryoid Bodies (EBs) or in monolayers and these 
strategies can be grouped into three major approaches that will be described in 
detail in the next Paragraph 1.4 [21][46].  
More recently, new proof-of-concept studies have been developed, based on 
direct lineage conversion of somatic cells via the overexpression of a 
combination of evolutionarily conserved transcription factors (TFs) involved in 
cardiac gene expression, heart development and function[27][47]. In literature 
it is reported that the transgenic expression of a combination of 3 cardiac-
specific TFs (GMT, Gata4, Mef2c and Tbx5) resulted in the transdifferentiation 
of murine fibroblasts into contracting CMs, named for this reason induced CMs 
(iCMs)[36][48]. Figure 1.7 summarizes the approaches described.  
 
 
Figure 1.7: Strategies to generate CMs in vitro that rely on 2 major approaches: directed differentiation from 
PSCs and direct lineage conversion of fibroblasts. Directed differentiation closely recapitulates the stages of 
cardiac development with GFs and small molecules. On the other hand, with direct lineage conversion, cells 
pass directly from one somatic cell type to the cardiac lineage by forced expression of a combination of TFs 
(adapted from [27]). 
 
Recently, direct reprogramming of human fibroblasts has also been achieved 
with the application of randomly integrating vector systems such as 
oncoretroviaral and lentiviral vectors converting human and murine fibroblasts 
to CMs, but it resulted in modestly controlled and long-lasting constitutive 
(human)
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transgene expression, with the associated risk of genomic integration and 
insertional mutagenesis; moreover, all these strategies were characterized  by low 
efficiencies.  
Other studies tried repeated administration of transient plasmids, episomal and 
adenovirus vectors, DNA- or protein- based carrying the TFs, however, also these 
methods for directing cardiac fate suffered low efficiencies compared to direct 
iPSC differentiation protocols using GFs and small molecules. Other technologies, 
described in literature for the generation of iPSCs, used DNA-free methods: serial 
protein transduction with recombinant proteins incorporating cell-penetrating 
peptides and transgene delivery with Sendai virus, which has a completely RNA-
based reproductive cycle. Despite such progresses, also these approaches present 
low efficiencies and require stringent steps of purification[49][52][51][52]. 
 In 2010 Warren L. and collaborators described a simple, non-integrating 
strategy for reprogramming cell fate, based on repeated administration of 
synthetically modified messenger RNA (mmRNA), specifically designed to bypass 
innate immune response [49][50]. The details of some of the principal 
reprogramming approach using TFs is described in Figure 1.8.  
 
 
Figure 1.8: Schematic representation of some of the principal approaches for TFs administration to guide cell 
fate. Initial approaches of TFs delivery used integrating retroviral or lentiviral vectors while, more recent 
strategies applied non-integrating methods, using DNA and non-DNA-based procedures. Once reprogrammed 
to a pluripotent state, iPSC fate could be further programmed to a terminally differentiated cell, as 
demonstrated by Warren L. and collaborators (modified from [53]).  
Integrating Non-integrating
Fibroblast
DNA Non-DNA
Chapter 1 
 
Introduction: strategies for cardiac regeneration 
 
14 
 
 
Warren’s group showed that this approach could reprogram multiple 
human cell types to pluripotency with conversion efficiencies higher than 
established viral and non-viral protocols, as reported in Table 1.1. Moreover, 
they also demonstrated the possibility to use this non-integrating and non-
mutagenic technology to direct the differentiation of RNA-induced Pluripotent 
Stem Cells (RiPSCs) into terminally differentiated myogenic cells, using a 
MYOD-encoding mmRNA, rendering it applicable to a range of regenerative 
medicine tasks [49][50]. 
 
Table 1.1: Advantages of using mmRNA delivery of TFs as compared to other reprogramming techniques. 
mmRNAs provide efficiencies greater than 1% as compared with the other reprogramming strategies, showing 
efficiencies varying from 0,00001-0,01%. Moreover, mmRNA does not require multi-step passaging or 
screening for virus or genomic integration once generated the desired cells (modified from Stemgent website). 
 
  
Taken together, this new approach pioneered and described by Warren’s 
group, provides proof-of-principle that modified mRNAs can be used to both 
efficiently reprogram and program cell fate. Finally, this technology represents 
a safe strategy that can be applied for basic research, disease modeling and 
regenerative medicine, offering key insights into the mechanisms of 
cardiopoiesis and TFs network, providing hope that in the future injured hearts 
may be repaired through clinical applications of these cells[49][50]. All these 
mentioned strategies will be discussed in detail in this work; in Particular, in 
Chapter 2 will be described and applied a monolayer-based hPSC cardiac 
differentiation using small molecules that modulate a specific signalling 
pathway, whereas in Chapter 4 the mmRNA technology was investigated to 
efficiently drive cardiac hPSCs fate. 
 
 
Modified
mRNA
Protein Sendai Virus Adenovirus
Episomal/
Mini circle
Lentivirus/
Retrovirus
Efficiency >1% 0,00001% 0,01%
0,0001-
0,001%
0,0001% 0,001-0,01%
Integration NO NO NO Possible Possible YES
Screening/ 
purification
NO NO YES YES YES YES
Clinically
relevant
YES Possible Possible NO NO NO
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1.4. Direct cardiac differentiation of Pluripotent Stem Cells: 
the three major approaches 
As mentioned in the previous Paragraph, the most applied strategies to direct 
hPSCs differentiation into CMs relied generally on the timed application of 
cardiomyogenic GFs or small molecules. In the last 10 years, this ability has 
progressed rapidly. The most reproducible and efficient strategies are based on 
stage-specific modulation of different signaling pathways in defined culture 
conditions, recapitulating key events of cardiac development [21].  
These strategies can be grouped into three major approaches: 
1. hPSCs co-culture on a feeder layer of stromal cells; 
2. hPSCs aggregation to form tridimensional colonies known as Embryoid 
Bodies (EBs) 
3. hPSCs differentiation in a monolayer composed of extracellular matrix 
(ECM) proteins; 
The first strategy of direct differentiation involved hESCs co-cultured on a 
feeder layer of mouse visceral endoderm-like cells (END-2); in developing 
embryos it was observed, in fact, that visceral endoderm played an important 
inductive role in the differentiation of cardiogenic precursor cells of the cardiac 
mesoderm. However, this approach is relatively inefficient even though it 
generated mostly ventricular-like CMs[21][54][55]. The other two widely applied 
methods are: the formation of Embryoid Bodies (EBs), and differentiating hPSCs 
as a monolayer. The EB strategy initially involved the formation of spherical 
tridimensional aggregates from the suspension culture of hPSCs colonies in media 
supplemented with 20% FBS [21][56]. This method yielded only a low percentage 
of CMs, displaying early and immature phenotypes. Additional studies revealed 
that a higher efficiency of cardiac differentiation could be reached with the timed 
administration of defined extracellular molecules [28]. In fact, the temporary 
application of Activin A and BMP4 efficiently induced cardiac mesoderm 
formation in mouse and human EBs [27][57][58]; furthermore, the addition of 
FGF2, VEGF and DKK1, and the inhibition of Nodal or TGFβ receptor 2 signaling, 
enhanced the CMs differentiation efficiency greater that 50%[27][57][59][60]. 
However, the EBs differentiation methods are technically complex with high intra- 
and inter-experimental variability in the efficiency of CMs formation while cell 
phenotype is still immature. The reproducibility of this method is also problematic 
for reasons such as the undefined medium and serum components and the 
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constant presence of complex diffusion barriers within the tridimensional EB 
structure [61]. This leads to the development of monolayer-based methods, the 
third major approach presented, where hPSCs were cultured at high density on 
extracellular matrix proteins (e.g. Matrigel), applying sequential exposure to 
Activin A and then BMP4 in a defined RPMI/B27 supplemented medium. This 
strategy initially generated ̴ 30% of beating CMs [27][60]. Finally, endogenous 
canonical Wnt signalling was identified to be indispensable for hPSCs to 
differentiate into contracting CMs sheets: in fact, as demonstrated by Paige S.L 
in 2010 [62]. and Lian X in 2012 and 2013 [63][64], the temporal perturbation of 
canonical Wnt/β-catenin signalling with small molecules, in a completely 
defined, GFs-free culture settings, determined the production of  80-98% CMs 
from multiple hPSCs lines [27][63][64].  
The three major approaches for the generation of CMs in vitro are outlined 
in Figure 1.9. 
 
 
Figure 1.9: The three major approaches to differentiate PSCs (adapted from [46]). 
These 3 approaches for PSCs differentiation possess specific advantages as 
well disadvantages. The EBs three-dimensional structure promotes cell-cell 
interactions needed for the activation of cardiac programs, but their 
disadvantage is represented by the different levels of expression of cytokines 
and inducing factors of endogenous pathways from these 3-D structures, 
leading to a high intra- and inter-experimental variability. Co-culture with 
stromal feeder cells provides the beneficial effects to cell growth thanks to the 
feeder cell layer. However, also in this case, the high variability due to 
undefined components produced by these supportive cells may influence the 
differentiation of the PSCs to desired cell types. An additional concern with this 
method is the difficulty to isolate PSCs-CMs from the stromal layer [46]. In 
Initiate differentiation: 
feeders
Undifferentiated
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general, the significant variability between cell lines used and experiments 
performed could be due to differences in the sensitivity of cells to GFs, passage 
numbers and, in the case of hiPSCs, their retention of the epigenetic memory from 
the original organ or tissue, which appears to influence the response to 
extracellular signaling molecules [65].  
Differentiation in monolayers on known substrates can lower the influence of 
neighbouring and feeder stromal cells and is also one of the simplest, fastest and 
efficient protocol [46]. A recent improvement to this protocol was described and 
patented by Burridge P.W. in 2014 in which he demonstrated that a drastic 
reduction of the number of components for the hPSCs differentiation produced 
contractile sheets of up to 95% of Troponin T positive CMs, using a xeno-free 
medium which is chemically defined and composed by only three elements: the 
basal medium RPMI, L-ascorbic acid 2-phosphate and rice-derived recombinant 
human albumin [66].  
To conclude, the principal limitations of the strategies here described include: 
presence of xeno-contaminants (e.g. the stromal feeder cells), undefined medium 
components (presence of FBS, composition of media supplements…), differences 
in expression of cytokines of endogenous signalling pathway and, above all, the 
CMs produced are largely immature necessitating additional studies to determine 
which, if any of these approaches, could eventually be promoted to clinical 
practice.  
In light of these considerations, synthetic modified mRNAs, described in the 
previous Paragraph, although in its infancy, could represent a useful and valuable 
tool for programming cell fate because these modified nuclei acids directly act on 
cell trascriptome to finely regulate protein expression and could solve the concern 
regarding cell maturation by forcing the expression of late maturation genes. 
 
 
1.4.1. Challenges and limitations of the developmental status of hPSCs-
derived CM 
As mentioned in the above Paragraph, the CMs produced to date from hPSCs 
are largely immature and most analogous to fetal stages of cardiac development. 
For this reason, several research groups recently studied and characterized deeply 
the structural, functional and molecular features of  hPSC-CMs (Figure 1.10). While 
adult human CMs (aCMs) are rod shaped with lengths in the 100 µm range, hPSC-
CMs are smaller in size (10 to 20 µm in diameter) showing a round shape [67]. 
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hPSC-CMs show poor contractile proteins organization and very low 
myofibrillar density with incomplete and randomly distributed structures 
[67][68]. Moreover, as compared to aCMs contractile apparatus, the hPSCs-CMs 
sarcomeric length is markedly shorter. Although the sarcomeric organization 
tends to mature with long-term culture, hPSC-CMs continue to show 
underdeveloped or absence of T-tubules, or M bands formation, demonstrating 
their inability to reach the necessary level of maturity comparable to functional 
adult CMs. While aCMs tend to be multinucleated, hPSCs-derived CMs are 
mononucleated [16][67][69]. 
The mitochondrial volume of mature aCMs represents over 35-40% of total 
cell volume [16][70]. Moreover, while aCMs mitochondria are aligned with 
myofibrillar proteins to provide the necessary functional energetic units for 
energy production and excitation-contraction (EC) coupling, in hPSc-CMs, the 
number of mitochondria is lower; moreover, the organelles are misaligned with 
sarcomeres and mostly concentrated all around the peri-nuclear area. aCMs 
derive their energy primarily from oxidative metabolism; in contrast with 
hPSC-CMs that are predominantly glycolytic, indicating once more their 
immature and fetal like phenotypes [16][67][72]. 
 
 
 
 Figure 1.10: Comparison between early hPSC-CM, late hPSC-CM and adult CM morphology during in vitro 
maturation process. Note the differences in shape, sarcomeric area and receptor expression between late hPSC-
CM and early hPSC-CM. aCM is larger, with multiple nuclei, large sarcomeric area and large number of 
mitochondria (adapted from [69]). 
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Three major subtypes of hPSC-derived CMs can be derived, that present atrial, 
ventricular-, or nodal-like phenotype as determined by electrophysiological 
analysis of action potentials (APs)[21][71]. The 3 principal strategies, previously 
described, for deriving CMs from hPSCs create a mixture of these three cell types 
[21]. Most reported AP characteristics, well reviewed by Robertson C and 
collaborators in 2013, are less mature than aCM: precisely, maximum diastolic 
potential (MDP) for adult ventricular CM is -85mV, whereas in early hPSC-CM it 
is approximately -30mV; in late  hPSC-CM  can improve at a maximum of -60 to -
75mV. The maximum rate of depolarization (dv/dt or vmax) in aCM is extremely 
fast, ranging from 300V/s; on the contrary, early hPSC-CM displays slow 
depolarization speeds (2V/s, improving to 10-40 V/s in late hPSC-CM). 
Mature aCMs are electrically quiescent but excitable upon stimulation while 
hPSC-CMs display a greater degree of automaticity because they contract 
spontaneously and simultaneously [69]. hPSC-CMs express frequently abnormal 
levels of the major ionic currents normally present in aCM (calcium channels, 
hyperpolarization-activated cyclic nucleotide-gated channels HCN, and 
Na2+/Ca2+ exchangers NCX [69][73][74][75][76]). hPSCs-CMs expressed the 
potassium currents genes, considered responsible for arrhythmias so these cells 
could be apllied for anti-arrhythmic drug screening [77]. Calcium-induced calcium 
release (CICR) from the sarcoplasmic reticulum (SR) of aCMs is responsible of the 
major total total Ca2+ release (70%). On the contrary, hPSC-CMs possess very little 
SR development and function, similar to fetal CMs in which SRs are smaller in 
volume and possess limited capacity to load Ca2+. Consequently, an abnormal 
diffusion of Ca2+ in the cell reduces the contractile synchronicity necessary for the 
generation of large contractile forces [69]. Figure 1.11 shows differences between 
early-, late hPSC-CMs and adult CMs phenotype. 
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Figure 1.11: Comparison of early hPSC-CM, late hPSC-CM and aCM. A. Overview of the major changes 
observed with increasing culture time; action potential (orange), key ion channels (blue). B. Comparison 
between calcium influx profiles for early and late hPSC-CM with aCM (adapted from [69]). 
 
From the study of the gene expression profile from the microarray analysis 
the upregulation of genes involved in cell-cell communication and signal 
transduction as well as host defence responses are observed in aCMs and fetal 
CMs but not in hPSC-CMs[69][78]. In contrast, hPSC-CMs show overexpression 
of genes involved in cell developmental processes, indicating their developing 
state. Other genes, especially those involved in structure, function and 
maturation, show increased expression proceeding from fetal to aCMs, 
rendering them useful as maturation markers. These genes include: the light 
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chain of myosin MYL2, MYL7, MYL3 and MYL11(or MLC); the cardiac troponin 
genes cTnT2 (TNNT2), cTnI3 (TNNI3) and cTnC1 (TNNC1). Calcium handling 
genes resulted upregulated in hPSC-CMs [79]. The main features discussed that 
distinguish hPSC-CMs from aCMs are summarized in Table 1.2. 
Table 1.2: Main reported differences between immature hPSC-CMs and aCMs extracted from literature. 
 
 
Although the discovery of hiPSCs has represented a great breakthrough with 
the opportunity to publish numerous successful studies, their clinical application 
is still quite far to be used in the preclinical phase of human trials. Further 
optimization together with a great effort are necessary to overcome the major 
challenges of hPSCs for cardiac regenerative medicine applications prior the 
translation into clinic [80]. The major safety concerns on using hPSC-CMs include: 
A) the potential for teratoma formation; B) arrhythmogenesis, and C) rejection. 
While rejection represent the most frequent issue in transplantation/implantation 
Cardiac feature hPSC-CMs Adult CMs Reference
Morphology
Multi-angular, 
round shape
Large, rod shape
Robertson, C. et al., 
2013
Number of nuclei Mononuclear Multinuclear
Robertson, C. et al., 
2013
Proliferation rate Low None
Robertson, C. et al., 
2013
Contraction Spontaneous Only induced Ma, J. et al., 2011 
Action potential
features
Low diastolic
potential
(-30mV to  -75mV)
Slow depolarization
rate 
(2V/sec to 40V/sec)
Diastolic potential
(-85mV)
Depolarization rate
(300V/sec)
Ma, J. et al., 2011 
Metabolism Glycolytic Oxidative Cao, F., et al., 2008
Ionic currents and 
Ca2+ handling
machinery
Expression
frequently at
abnormal levels
Correct expression
levels
Cao, F., et al., 2008
Gene expression
pattern
• Downregulated: 
cell
communication, 
signal
transduction and 
host defence
responses genes
• Upregulated: 
Ca2+ handling
genes
• Overexpressed: 
cell development
genes
Upregulated: cell
communication, 
signal transduction
and host defence
responses genes
Synnergren, J. et al., 
2008
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medical interventions and the use of hiPSC-for autologous applications can 
avoid immunological response, the first two mentioned concerns are related to 
the culture purity and the immature stages of hPSC-CMs, described previously. 
In fact, the persistence of a minimal pluripotent residual of OCT4+ve  can bring 
to unpredictable teratoma formation and malignant transformation in vivo. 
Moreover, since hPSCs are able to differentiate into various subclasses of hCMs 
with different electrophysiological properties, there is a risk of 
arrhythmogenesis [73]. Although current methods can generate CMs 
population with a purity of up to ~99%, it is still difficult to remove the residual 
undifferentiated cells. Moreover the purification process has to be 
highthroughput, non-destructive, efficient, appropriately selecting and cost-
effective [81]. 
Scientists continue to study for refining or developing novel approaches to 
improve cardiac differentiation of hPSCs but the final and great challenge in 
this field remains the morphological and electrophysiological CMs maturation 
in vitro as a tool to better understand the mechanisms of cardiac development 
and accelerate the application of hPSCs to the clinic. 
 
 
1.5. Aim of the Thesis 
As described previously, the major concern of current protocols for deriving 
CMs from hPSCs is their early and immature phenotype. In light of the 
considerations illustrated in this introductive Chapter, this work couples three 
of the major strategies discussed: (I) the monolayer-based cardiac 
differentiation of hPSCs that relies on the perturbation of Wnt/β-catenin 
signaling pathway, considered to date as the gold standard for producing a 
high yield of CMs; (II) the programming of hPSCs fate using the synthetic 
modified mRNA (mmRNA) technology and (III) the integration of these two 
strategies into an ad hoc microfluidic (µF) platform, fabricated in our BioERA 
laboratory, to finely drive the cardiac commitment with high efficiency. 
In particular, this thesis aims at developing an efficient and robust method 
for cardiac differentiation of hPSCs in microfluidics, through the 
overexpression of a defined set of cardiomyogenic TFs, which play key role in 
cardiac development and function. As a proof-of-concept, this strategy has the 
purpose of forcing the endogenous TFs expression via the mmRNA 
administration to drive cardiac differentiation toward cell maturation. The 
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combination of cardiac TFs and signaling pathway perturbation will be 
investigated to improve CMs formation from hPSCs. Moreover, in order to 
improve the delivery of the cardiac TFs, the microfluidics technology was 
exploited to perform an efficient differentiation of hPSCs in a high controllable 
microenvironment that allows high efficient, combinatorial and multiparametric 
analysis at one time, in a cost effective manner. 
In conclusion, the approaches studied in this PhD project represented safe and 
efficient strategies for cell fate programming, holding great promise for cardiac 
research, disease modelling and regenerative medicine and for producing 
clinically useful CMs.  
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This Chapter focuses on human pluripotent stem cells (hPSCs) used in this 
work, describing the human embryonic stem cell (hESC) lines and the human 
induced pluripotent stem cell (hiPSC) clones produced in our laboratory. The main 
characteristics of these cells are elucidated with their culture, maintenance and 
expansion procedures. Moreover, a hESC line, dual reporter for two cardiac 
transcription factors (TFs), is described in details and employed in all the 
experiments performed as a useful tool for monitoring the progression of cardiac 
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differentiation. It is then introduced the first experimental approach in 
conventional culture for the differentiation of hPSCs into beating CMs. To date, 
the monolayer-based strategy here applied, is considered the gold standard for 
the fast generation of a high yield of CMs in approximately 15 days and the 
results obtained from 2 hESC lines and 4 hiPSC clones are showed. CMs 
obtained are characterized for the expression of cardiac-specific markers and 
the cell-cell communication is studied with a functional test. 
 
2.1. Human Stem Cells 
Stem cells are primitive, undifferentiated cells characterized by their 
capacity to self-renew indefinitely and give rise to other stem cells or to 
specialize and form cells of somatic tissues [82][83].  
The self-renewal ability allows the maintenance of the undifferentiated state 
while the plasticity is involved in stem cells differentiation into a wide range of 
cells. The degree of potency (Figure 2.1) is commonly used to make a 
hierarchical classification of cells into: 
- totipotent stem cells that can generate all cells of an organism, together with 
the extraembryonic cell types  (zygote); 
- pluripotent stem cells (PSCs) that have can give rise to cells of the three germ 
layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), 
mesoderm (muscle, heart, bone, blood, urogenital tract), or ectoderm 
(epidermal tissues and nervous system); (ESCs, Embryonic Stem Cells; 
iPSCs, induced-Pluripotent Stem Cells, ICM, inner cell mass of the 
blastocyst-stage embryo); 
- multipotent progenitor cells differentiate into limited cell types (tissue-
specific stem cells, HSCs, Hematopoietic Stem Cells); 
- unipotent cells generate only a single cell type (hepatoblasts differentiate 
into hepatocytes) [84]. 
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Figure 2.1: Hierarchical classification of cells based on the degree of pluripotency with the related gene 
expression and epigenetic patterns involved. At the top, there is the totipotent cells at the morula stage. 
Proceeding down the lineage potential, pluripotent cells loose the capacity to form extraembryonic tissues.. 
Multipotent stem cells can originate multiple cell lineages, while, at the end, unipotent cell can only 
differentiate to somatic cell (adapted from [85]).   
The self-maintenance capacity depends on two main mechanisms of cell 
division: the symmetric proliferative division to maintain the stem cell pool that, 
in case of necessity can expand, whereas the symmetric differentiative division 
makes the stem cell pool depleted in order to generate differentiating progenitor 
and/or postmitotic cells. Moreover, stem cells can divide symmetrically or 
asymmetrically in order to regulate the number of stem cells and their 
differentiating progeny, both in developing embryo and adult individuals [86]. 
In conclusion, stem cells allow tissues to maintain a proper architectural, 
cytological and biochemical structure and identity in order to guarantee the correct 
functionality of the different organs in an entire complex organism [82].  
 
 
2.2. Human Pluripotent Stem Cells: human Embryonic Stem 
Cells and human-induced Pluripotent Stem Cells 
Pluripotent Stem Cells include human Embryonic Stem Cells (hESCs), derived 
from the inner cell mass (ICM) of the blastocyst of a human embryo, and human 
induced-Pluripotent Stem Cells (hiPSCs), obtained from the reprogramming of 
adult somatic cells with specific factors. 
In November 1998, a group in the United States guided by Thomson J. 
published the first data describing the isolation and derivation of human 
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Embyonic Stem (ES) cell lines from blastocyst [42]. They derived hESCs from 
the ICM of a 5-days fertilized blastocyst of fresh or frozen embryos. The 
blastocysts were then extracted and cultured in presence or absence of mouse 
supportive layer cells. Once the clonal expansion started, only the cell colonies 
showing undifferentiated state (high ratio of nucleus to cytoplasm and 
prominent nucleoli), high clonal capacity, pluripotency and normal karyotype 
were picked and expanded. As explained in Paragraph 2.1, hESCs are able to 
form all somatic tissues with the exception of extraembryonic ones required for 
complete development (placenta and membranes) for this reason they are 
incapable to give rise to a complete new individual [87]. hESCs are considered 
immortal because they express high levels of  telomerase, the gene protein 
product  that assures the preservation of telomere ends at each cell division, 
avoiding cells senescence. Pluripotency state of these cells was verified by their 
capacity to aggregate in Embryoid Bodies (EB), in which cells differentiate into 
cells from the three embryonic germ layers. Furthermore, when injected into 
severe combined immunodeficient mice (SCID), the hESCs lines produced 
teratomas containing endoderm (gut epithelium); mesoderm (cartilage, bone, 
smooth muscle and striated muscle); ectoderm (neural epithelium, embryonic 
ganglia and stratified squamous epithelium)[42][88]. Thanks to these abilities, 
hESCs are a promising candidate for the generation of tissues useful in 
regenerative medicine approaches, as well as a valuable tool for disease 
modeling and drug screening to identify new chemical entities (NCEs) that can 
be developed as novel therapeutics.  
However, the use of human embryos for deriving hESCs is currently under 
a high ethical and political debate in the world. Despite the great potential 
offered by the use of  hESCs for treating diseases and many other applications 
above mentioned, their use remains controversial because implies the 
destruction of early embrios [83][88]. In fact, hESCs are currently discussed by 
the biologists as well as by the medical profession, media, ethicists, 
governments and politicians: surely, these cells possess a great clinical potential 
for tissue repair and/or replacement but the major ethical concern is that hESCs 
are derived from human pre-implantation embryos. To date, most embryos 
used for the generation of hESC lines came from spare ones conserved for in 
vitro fertilization (IVF), but also the creation of embryos for the unique 
derivation of hESCs is under debate.  
In 2006 and 2007, another breakthrough in science, first on mouse and then 
on human cells, was reported by researchers at Kyoto University in Japan by 
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Yamanaka S and coworkers. In contrast to hESCs, these cells, called induced 
Pluripotent Stem Cells (iPSCs) were derived by the reprogramming of somatic 
cells to a pluripotent state forcing the overexpression of a key set of transcription 
factors (TFs) indispensable for pluripotency maintenance. This process does not 
destroy human embryos ex utero, avoiding a great portion of the ethical and 
political debates surrounding hESCs generation [43][44]. Thanks to this discovery, 
Yamanaka S. was awarded with the 2012 Nobel Prize for the ability to 
reprogramme mature, differentiated cells to a pluripotent state. 
iPSCs are obtained with the introduction of a specific combination of 
pluripotency genes, also named  “reprogramming factors” (RFs) or“Yamanaka’s 
factors” , into a differentiated somatic cell type. Yamanaka’s factors were the 
following genes: Oct4 (Pou5f1), Sox2, c-Myc and Klf4. iPSCs were firstly generated 
from mice fibroblasts in 2006 by researchers of Yamanaka’s group to identify the 
genes important for inducing an embryonic state in adult cells. Before the 
identification of the  4 RFs above mentioned, Yamanaka’s team tested 24 genes that 
were identified in literature as essential in embryonic stem cells and delivered 
them into fibroblasts using retroviruses. They arrived at the identification of the 
set of 4 candidates by removing one factor step-by-step. These cells are defined as 
the first-generation of iPSCs and displayed typical pluripotency features such as 
self-renewal and ability to form all three germ layers derivatives both in vitro, 
within EBs, and in vivo teratomas. In 2007, another milestone was achieved by 
deriving iPSCs from the reprogramming of human adult  cells [43][44] with two 
independent research teams studies published one by Thomson J. at University of 
Wisconsin-Madison, and the other by Yamanaka S. himself and colleagues at 
Kyoto University. With the same principle adopted by Yamanaka in 2006 in mouse 
models, his group successfully converted human fibroblasts into hiPSCs using 
these 4 genes: OCT3/4, SOX2, KLF4 and c-MYC, delivered with a retroviral vector 
[44]. On the other hand, Thomson and colleagues used lentiviral systems for 
delivering OCT4, SOX2, NANOG plus LIN28 [89][90]. Moreover, in 2012, 
researchers from Austria, Hong Kong and China published a work in which they 
were able to generate hiPSCs using a protocol that reprogrammed the exfoliated 
renal epithelial cells present in urine to a pluripotent state. This method is less 
invasive and more compliant, compared to the extraction of cells from, for 
example, skin biopsies, providing an alternative way to derive hiPSCs from 
healthy and diseased individuals [91]. Figure 2.2 summarizes the strategies to 
generate hESCs and hiPSCS. 
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Figure 2.2: Protocols for ESCs (A)  and iPSCs derivation (B) (modified from [88]). 
 
However, these first reprogramming methods based on viral vectors were 
characterized by low efficiency, yielding iPSCs in less than 1% of the starting 
somatic cell used; moreover, these approaches are accompanied by the great 
obstacle for future therapeutic applications represented by the modifications of 
the genome. The use of synthetic modified mRNA (mmRNA), pioneered by 
Warren L. in 2010 is an appealing tool for cell fate manipulation because allows 
the modulation of cellular protein expressionon  daily, with repeated 
transfection of selected combinations of TFs, circumventing at the same time, 
additional stages of purification from residual vector traces [49][50]. 
The technologies presented and discussed in this thesis have been performed 
using both hESCs and hiPSCs in order to develop more relevant in vitro studies. 
 
 
2.3. hPSCs culture, passaging and expansion 
In this work, the following hPSCs were employed: hESC line HES2 and hESC 
line MESP1mCherry/w/NKX2.5eGFP/w dual reporter [92][93]; mmRNA Clone 1; 
mmRNA Clone 7; mmRNA Clone A and mmRNA Clone G. The designation 
and origin of the hPSCs lines and clones employed in this thesis are listed in the 
Table 2.1. 
A. Embryonic stem cell derivation
B. Methods of induced pluripotent stem cell derivation
Spermatozoa
Oocyte
Cleavage
ICM ESCs
Continued
embryogenesis
Isolation and expansion
of inner cell mass
Viral transduction
Oct4 Sox2
c-MycKlf4
Viral vector
expression
Plasmid
transfection
Oct4
Sox2
Klf4
c-Myc
mmRNA
translation
Protein
transduction
Sox2
Klf4
c-Myc
Oct4
Oct4 Sox2
Klf4 c-Myc
Somatic cell
(e.g. fibroblasts)
Selection iPSCs
Nuclear
reprogramming
Intermediate 
partially
reprogrammed
celll
Isolation of 
pluripotent cell
Cell 
Differentiation
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Table 2.1: List of hPSCs employed in this work 
 Line/Clone Type Vector Status Reference 
h
E
S
C
s 
HES2 WiCell bank - Healthy 
Giobbe, G.G. 
et al., 2015 
hESC 
MESP1mCherry/w/NK
X2.5eGFP/w 
R. Passier’s 
Laboratory, 
Leiden University 
Recombineering 
modification of 
bacterial artificial 
chromosome 
Healthy 
Den Hartog, 
S.C. et al., 2015 
h
iP
S
C
s 
mmRNA-Clone 1 N. Elvassore’s 
BioERA 
Laboratory, 
Padova 
Univerisity 
mmRNA transfection Healthy 
Luni C. et al, 
2016 
mmRNA-Clone 7 mmRNA transfection Healthy 
mmRNA-Clone A mmRNA transfection Healthy 
mmRNA-Clone G mmRNA transfection Healthy 
 
For more details on the culture settings of the hiPS employed, please see the 
publications produced by the colleagues of BioERA laboratory Giobbe G.G et al. 
and Luni C. et al. in 2015 and 2016 respectively [94][95].  
hPSCs were cultured in 0,5% v/v matrigel reduced factor (MRF 50%; BD) 
coated 6-well plates, maintained and expanded in StemMACS™ iPS-Brew XF 
medium (Miltenyi Biotec), a feeder-free and xeno-free medium which formulation 
supports rapid adaptation of feeder-based cell cultures to a feeder-free 
environment and shows compatibility with commonly used matrices like MRF or 
vitronectin. 
hESC line HES2 (from National Stem Cell Bank, Madison, WI and used in the 
work published by the colleagues Giobbe G.G. et al. in 2015 [94]) was initially 
expanded in gelatine-coated Petri dishes, in co-culture with mouse embryonic 
fibroblasts (MEF, Chemicin) mytomicin C-inactivated, for various passages in 
expansion medium (DMEM F-12 , Invitrogen; 20% Knock-Out serum, Invitrogen; 
10% MEF conditioned medium, 20ng/mL basic Fibroblast Growth Factor bFGF, 
Invitrogen; 0,1% mM β-mercaptoethanol, Invitrogen; 1% non-essential amino 
acids, NEAA, Invitrogen; and 1% Pen/Sterp, Invitrogen). These cells were then 
seeded in 6-well plates with 0,5% v/v MRF coating and maintained in 
StemMACS™ iPS-Brew XF feeder-free medium. 
hESC line MESP1mCherry/w/NKX2.5eGFP/w dual reporter [92][93], kindly gifted by 
Robert Passier, was generated by Passier’s laboratory (Leiden University Medical 
Centre, the Netherlands) through the modification of the bacterial artificial 
chromosome RP11-975L13 (Lifesciences) by recombineering (Gene Bridges), 
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leading to this dual reporter system for the early cardiovascular lineage markers 
MESP1 and NKX2.5 (described in Paragraph 2.4) [92][93]. 
The human induced pluripotent stem cell clones used in this PhD thesis are 
classified with different names indicated in the work published by Luni C. et al 
in 2016 (µF#501 for mmRNA Clone 1 and µF#505 for mmRNA Clone 7, 
Well#401 for mmRNA Clone A and Well#405 for mmRNA Clone G;) [95] but 
for simplicity, the denominations adopted routinely in our laboratory are 
reported in Table 2.1.  
hiPSC mmRNA Clones 1, 7, A and G were generated in our BioERA 
laboratory through the reprogramming of human fibroblasts with synthetic 
modified mRNA, according with the protocol described by Warren, L. et al., in 
2010[49][50], both in multiwell plates and in microfluidic devices developed in 
BioERA lab [95]. The reprogramming to pluripotency was performed by Giulitti 
S. and Luni C. of our BioERA laboratory and the details of the protocol is 
reported in their work [95]. The reprogramming of target fibroblasts (BJ, 
Miltenyi Biotec or HFF-1, ATCC) was performed both in presence of feeder cells 
(NuFF-RQ, newborn foreskin fibroblasts AMS Biotechnology) or in feeder-free 
conditions. Briefly, in case of reprogramming with feeder cells, NuFF were 
seeded in gelatine-coated plates and, after 24 hours, the target fibroblasts (BJ or 
HFF) were seeded on feeder cells at different densities in DMEM (Life 
Technologies) supplemented with 10% fetal bovine serum (FBS, Life 
Technologies). When starting the reprogramming transfections on day 0, the 
medium was switched to Pluriton reprogramming medium (Stemgent) 
supplemented with 200ng/ml of the protein for interferon inhibition B18R 
(eBioscience). The transfections were conducted for 12 consecutive days using 
mmRNAs encoding OCT4, SOX2, KLF4, c-MYC, NANOG, LIN-28 and nuclear 
GFP (Milteny Biotec) according to the StemMacs mRNA reprogramming kit 
(Miltenyi Biotec), respecting the correct stoichiometry of each mmRNA 
indicated in the data sheet. All the mmRNAs (concentrated 100ng/µL) were 
diluted 5X in the transfection mix made by pooling two solutions composed by 
the transfection buffer (TB) and the transfection reagent (TR) of the 
reprogramming kit. After 15 minutes of equilibration at room temperature, the 
transfection mix was then added to the culture medium. For the progressive 
NuFF death observed during the experiments, from day 6 NuFF conditioned 
B18R-supplemented Pluriton was always used. Feeder-free reprogramming 
was performed with the same scheme above described by solely transfecting BJ 
or HFF fibroblasts using B18R supplemented Pluriton until the end of the 
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experiment. At the end of the transfection regimen, hiPSCs obtained were 
maintained in culture with Pluriton for 2 days while some experiments were 
stopped to verify the pluripotency via immunofluorescence staining against the 
pluripotency markers NANOG and TRA1-60 [95]. hiPSCs colonies were then 
picked and cultured on 0,5% v/v MRF coated plates in feeder-free StemMACS™ 
iPS-Brew XF medium (Miltenyi Biotec). In Figure 2.3 are reported bright field 
images of hESCs and hiPSCs colonies in feeder-free culture on MRF-coated plates. 
hPSCs colonies grow in colonies showing defined edges. 
 
Figure 2.3: Bright field images of hESCs (MESP1mCherry/w/NKX2.5eGFP/w dual reporter) and hiPSCs 
(mmRNA Clone 7) colonies grown on MRF-coated plates. Note the homogeneity and compactness of 
pluripotent stem cells; undifferentiated colonies presented different dimension showing defined and bright 
edges with regular shape. 
 
hPSCs medium was changed daily and, for passaging, two methods were 
adopted: mechanical and with dissociating buffer. The first one was performed 
under the stereomicroscope inside the biological safety cabinet to dissect 
undifferentiated colonies into several pieces using a cutting glass pipette, 
specifically modified for this procedure; this is considered a gentle method, useful 
to remouve also the differentiated parts in the culture. The picked colonies were 
them replated onto 0,5% v/v MRF-coated six-well plates.  
The second strategy consisted on the treatment with Gentle Stem Cell 
Dissociation Reagent (Stem Cell), an enzyme-free method recommended for the 
ease of use, high cell recovery and for preserving the integrity of cell surface 
proteins that aid in the reattachment of cells to the matrix. Briefly, medium was 
aspirated from the well and cells were rinsed with phosphate-buffered saline (PBS, 
Gibco). Cells were then incubated with the dissociation reagent for 2-4 minutes at 
hES
MESP1mCherry/w/NKX2.5eGFP/w
dual reporter hiPS mmRNA Clone 7
500µm 500µm
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room temperature. The dissociation reagent was removed and stem cell 
medium was added; gently the colonies were detached by scraping with a cell 
scraper, taking care to minimize the breakup of colonies. Carefully, the cell 
aggregate mixture was pipetted up and down and replated at the desired 
density onto a new 0,5% v/v MRF-coated six multiwell plate. The split ratio 
could vary between 1:3 and 1:10, depending on the different rate of cell growth, 
so the split ratio need to be adjusted. Ususally it is recommended to observe the 
last split ratio and adjust it, taking into account the aspect of the hPSC colonies. 
If the cells look healthy and colonies have enough space, the cultures can be 
split every 4-7 days. 
A daily check of hPSCs is recommended for both medium refresh and for 
preventing possible differentiation. When differentiation emerges, two 
strategies for its removal are possible: “pick-to-keep” (PTK) and “pick-to-
remove” (PTR). If only few undifferentiated colonies are present, “pick-to-
keep” is preferred, in which the differentiated cells are left on the plate and 
discarded. On the contrary, if there are mostly undifferentiated colonies, the 
few differentiated cells undergo the “pick-to-remove” methodology in which 
they are picked, removed and discarded. Representative pictures of the two 
strategies mentioned for the removal of differentiated cells are reported in 
Figure 2.4. 
 
  
Figure 2.4: Example of cell differentiation in hiPS (mmRNA Clone 1) culture. A. White dotted line marked the 
hiPS colony for the “pick-to-keep” (PTK) strategy in presence of consistent differentiation in the plate. B. White 
dotted line indicate the differentiated cells that will be removed with the “pick-to-remove” (PTR) strategy in 
presence of mostly undifferentiated cells. 
 
The two hESC lines (HES2 and hES MESP1mCherry/w/NKX2.5eGFP/w dual 
reporter) and the four hiPSC clones (mmRNA Clone1, 7, A and G) were 
successfully cultured and maintained and the pluripotency state was routinely 
verified by immunofluorescence staining against pluripotency markers: OCT4, 
PTK
A
PTR
B
Chapter 2 
 
Human Pluripotent Stem Cells for Cardiomyocytes generation 
 
35 
 
NANOG, c-MYC, KLF-4, TRA1-60, TRA1-81, TRA2-49 (alkaline phosphatase ALP 
or AP) and SSEA4, as reported in the panel of Figure 2.5, confirming that our cells 
were bona fide pluripotent stem cells. All the immunofluorescences were 
performed according to the standard 5 steps protocol: fixation, permeabilization, 
blocking, incubation with primary protein-specific antibody followed by 
secondary fluorescent-labeld antibody. The details for each antibody with the 
related 5 steps used are listed in Table 2.2. 
The species-specific secondary antibodies employed were from Life 
Technologies and were visualized by Alexa Fluor-488 (green) or Alexa Fluor-594 
(red) and from Jackson ImmunoLab Cy3 (red) fluorophores. Nuclei were 
counterstained in blue with Hoechst (Sigma Aldrich). Leica DMI6000B 
epifluorescence microscope, provided with a mercury short-arc reflector lamp or 
Leica SP5 confocal microscope, equipped with Argon laser were used for taking 
pictures. 
 
Table 2.2: Summary of all the primary antibodies employed in this thesis for pluripotency characterization, 
with all the parameters of the assay listed. 
 
 
 
 
 
 
 
 
Antibody Manufacturer Fixation
Permeabilization
and Blocking
Dilutio
n
Incubation
Oct4 Santa Cruz #sc5279
4%PFA,
10min, RT
PBS-0,1% Triton X 
10% FBS
1:200
12 h, 4°C
Nanog ReproCell #RCAB0004P-F 1:100
Klf-4 Santa Cruz #sc20691
1:250
c-Myc Santa Cruz #sc764
TRA1-60 Cell Signaling #4746
PBS 
10%FBS
1:200
60 min, 
37°C
TRA1-81 Millipore #MAB4381
60 min, 
37°C
TRA2-49 Millipore #MAB4349
60 min, 
37°C
SSEA4 Santa Cruz #sc21704 
60 min, 
37°C
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Figure 2.5: The correct pluripotency maintenance of hPSCs employed in this work was verified by immunofluorescence 
staining of Oct4 and Nanog (mmRNA Clone 7), Klf4, c-Myc (mmRNA Clone 1), TRA1-60 (mmRNA Clone G), 
TRA1-81 (mmRNA Clone A), TRA2-49 (hESCs line HES2) and SSEA4 (hES MESP1mCherry/w/NKX2.5eGFP/w dual 
reporter) expression. Nuclei were counterstained with Hoechst. Scale bar 250µm. 
 
Oct4 Nanog Hoechst Merge
Klf4 Hoechst Merge
C-Myc Hoechst Merge
TRA1-60 Hoechst Merge
TRA1-81 Hoechst Merge
TRA2-49 Hoechst Merge
SSEA4 Hoechst Merge
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Undifferentiated hPSCs cells express high levels of alkaline phosphatase (AP), 
responsible of the self-renewal potential of the cells (Figure 2.6). hPSCs were 
stained using the AP staining kit (Stemgent), undifferentiated cells appeared red 
or purple, whereas differentiated cells appeared colorless. 
 
 
Figure 2.6: AP activity on mmRNA Clone1. The pluripotent status of stem cells can be characterized by a high 
level of AP expression. Note that AP positive colonies appear purple. 
 
 
2.4. A Dual Reporter MESP1mCherry/w/NKX2.5eGFP/w human 
embryonic stem cell line as a tool to monitor the 
progression of cardiac differentiation 
Passier R. and colleagues of Leiden University in the Netherlands in 2014 
developed a new cellular tool to visualize the course of early cardiac mesoderm 
and cardiomyocyte differentiation in vitro: they generated a fluorescent dual 
MESP1mCherry/w/NKX2.5eGFP/w reporter line in hESCs to unravel the developmental 
signals orchestrating the formation of cardiac progenitors and their subsequent 
specification toward cardiac differentiation. The use of fluorescent reporter lines, 
in fact, helps reserchers to properly monitor cells behaviour during, for example, 
hPSCs cardiac differentiation in vitro or to track cells in vivo experiments [93]. In 
Figure 2.7 is reported a schematic representation of human fluorescent reporter 
lines applications.   
 
750µm
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Figure 2.7: Schematic overview of functional applications of human fluorescent reporter lines for monitoring 
the cardiac differentiation process and for cardiac disease and toxicity studies. Abbreviation: CPC, Cardiac 
Progenitor Cell (adapted from [93]).  
 
 As already mentioned in Chapter 1 (Paragraph 1.2.1), MESP1 is an early 
pivotal TF expressed in embryonic precardiac mesoderm. Transcription factor 
NKX2.5 is expressed in heart precursor cells of the First Heart Field (FHF) and 
is maintained in the committed cells of the cardiac lineage [92][93]. During the 
cardiac differentiation of the dual reporter hESCs, cells transiently express 
MESP1-mCherry (red fluorescence), followed by a constant expression of 
NKX2.5-eGFP (green fluorescence). 
To generate the MESP1 targeting vector, Passier’s group used the artificial 
bacterial chromosome RP11-975L13, modified by recombineering. Exon 1 
sequence was replaced by the mCherry cassette and a selection marker. The 
modified MESP1 locus with the surrounding 5’ and 3’ homology arms were 
then subcloned into the MESP1 targeting vector which was then linearized 
through Pvul digestion and electroporated into the mono reporter NKX2.5-
eGFP hES line generated in 2011 in a previous work, published by the same 
research group [92][96]. To demonstrate that cardiogenic ability of the dual 
reporter line to fully recapitulate the timing of expression of the two TFs, Passier 
and collaborators performed a monolayer cardiac differentiation in the low-
insulin, serum-free medium BPEL (BSA, polyvinyl alcohol and essential lipids) 
in which they added the growth factors BMP4 and Activin-A, the small 
molecule CHIR99021 to inhibit GSK3-β from day 0 to day 3, followed finally by 
the Wnt signalling antagonist inhibitor Xav939 from day 3 to day 7 of the 
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protocol. They clearly detected the mCherry red fluorescence of mCherry on day 
3 of differentiation with cells undergoing epithelial-to-mesenchymal transition 
(EMT). The details on the generation of the dual reporter stem cell line performed 
by the researcher of Passier’s laboratory are reported in Figure 2.8.   
 
 
Figure 2.8: Generation of MESP1mCherry/w-NKX2.5eGFP/w  dual reporter hESC line by Passier R. et al. A. Wild-
type MESP1 allele, MESP1 targeting construct, and targeted MESP1 allele. B. Dual cardiac fluorescent 
reporter line. p: endogenous gene regulatory elements of either MESP1 (MESP1p) or NKX2.5 (NKX2.5p). C. 
Cardiac monolayer-based differentiation in BPEL. D. MESP1-mCherry signal at day 3 of cardiac 
differentiation. MG, matrigel; Tg, transgenic (adapted from [92]).  
 
Passier R. and co-workers performed a quantitative PCR (qPCR) gene 
expression analysis of their dual reporter cells undergoing cardiac differentiation 
and observed the transient expression of mCherry, with an intense peak on day 3 
which mirrored the endogenous MESP1 expression. In agreement with previous 
in vitro and in vivo studies reported in literature, they found that expression levels 
of mesendodermal genes Brachyury T (T) and Eomesodermin (EOMES) showed peak 
A
B
C
D
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values at day 2, 24 hours before MESP1 peak. Expression levels of NKX2.5 were 
markedly detectable strating from day 9 of differentiation,  just before cells 
strated to form beating areas, with further increase on day 12 (Figure 2.9). 
 
Figure 2.9: Gene expression pattern analysis performed by the researchers of Passier’s laboratory. A. mRNA 
levels of T and EOMES, MESP1, mCherry, and NKX2.5. Results are normalized for day 0 transcript 
expression in undifferentiated hESCs (n=3, error bars indicate SEM). B. The quantification of percentages of 
mCherry and eGFP expressing cells during monolayer differentiation (n=4-8; error bars indicate SEM; adapted 
from [92]). 
 
Passier and his group demonstrated the importance of using genetically 
modified reporter lines as a tool for developing and monitoring protocols that 
enable a real time observation of the mechanisms of cell differentiation. As 
demonstrated in their work, in the dual reporter MESP1mCherry-NKX2.5eGFP line, 
firstly mCherry started to became visible indicating the mesoderm induction, 
followed by the later appearance of GFP+ cardiac progenitors and subsequent 
CMs, unveiling, in vitro, previously inaccessible stages of early human cardiac 
development [92][93][96]. 
 
 
A
B
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2.4.1. MESP1mCherry/w/NKX2.5eGFP/w expression monitoring during 
monolayer differentiation using Wnt/β-catenin pathway modulators 
in standard cultures 
In this thesis, the dual reporter MESP1mCherry/w-NKX2.5eGFP/w  line was used to 
monitor the progression of cardiac differentiation. 
The dual reporter line was differentiated using the monolayer-based cardiac 
differentiation protocol in standard cultures via the temporal modulation of 
Wnt/β-catenin pathway that will be described in the next Paragraph 2.5. Briefly, 
on day 0 of cardiac differentiation was applied the GSK3-β inhibitor CHIR99021 to 
drive mesoderm induction, followed by Wnt inhibiton with IWP4 on day 3 of 
differentiation. For every cardiac differentiation experiment, the fluorescence of 
mCherry and eGFP for the expression of MESP1 and NKX2.5 respectively was 
monitored daily under the fluorescence microscope.  
Because the temporal expression window of MESP1 is very short (2-3days), the 
mCherry monitoring was performed 3 times/day during the first three days of 
differentiation. As reported in Figure 2.10, the peak of expression of mCherry 
appeared on day 3 of cardiac differentiation, accordingly to Passier’s work, 
whereas the NKX2.5 signal associated to eGFP became visible between day 7 and 
8 of differentiation, just 1-2 days before of the detection of beating CMs. 
 
 Cardiac Differentiation Timecourse [days]
0 3-4 6 9 14
Pre-Cardiac Progenitors Cardiac Progenitors and Cardiomyocytes
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Chapter 2 
 
Human Pluripotent Stem Cells for Cardiomyocytes generation 
 
42 
 
 
Figure 2.10: Dual cardiac fluorescent reporter line MESP1mCherry-NKX2.5eGFP in hESCs allows visualization 
and isolation of precardiac MESP1+ progenitors with a peak on day 3 of differentiation and their further 
progression to NKX2.5 eGFP+ derivatives starting to be detectable on day 7-8 of differentiation. 
 
This dual cardiac reporter line allowed the spatiotemporal monitoring of the 
molecular pathways involved in the switch from hPSCs, pre-cardiac precursors 
and CMs representing also an useful tool for in vivo lineage tracing studies in 
which, for example, these cells could be implanted in infarcted hearts 
[92][93][96]. 
 
2.5. The gold standard approach for cardiac differentiation of 
hPSCs in conventional cultures 
As described previously in Chapter 1, Paragraph 1.4, recently, significant 
progress has been made in cardiovascular research to improve the cardiac 
differentiation of hPSCs. hPSC-CMs were firstly isolated from serum-
stimulated EBs in 2001 by  Gepstein J.’s laboratory [56], and later derived by co-
culture on a feeder layer of mouse stromal cells by Mummery C. and coworkers 
in 2003 [9]. Early differentiation protocols, presented by Laflamme M.A. et al. 
and Keller G. et  al., in 2007 strogly improved cardiac purities, of ~30-70% CMs. 
Additional optimization of these protocols were performed using Activin-
Nodal signaling made by Keller’s laboratory in 2011 [21][57], culturing cells on 
extracellular matrix (ECM) proteins by Zhang J.’s laboratory in 2012 [97] and 
the modulation of Wnt signaling described in 2012 by Palecek S.  and colleagues 
[63][64]. 
BF mCherry Merge
BF eGFP Merge
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In this thesis was applied the monolayer-based differentiation protocol in 
standard 24-well plates presented by Lian X, Palecek S. and co-workers in 2012 
that efficiently directs hPSCs differentiation to beating CMs in a completely 
defined, GFs and serum-free culture setting by temporal activation and inhibition 
of canonical Wnt/β-catenin signaling pathway. This method, described in Figure 
2.11., is reported in literature as the most efficient to date for producing a high 
yield of CMs from hPSCs; in this work, this protocol was used as the gold standard 
to study cardiac differentiation of hPSCs in conventional culture systems for these 
reasons: 
- it allows a simple and fast CMs generation with high efficiency in 
approximately 15 days solely via small molecules that modulate canonical 
Wnt/β-catenin pathway; 
- the use of small molecules instead of GFs determine a more controllable 
and reproducible generation of CMs, lowering the intra- and inter-
experimental variability observed when using the other methods described 
for direct cardiac hPSCs differentiation; 
- the temporal modulation of Wnt/β-catenin pathway leads to a high yield 
of CMs (80%-90%) from multiple hPSCs lines; 
- CMs produced can be maintained in culture up to 6 months allowing a 
complete structural, functional and molecular characterization [63][64]. 
 
 
Figure 2.11: Schematic of the monolayer-based protocol for defined, GFs-free and serum-free differentiation of 
hPSCs to CMs by temporal modulation of regulators of canonical Wnt/β-catenin signaling pathway. Basal 
medium indicates RPMI with or without insulin (modified from [63]). 
 
 hPSCs were initially cultured on 0,5% v/v MRF (BD)-coated 6-well plates and 
maintained in StemMACS™ iPS-Brew XF medium (Miltenyi Biotec) until they 
achieved the confluence. Differentiation was initiated by seeding hPSCs on 0,5% 
v/v MRF-coated 24-well plates, removing the hPSCs medium and switching to 
6 months
Cell seeding
-2 0 1 3 5
hPS medium WNT ON Basal medium WNT OFF Basal medium
CHIR99021 IWP4
Time line [days]
- CHIR99021= GSK3-βinhibitor
- IWP4= Inhibitor of Wnt Production
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RPMI (Life Technologies) with 1X B27 nutrient supplement (Life Technologies) 
medium lacking insulin (basal medium) and containing a glycogen synthase 
kinase 3-β (GSK3-β) inhibitor, CHIR99021 for 24 hours. CHIR99021 is an 
aminopyrimidine considered the most selected inhibitor of the GSK3-β to date, 
leading to the activation of the canonical Wnt pathway [69]. After 48 hours in 
basal medium, Wnt secretion was suppressed for 48 hours by adding 10µM of 
the inhibitor of Wnt production-4 (IWP-4, Life Technologies). IWP-4 was 
identified with a highthroughput screen for the identification of Wnt/β-catenin 
pathway antagonists; its mechanism of action relies on palmithylation of Wnt 
proteins by Porcupine (Porcn) by blocking Wnt secretion and activity; it also 
blocks the accumulation of β-catenin [98].On day 7 of differentiation, the hPSCs-
derived CMs were maintained in RPMI + B27 complete of insulin (basal 
medium) until use for further experimental procedures.  
The cardiac differentiation of hPSCs was monitored daily under microscope, 
performing a time-lapse analysis for 11 days, and the contractions were 
recorded (Figure 2.12). 
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Figure 2.12: Schematic of the protocol for the differentiation of CMs from hPSCs (in this pictures mmRNA 
Clone 7) with  modulators of canonical Wnt/β-catenin signalling in standard multiwells. Bright-field images 
of the typical morphology of day 0, 1, 5, 9 and 11 cells shown at 10X and 20X magnifications. Scale bars, 
100µm. 
 
From day 8 to 14, depending on hPSCs line and clone of origin, cells started to 
contract spontaneously, firstly as isolated points and then the consistent part of the 
monolayer. Robust spontaneous contractions occurred approximately on day 10-
12. 
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MRF-coated 24-well plates
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7days
Beating CMs detection
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2.5.1. Cardiomyocytes disaggregation for cell characterization 
To prepare the sample for the following CMs characterization, cells were 
firstly detached and disaggregated from the 24-well plate, accordingly to the 
protocol of Lian X. and colleagues and described in Nature protocols in 2012 
[63][64]. Briefly, cells were incubated with 10µM Y-27632 (Tocris), an inhibitor 
of Rho-associated coiled-coil forming protein serine/threonine kinase (ROCK) 
for 75 minutes at 37°C, to prevent dissociation-induced apoptosis. Glass 
coverslip for CMs seeding were coated with 2,5%v/v MRF. After 75 minutes, 
cells were incubated with the digestion mix composed of 2mg/ml collagenase 
I (Gibco), 1mg/ml collagenase IV (Gibco), 2U/ml DNase I (Invitrogen) and 
10µM Y-27632 in PBS with Ca2+ and Mg2+ (Life Technologies) for 25 minutes at 
37°C, after removing the basal medium and gently washing CMs with PBS. 
Then the digestion mix was aspirated and cells were washed in PBS and 
incubated with TrypLE™ Select (Gibco), a cell-dissociation enzyme. CMs were 
detached vigorously and suspended in single cell suspension. Finally STOP 
medium (1:1 DMEM and FBS, Life Technologies; with 2U/ml DNase I) was 
added and cells were centrifuged and resuspended in basal medium. CMs are 
now ready for quantification by flow cytometry or for seeding them in the MRF-
coated glass coverslip previously prepared, for further characterization by 
immunofluorescence and patch clamp assay described in the next Paragraphs. 
  
 
2.5.2. Characterization of hPSC-derived cardiomyocytes 
At day 14 after differentiation, the cells should show hallmarks of CMs, 
including spontaneous contraction and cardiac-specific protein expression. 
CMs obtained were disaggregated as described in Paragraph 2.5.1 and 
characterized by immunofluorescent staining against nuclear markers GATA4 
and NKX2.5 and structural cardiac markers (Figure 2.13) including Troponin T 
(cTnT), α-Actinin, an embryo/fetal Troponin T (RV-C2) and adult Troponin I 
(Ti1) isoforms and Myosin Heavy Chain (MYH7 or BA-D5 used in Chapter 4). 
To determine the expression of proteins involved in cell-cell communication, an 
immunofluorescence staining for the Connexin 43 (Cnx-43), the major gap 
junction protein in the heart that promotes electrical coupling and synchronizes 
contractions of CMs, was performed (Figure 2.13 A and C). All the 
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immunofluorescences were performed in accord to the five-steps protocol 
previously described in Paragraph 2.3. 
 
A hES  HES2-CMs 
 
 
 
B hES Dual Reporter-CMs 
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C hiPS-CMs 
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Figure 2.13: Molecular markers in hPSC-CMs.  Expression of cardiac markers in human CMs derived from 
A. hES HES2 line B. hES MESP1mCherry/w/NKX2.5eGFP/w dual reporter (note the expression of eGFP related to 
the NKX2.5 locus) and C. hiPSCs (mmRNA Clone 7); Immunofluorescence staining showed a remarkable 
organization of the sarcomeres. 
 
Supplementary information on antibodies used and immunofluorescence 
steps are reported in Table 2.3. 
 
Table 2.3: Summary of all the primary antibodies employed in this thesis for the characterization of the CMs 
obtained from hPSCs, with all the parameters of the assay listed. 
 
 
With this monolayer-based differentiation, it was possible to obtain a high 
yield of CMs, positive for the principal cardiac-specific markers; in particular, 
as reported in the magnification of the panels in Figure 2.13, immunostaining 
showed a remarkable organization of the sarcomere, the contractile unit of this 
cell type.  
CMs obtained were then quantified by counting the cardiac troponin T 
(cTnT) positive cells from immunofluorescence staining, as reported in the 
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Antibody Manufacturer Fixation
Permeabilization and 
Blocking
Dilution Incubation
GATA4 Santa Cruz #sc1237
1%PFA, 10min, 
RT
PBS-0,1% Triton X 
10% FBS
1:50
12 hours, 
4°C
Nkx2.5 Santa Cruz #sc8697
cTnT Thermo Scientific #MS295P
4%PFA, 10min, 
RT
1:200
60 min, 
37°C
α-Actinin Sigma-Aldrich #A7811 1:250
Ti1 DSHB, S. Schiaffino’s Lab
PBS-0,1% Triton X 
0,5% BSA 1:50
12 hours, 
4°C
RV-C2 DSHB, S. Schiaffino’s Lab
BA-D5 DSHB, S. Schiaffino’s Lab
Cnx-43 Millipore #MAB3067
Acetone, 
20min,
-20°C
PBS-0,25% Triton X 
10%FBS,
10 min
1:200
12 hours, 
37°C
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graph in Figure 2.14 with the related Table reporting the percentages of cTnT+ve 
cells obtained from each hiPS Clone and hES line. 
 
 
 
 
 
hPSCs cTnT+ve cells [%] 
HES2 92±2% 
hES Dual Reporter 93±10% 
Clone 1 94±7% 
Clone 7 98±2% 
Clone A 63±9% 
Clone G 86±2% 
Figure 2.14: Percentage of cardiac troponin T (cTnT) positive CMs obtained from the monolayer cardiac 
differentiation of hPSCs using Wnt/β-catenin modulators with 12µM CHIR99021, (n=3, error bars indicate 
SEM). 
 
In Palecek’s work, 12µM CHIR99021 was reported as the optimal concentration 
for cardiac differentiation but he suggested that an optimization of concentrations 
was required for each hPSCs line used [64].  
As observed in the cTnT+ve quantification reported in the graph of Figure 2.14, 
a hES line and a hiPS clone were selected for their cardiogenic ability to give the 
highest CMs yield: hES Dual reporter line (93% cTnT+ve cells) and hiPS mmRNA 
Clone 7 (98% cTnT+ve cells).  
To assess the ability of these cells to generate beating CMs, the concentration of 
CHIR99021 for an optimal GSK3-β inhibition was optimized in a range from 6-
12µM and. The CMs obtained were then quantified by counting the cTnT+ve cells 
from immunofluorescence staining and the graph reported in Figure 2.15 
demonstrated that hiPS Clone 7 gave a high yield of CMs from 6 to 10µM 
CHIR99021, while the hES Dual Reporter line ranged from 9 to 10µM. CHIR99021 
10µM emerged as the best concentration for the generation of the highest yield of 
beating CMs (94% for hES Dual Reporter-CMs and 98% for hiPS Clone 7). 
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Figure 2.15: Optimization of CHIR99021 concentration for hiPS mmRNA Clone 7 (grey bars) and hES Dual 
Reporter (black bars), selected for the following experiments. (n=3; error bars indicate SEM). 
 
For the following experiments presented in this work, hES Dual Reporter 
and hiPS Clone 7 were always used and the Wnt perturbation performed using 
always 10µM CHIR99021.  
Furthermore, to make a more complete characterization and to investigate 
the uniformity of CMs population obtained and the degree of maturation, on 
day 30 cells were immunostained for two other structural markers: an 
embryo/fetal isoform of Troponin T (RVC2) and an adult isoform of Troponin 
I (Ti1).  
Cardiac Troponin relies on a complex of three regulatory proteins: Troponin 
C (cTnC), Troponin I (cTnI) and Troponin T (cTnT), which regulate muscle 
contraction. The analysis of developmentally regulated and tissue-specific 
isoforms of Troponins due to the presence of a large number of variants derived 
from different genes and/or differential gene splicing. In 1988 Schiaffino S. and 
colleagues, using a monoclonal antibody specific for cardiac Troponin T, 
obtained direct evidence for developmentally regulated isoform of the 
embryo/fetal RVC2 in rat hearts [99]. One year later, in 1989 Schiaffino’s lab 
investigated also the developmental switching of Troponin I in rat muscle and 
identified through immunoblotting and affinity chromatography procedures a 
distinct cTnI isoform expressed in the adult myocardium [100]. TnI acts by 
holding actin-tropomyosin complex in place. Because of this inhibitory action, 
myosin cannot bind actin in when the cardiac cell is relaxed. 
Immunofluorescence staining for these markers (the antibodies used were 
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kindly given by Professor Schiaffino S., University of Padova and deposited at 
Developmental Studies Hybridoma Bank, DSHB) was performed for two cell 
types: hiPS mmRNA Clone 7, hES Dual Reporter. Embryo/fetal RVC2+ve and adult 
Ti1+ve cells were quantified and the percentages are reported in Figure 2.16 with 
the related Table. 
 
 
hPSCs 
Embyo/fetal 
Troponin T+ve 
cells [%] 
Adult Troponin I+ve 
cells [%] 
hES Dual Reporter 38±4% 17±8% 
hiPS Clone 7 14±5% 2±1% 
 
Figure 2.16: Percentage of RVC2 embryo/fetal Troponin T and Ti1 adult Troponin I in day 30 CMs obtained 
from monolayer cardiac differentiation using Wnt/β-catenin modulators, (n=3, error bars indicate SEM). 
 
As reported in the graph, the hPSC-CMs expressed a higher percentage of the 
embryo/fetal isoform of Troponin T. Although with this gold standard protocol 
the cells expressed a good percentage of the adult isoform of Troponin I, it leaves 
room for improvement regarding cell maturation because it is clear from these 
results that a random differentiation toward subpopulations occurred and the 
CMs obtained are partially immature. 
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2.5.3. Flow cytometry quantification of cardiomyocytes 
After the disaggregation on day 14, the percentage of cTnT+ve cells was 
calculated by flow cytometry analysis of at least 20.000 total cells per test, using 
indirect immunofluorescence assay. From two wells of a 24-well plate, five 
samples were prepared for the quantification: 
- 2 samples, 1 composed of 1.000.000 cells and 1 of 500.000 cells, incubated 
with cTnT antibody diluted respectively 1:100 and 1:200 for each sample; 
- 2 samples as negative control, 1 composed of 1.000.000 cells and the other 
with 500.000 cells incubated respectively with 1:100 and 1:200 ßIII-Tubulin 
antibody (TUJ1, Sigma –Aldrich), a protein involved in neural 
development and costitutively expressed in neural tissues, absent in CMs; 
- 1 sample with 500.000 cells incubated only with the secondary antibody 
Alexa Fluor-488 to exclude background signals. 
All the samples were prepared using the FIX & PERM® Cell Fixation and 
Cell Permeabilization kit (ThermoFisher) that consists of matched Fixation 
Reagent (Medium A) and Permeabilization Reagent (Medium B). This kit 
facilitates antibody access to intracellular structures and leaves the 
morphological light-scattering characteristics of the cells intact. Moreover, these 
formulations reduce background staining allowing simultaneous addition of 
permeabilization medium and fluorophore-labeled antibodies.  
Cells were incubated firstly with Medium A for 15 minutes at room 
temperature and then washed with wash medium (5% FBS in PBS w/o Ca2+ and 
Mg2+). After a centrifugation, the samples were incubated with the primary 
antibody diluted in Medium B for 20 minutes at room temperature. Another 
washing with the wash medium and, after a second centrifugation, cells were 
incubated with the secondary antibody for 20 minutes at room temperature. 
Analysis were performed at Venetian Institute of Molecular Medicine (VIMM) 
of Padova on a FACSCanto™II (BD Biosciences) Flow Cytometer System, with 
the collaboration of Dr. Cabrelle A. The quantifications of cTnT+ cells are 
reported in Figure 2.17. 
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Figure 2.17: Quantitative flow cytometry analysis of 14 days CMs showed cTnT expression in the sample 
(hiPSCs mmRNA Clone 7). A. Dot-plot of the sample population. The gate-box identifies the cTnT+ 
subpopulation in the sample, based on the forward- and side-scatter intensity profile. B. Blue histograms 
represent the negative control (left panel:  secondary antibody Alexa Fluor-488 for the exclusion of background 
signals; right panel: βIII-Tubulin antibody that is absent in CMs). C. Red histograms represent cTnT 
expression in samples consisting of 1.000.000 cells (left) and 500.000 cells (right).  
 
As reported in Figure 2.17, CMs quantified by flow cytometry revealed a lower 
percentage (45 and 42%) of cTnT expressing cells, compared with cTnT positivity 
resulting from immunostaining and reported in Figure 2.14 of Paragraph 2.5.2, 
showing a need for an optimization of the sample preparation to correctly quantify 
the CMs population. In particular, it becomes important the identification of a 
disaggregation protocol that more efficiently eliminates clusters of cells that can 
interfere with the analysis at flow cytometer.  
 
 
 
 
 
C
el
l 
co
u
n
t
Negative control-Alexa Fluor 488
0%
C
el
l 
co
u
n
t
Negative control-βIII-Tubulin
0%
1.000.000 cells
cTnT+ population
500.000 cells
A
B
C
45% 42%
Chapter 2 
 
Human Pluripotent Stem Cells for Cardiomyocytes generation 
 
56 
 
2.5.4. Dual-whole cell voltage-patch clamp to study cell-cell 
communication in gap junctions conductance 
2.5.4.1. Cardiac gap junctions 
Gap junctions (GJs) in cardiac cells are responsible of the uniform coupling 
that promotes the rapid, synchronous electrical activation and initiation of 
contractions [101]. GJs are channels, that directly connect the cytoplasm of one 
cell with the adjacent one, allowing the passage of ions and small molecules 
(<1kDa). For each CMs pair, every cell contributed with a hemichannel or 
connexon, which is formed by the oligomerization of six transmembrane 
connexins (Cx or Cnx). As illustrated in Figure 2.18, these connexins are 
encoded by a family of closely related, highly conserved genes; their structure 
relies on of 4 α-helical membrane-crossing segments (M1-M4) separated by 2 
extracellular (E1 and E2) and one intracellular loop (CL). Hydrophobic amino 
acids are predominantly present in the transmembrane segments 1, 2 and 4, 
while segment 3 is characterized by an amphiphatic character because it is 
confined in the inner lining of the channel pore [102]. These transmembrane 
segments are highly conserved, whereas differences in the sequence and 
lengths of other cytoplasmic domains are unique [103]. In mammalian heart, 
Cnx 37, 40, 43, 45, 46 and 50 (numbers related to the kDa molecular mass) are 
present. 
 
 
Figure 2.18: GJ ultrastructure. A. Electron micrograph of two connected cardiac membranes. B. Freeze-
fracture electron micrograph of a GJ (round particles are channels). C. Illustration of a part of a GJ. D. 
Molecular structure of a connexin. M1-M4 membrane spanning regions, E1 and E2 extracellular loops and  
CL cytoplasmic loop (adapted from [102]). 
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Connexin 43 (Cnx 43) is the most abundant cardiac GJ protein and  promotes 
CMs electrical coupling and contractions synchronization. The above mentioned 
GJs proteins are less abundant and specifically localized in single cardiac districts. 
GJs are mainly localized at the intercalated disks level, responsible of cell-to-cell 
attachment via desmosomes, strongly connected through adherent junctions with 
actin filaments [104].   
In this work, to determine the expression of proteins involved in cell-cell 
communication, following the immunofluorescence staining against Cnx 43 
showed in Figure 2.13, the dual-whole cell voltage-patch clamp was performed to 
characterize gap junction conductance (gj) in CMs pairs. This experiment is 
described in the following Paragraph. 
 
 
2.5.4.2. Principle of the method 
The voltage patch clamp is an application enabling the measurement of the ion 
currents passing the membrane of excitable cells, such as CMs. The patch clamp 
technique is an evolution of the classical voltage clamp presented by the two Nobel 
Prize in Physiology or Medicine (1991) Neher E. and Sakmann B. in the late 1970s 
and early 1980s. The development of this functional assay allowed the recording 
of currents in single ion channel molecules, giving precious insights into the 
mechanisms involving channels in processes such as action potentials [105]. 
Principle of the method relies on the highly precise isolation of small “patch” of 
cell membrane that becomes in contact with the inner part of a glass electrode tip; 
this near-perfect isolation is achieved through the application, by a specialized 
technician, of a gentle pipette suction. In order to obtain the gigaseal, the electric 
resistance of the cell-pipette connection must exceed 1 GΩ. This electrical seal is 
established by the creation of chemical bonds between cell membrane and the 
pipette tip; with this configuration, the inside of the pipette is connected uniquely 
with cell cytosol [106]. The technician generally applies a gentle suction with his 
mouth to seal the pipette with the cell and he can also position the pipette at a 
correct distance from the cell with the help of a micromanipulator to precisely 
identify variations in the electrical resistance between the fluid inside of the pipette 
and the surrounding fluid.   
Several patch clamp configurations are possible after the establishment of the 
gigaseal: cell-attached, inside-out or, as in the case presented in this work, the 
whole-cell measurements. The widely applied configuration of the whole-cell 
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patch clamp is the analysis of voltage-operated ion channels [107]. In the 
voltage clamp mode used in this thesis, the recorded signal is the 
transmembrane junctional current and the controlled input is the clamped 
membrane voltage delivered to the cells examined.  
 
 
2.5.4.3. Junctional current measurements in a cardiomyocytes pair 
This functional assay was performed at the Venetian Institute of Molecular 
Medicine (VIMM) in Padova with the collaboration of Professor Bortolozzi M., 
in his ad hoc equipped laboratory. In fact, to record and measure current flowing 
through gap junctions (Ij) of a CMs pair, the following instruments are 
necessary, as described by Hernandez V. and Bortolozzi M. and co-workers in 
2007 [108]: an inverted microscope (BX51, Olympus) for positioning the patch 
pipettes; a pneumatic table to isolate the system from mechanical vibrations;  a 
Faraday cage providing electrical noise isolation; a perfusion system to deliver 
the different solutions used and to remove debris and/or dead cells through 
glass capillaries; these capillaries were fabricated on a vertical puller (PP-83, 
Narishige) with 1,5mm outer Ø borosilicate glass (Warner Instruments) and 
filled with an intracellular sterile solution (the composition of ICS, intracellular 
and ECS,  extracellular solutions used in this experiment are reported in Table 
2.4 A and B); two patch clamp amplifiers (LIST EPC7); a pulse generator with 
at least two output channels; a pair of micromanipulators; an oscilloscope; a 
data acquisition software and data recording computer. 
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Table 2.4: Composition and concentrations of: (A) intracellular solution (ICS) and (B) extracellular solution 
(ECS) used for the Dual whole-cell patch-clamp measurement of gap junction conductance between a pair of 
hPSC-derived CMs. 
A. ICS 
Intracellular Solution (ICS) mOsM 300; pH 7,2 
Name Weight (g/mol) 
Molarity 
(mM) 
Molality (g/L) 
K-ASP 171,20 120 0,517 
KCl 74,56 20 0,037 
MgCl2-6H2O 203,30 1 0,005 
Cacl2 110,99 1,7 0,0047 
ATP-K 583,35 10 0,095 
EGTA 280,35 10 0,095 
HEPES 238,31 10 0,060 
Adjusted to pH 7,2 with KOH 
 
B. ECS 
Extracellular Solution (ECS) mOsM 320; pH 7,4 
Name Weight (g/mol) 
Molarity 
(mM) 
Molality (g/L) 
NaCl 58,44 135 7,90 
KCl 74,56 5 0,40 
CaCl2 110,99 1,5 0,16 
MgCl2-6H2O 203,30 1,2 0,24 
HEPES 238,31 20 4,77 
Glucose 180,20 10 1,80 
Adjusted to pH 7,4 with NaOH 
 
The experiment was performed at room temperature. 
Glass slide seeded with hPSC-derived CMs was transferred in a 35mm Petri 
dish (BD Falcon) and cells were perfused with 2ml/min ECS. Patch pipettes were 
filled with ICS and pipettes resistances were 3-5MΩ when immersed in the bath. 
To measure junctional conductance (gj), a CMs pair was identified and each cell 
was maintained under whole-cell patch-clamp conditions with one of the two 
amplifiers and kept at the same holding (or resting) potential (Φh) of ~ -70mV (-
70,8mV) [108]. 
A first 10mV voltage step (Figure 2.19 A and B) was applied by Bortolozzi M. 
simultaneously to both patch pipettes to monitor cell parameters; then, to elicit 
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junctional current (Ij) from cell to cell, five consecutive 10mV voltage steps were 
applied in cell 1 and cell 2 separately. 
To detect single gap junction channel events and thus measure the unitary 
conductance, the superfusion medium was transiently switched to ECS 
saturated with 100% CO2 to produce carbonic acid (H2CO3). In fact, gj between 
CMs pair is rapidly, substantially and reversibly reduced by sarcoplasmic 
acidification after CO2 treatment, as demonstrated by White R.L. and 
collaborators in 1990 [109]. When it is in the undissociated form, H2CO3 is able 
to permeate the cell membrane, causing a rapid closure of gap junction 
channels. The reopening of GJs connecting the two adjacent CMs was possible 
following a rapid wash-out by normal ECS (or NS, normal solution) with cells 
recovered from cytoplasm acidification, as reported in Figure 2.19 C. This 
functional assay demonstrated that the CMs obtained with this gold standard 
protocol in conventional cultures, showed functional features such as the 
presence of junctional current which responds to external stimuli. 
 
Figure 2.19: A and B: a first 10mV voltage step (top traces) was applied simultaneously to both patch pipettes 
to monitor cell parameters, followed by five consecutive 10mV steps applied separately to elicit junctional 
currents (bottom traces) from cell 1 to cell 2. C. Extracellular application of CO2 to HEPES-buffered normal 
ECS (or NS, normal solution) rapidly and reversibly acidified the cytoplasm and abolished junctional currents. 
Following a rapid wash-out by NS, stimulated re-opening of GJs connecting the two adjacent CMs. D. Plasma 
membrane currents were also observed to have similar behaviour after CO2 application, likely due to 
hemichannel closure (data not shown). 
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2.6. Conclusions 
During this thesis, the protocols and methodologies for hESCs and hiPSCs 
culture, maintenance and expansion were acquired and 2 hESCs line and 4 hiPSCs 
clones were successfully cultured and characterized, demonstrating that all the 
hPSCs used are bona fide pluripotent stem cells.  
Beating CMs were obtained in standard cultures from hPSCs by the application 
of a robust and consistent protocol that is currently considered the gold standard 
for the generation of cardiac cells from pluripotent stem cells. In fact, by the 
temporal administration of these small molecules, CHIR99021 and IWP4 to 
modulate canonical Wnt/β-catenin pathway, a high yield of CMs was successfully 
obtained, ranging from 63% to 98%. The contractions started between 8-14 days, 
depending on the cells. 
To precisely monitor the progression of cardiac differentiation of hPSCs, from 
pre-cardiac progenitors to CMs formation, a hES line, Dual Reporter for 2 cardiac 
TFs, MESP1 and NKX2.5, was used and showed a great cardiogenic ability. 
Two hPSCs emerged for their ability to give the highest yield of CMs: hES Dual 
Reporter line and hiPS Clone 7, that were selected for the following experiment 
described.  
To perform an optimal Wnt modulation, as suggested by S. Palecek [63], among 
the [CHIR99021], ranging from 6-12µM, 10µM was identified as the best 
concentration which gave the highest percentage of cTnT+ve cells from the 2 hPSCs 
selected. 
Next, a deep characterization of CMs obtained was performed: the expression 
of cardiac markers was assessed with standard cell imaging technique; a first 
quantification attempt was performed with flow cytometer and the functional 
assay patch clamp was adopted to study cell-cell communication. CMs expressed 
typical nuclear and structural markers, with marked sarcomeric organization. 
Cell-cell communication analysis showed also the presence of junctional current 
between a CMs pair, which responds to external stimuli. 
However, from the immunofluorescence staining against the embryo/fetal 
troponin T isoform and the adult isoform of troponin I, a higher percentage of cells 
expressing the embryo/fetal troponin T emerged, revealing their partially 
immature phenotype. CMs expressed also a good percentage of the adult isoform 
but these findings indicate the presence of a heterogeneity of CMs, with the 
differentiation toward random subpopulation, leaving room for improvement 
regarding cell maturation.  
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This Chapter reviews the microfluidic technology for cell culture in 
Regenerative Medicine applications, highlighting the state of the art and the 
related properties and advantages deriving from the convergence of micro-
engineering technologies with cell biology. By integrating cell cultures within ad 
hoc microfluidic devices it is possible to derive cost-effective in vitro models of 
relevant human diseases and to perform parallelized, multi-parametric analysis or 
drug screening assays at one time. Moreover, microfluidics opens the perspective 
for the development of “tissues- and organs-on-a-chip”, reconstructing tissue 
arrangements and complexity more close to cell microenvironment. 
In this Chapter, microfluidics was exploited to precisely drive the cardiac 
differentiation of hPSCs with high efficiency, exploring the ability to control hPSCs 
integration, expansion and differentiation into functional CMs. Since hPSCs 
differentiation into functional tissue-specific cells requires multi-stage process in 
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which exogenous and endogenous factors balance plays an important role, the 
optimal frequency of medium delivery and MRF concentration were 
investigated and identified, allowing proper functional differentiation of hPSCs 
to CMs. 
 
 
3.1. Microfluidic technology for cell culture in regenerative 
medicine research: state of the art 
10 year ago it was reported in literature that microfluidics (µF) can 
revolutionize significantly the way modern biology is conduced [110][111]. This 
optimism was warranted by the advantages of microfluidics over traditional 
cell biology assays in standard culture systems. In fact, in biology research, 
microfluidics could be used to: accelerate complex assays; dramatically reduce 
volumes and consequently the costs of research materials and reagents; perform 
parallelized, high-throughput experiments without consumption of precious 
samples and  enable a  more precise spatio-temporal control and predictability 
of the cell microenvironment [112][113]. In fact, the miniaturization of culture 
settings in microfluidic devices enables the creation of a highly controlled 
environment for the study of cell-cell and cell-extracellular matrix (ECM) 
interactions, with real time observation and analysis. The possibility to perform 
studies at single-cell level can help understanding the knowledge on stem cell 
niche to preserve cell stemness and to program cell fate[114][115]. As opposed 
to conventional culture systems, which uses a huge number of cells, 
microfluidics approaches allows to perform experiment at single-cell level 
where individual cells can be isolated from a starting population and trapped 
into ad hoc structure [4]. Microfluidic devices have found applications in the 
following cell-based in vitro systems: single cells studies, cell monolayers, cell 
tissues and organ-like models also named as “organ-on-chip” 
[4][114][116][117]. As deeply reviewed by Luni C. et al of our BioERA group in 
2014, the term “organ” is used to describe the tailoring of microenviroment 
architecture derived from studies on organ-level functions observed in vivo, 
whereas “chip” refers to the techniques for the design and microfabrication of 
microfluidic platforms [118]. Figure 3.1 summarizes the applications of µF in 
regenerative medicine. 
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Figure 3.1: Microfluidics for regenerative medicine (adapted from [4]). 
 
Governmental authorities are promoting the research that applies microfluidics 
for in vitro tissue-based models-on-a-chip because of the flexibility, reliability, and 
accessibility of these tools to a larger number of research groups. An example is 
given by the European commission that promotes “The body on-a-chip” project 
and the partnership between the principal medical research centers such as the 
National Institute of Health (NIH), Food and Drug Administration (FDA) and 
Defence Advanced Research Projects Agency (DARPA) that are collaborating for 
the realization of platforms for the study in vitro of in vivo human multi-tissue 
physiology (from circularoy system to musculoskeletal apparatus) [118].  
Three main sources of human biological material can be used for the organ-on-
chip studies: ex vivo biopsies; primary cells and hPSCs. Biopsies and primary cells 
best reflect the environment-related diseases because they retain the cellular in vivo 
phenotype. However, they are characterized by scarce availability, isolation 
difficulties and inability to sustain a long-term culture in vitro. Primary cells are 
derived from biopsies and they can be maintained in culture for a longer timespan 
but, to preserve their in vivo properties, they require a topological organization, 
such as the recreation of organ-like architecture with bioprinting 
technologies[118][119]. Finally, the third source is represented by tissues derived 
from hPSCs, hiPSCs in particular, because they represent an inexhaustible source 
of human cells, able to differentiate into any tissue in the body. Moreover, hiPS can 
be derived from skin biopsies and with other less invasive procedures such as 
blood or urine [91], opening the way for personalized therapy design (Figure 3.2). 
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Figure 3.2: The three major biological sources for organ/tissue-on-chip development. Bioptic tissue (left) and 
primary cells(center) are difficult to be maintained in culture and require the reconstruction of the in vivo 
topological organization. hPSCs can differentiate into any tissue of the body (adapted from [118]) 
 
One of the first work using a miniaturized PSCs culture was published by 
Figallo E. and co-workers in 2007 and described the ability to culture hESCs for 
4 days into a specific micro device [120], while Wan C.W. et al. in 2011 
performed cardiogenesis of murine ES-derived EBs in a microfluidic device 
[121]. However, few works demonstrated the ability to differentiate PSCs 
within a microfluidic platform toward multiple lineages such as CMs 
[118][120].  
To conclude, by combining cellular systems with specific microfabricated 
structures, our BioERA laboratory, have been able to create sophisticated 
models that emulate the organ architecture, in particular generating functional 
hepatocytes and cardiomyocytes with high efficiencies [94]. It is important to 
underline that the creation of organ-on-chip models enables the reconstruction 
of the organ microenvironment offering a powerful tool to study human 
physiology and pathophysiology with unprecedented control over the culture 
conditions, avoiding or limitating animal experimentation [118][122][123]. 
In this work, µF was exploited to drive the cardiac differentiation of hPSCs 
in an unprecedented and high controllable microenvironment, aiming at the 
implementation of the culture conditions during the differentiation with a high 
efficient and precise delivery of components (small molecules and/or 
transcription factors, TFs). With the miniaturization of the entire culture system 
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and more reproducible conditions, in fact, a real-time control over the 
differentiation process is possible, lowering the intra- and inter-experimental 
variability observed when using conventional systems. Downscaling the culture 
settings with µF, best mimics the in vivo cellular dynamics occurring in a a tiny 
soluble environment and in little time interval, enabling high-throughput 
experiments not achievable and not economically sustainable with macroscopic 
conventional cultures [118][94]. 
This Chapter will explore the ability to control hPSCs integration, expansion 
and differentiation into functional CMs through a microfluidic-based process. The 
microfluidic-aided cardiac differentiation of hPSCs will be further discussed in 
Chapter 4 with the association of the synthetic modified mRNA technology for 
programming hPSCs fate at the microscale with specific cardiac TFs. 
 
 
3.2. Properties and advantages of microfluidics for cell culture 
in a high controllable microenvironment 
Cells live in a milieu composed of soluble factors, cell-matrix interactions and 
cell-cell contacts within an environment with specific physicochemical properties 
given by pH, oxygen, tension, temperature and osmolarity. These elements 
cooperate for the regulation of cell structure, function and behaviour, influencing 
the growth, development and repair of tissue. The combination of these 
biochemical, physical and physiochemical factors make up the cell 
microenvironment and, for stem cells, it is called stem cell niche,  indispensable for 
the regulation of stem cell survival, self-renewal and differentiation [124][125]. As 
mentioned before, in order to improve quality of the regenerative medicine 
research models, it is important to both mimic the cell biological 
microenvironment, which presents a high level of confinement, and to reach a high 
level of tissue/organ complexity [4]. Microfluidics, with his miniaturized 
dimensions, determines a high level of confinement, which resembles the milieu 
cells experience in vivo. Compared to standard cultures, microfluidics is 
characterized by a convection-free culture system enabling the local accumulation 
of autocrine-paracrine substances secreted by cells, offering the possibility to 
automatize the culture and perform parallelized analysis[4][126].  
Moreover, the downscaled culture support is characterized by a higher 
surface/volume ratio, compared with large conventional cultures, offering a more 
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precise control over the physical parameters (e.g. temperature or gas 
concentrations in solution) [4][127] and for the delivery of transcription factors 
when performing reprogramming experiments. In fact, in 2016, Luni C. and 
Giulitti S. in our BioERA laboratory demonstrated the ability to perform cell 
reprogramming of human fibroblasts for the generation of hiPS clones with the 
highest efficiency reported to date using a microfluidic platform (50-fold higher 
than other published works). They delivered the pluripotency factors as 
synthetic modified mRNA with daily transfections, the same approach adopted 
in this thesis to generate CMs from hiPSCs (described in Chapter 4); thanks to 
the scaling down of the system, there is an optimal balance between 
endogenous factors and the transfected exogenous ones during cell 
reprogramming process. These advantages offer consequently reduced 
consumption of reagents with significant costs reduction, reduced 
contamination risk and efficient throughput experimentation [95].  
The fluid dynamics at the microscale is markedly different from those 
characterizing the macroscale; for example, the gravity force effects are 
dramatically reduced in microfluidics while surface tension and capillary forces 
are dominant in miniaturized systems [110]. Furthermore, the laminar character 
of the flow in microchannels offer new experimentation configurations, not 
achievable in conventional culture systems such as the possibility to perform 
dynamic cultures with cells under continuous perfusion of fresh medium with, 
for example different flow composition or with the contemporary application 
of biologically relevant shear stresses[115][128].  
In fact, thanks to the laminar flow of medium, microfluidics allows the 
generation of precise gradients, mimicking the chemical signals cells experinece 
in vivo during embryogenesis as well as during the processes of regeneration 
and wound healing: gradients of morphogens elicit cell recruitment and 
stimulate ECM deposition[4][129].  
Cells are also influenced by the mechanical properties, with variations of 
stiffness/softness, of the substrate in which they are put to grow. The first 
microfluidic systems were initially realized in rigid materials such as silicon 
and glass; however, these materials required long production procedures and 
specific cleanroom spaces. Because of the opacity of silicon to visible and UV it 
is impossible to use it with common microscopy equipment. Glass and silicon 
are too fragile and require difficult, long and expensive production protocols. 
Between 1970s and 1980s new elastomeric micromoulding techniques, using 
polymer materials, were developed by Bell Labs [130]: these polymers could be 
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photo-curable such as such as SU-8 epoxy, polyimide photoresist, or heat- curable 
such as the polydimethylsiloxane (PDMS) [110], thermoplastics such as 
polymethylmethacrilate, polycarbonate, polystyrene (PS), cyclic-olefin-
copolymers, or Teflon® [131]. These elastomeric materials allow great flexibility 
and customization in microfluidic platforms design, taking into account the 
precise requirements of the cell types studied [132]. PDMS [(CH3)2Si-O] has two 
methyl groups attached to the silicon and, as a typical feature of all silicones, it is 
able to cross-link after the addition of a curing agent containing a catalyst, usually 
platinum. In this PhD thesis, PDMS has been used for the fabrication of 
microfluidic devices thanks to its ease to mould without the need of dedicated 
cleanroom environment and because it is cheap, inert, biocompatible, gas- but not 
fluid-permeable, optically transparent, allowing the observation of microchannels 
contents visually and through a microscope [133]. After a simple plasma treatment 
it is possible to tightly bond PDMS to a glass slide or another PDMS layer for the 
production of multilayers PDMS devices.  
Figure 3.3 describes the most significant advantages and challenges when using 
macroscopic versus microfluidic cell culture. 
 
 
Figure 3.3: Pros and cons of both macroscopic and microfluidic cell culture (modified from [132]). 
 
Integrating cell cultures in microfluidic devices requires experience and 
accurate knowledge of the fundamental principles of cell biology, biochemistry, 
physics and engineering.  
Macroscopic cell culture Microfluidic cell culture
Typical advantages Typical advantages
• Established culture material
• Standardized measurements
of pH, CO2 and O2
• Established culture 
protocols
• Standardization and 
availability of assays
• Ability to scale up a single 
experiment
• Flexibility of design device
• Precise flow control 
• Low number of cells required
• High-throughput platform
• Real-time on chip analysis
• Possibility of automation
• Direct coupling to downstream 
analysis systems
• Ability to perform perfusion
cultures
• Reduced reagent consumption
• Cost effective
Typical challenges
Typical challenges
• Rigid culture surface
• Fixed device architecture
• High reagent consumption
• Perfusion and chemical
gradients are difficult to 
achieve
• No fluid control (static or 
chaotic)
• Mainly end-point analysis
• Non-standard culture protocols
• Novel culture surfaces (e.g. PDMS)
• Complex operational control and 
chip design
Cell culture maintenance
µF device
Cell culture plate
Live-cell imaging, 
real-time on chip 
analysis
End-point analysis
Chapter 3 
 
Microfluidic technology for cardiac differentiation of hPSCs 
 
70 
 
First, in order to develop in vitro models more closely to the conditions in 
which cells reside in vivo, it is necessary to know and study the key elements of 
the cellular microenvironment. Second, it is imperative to have a strong 
experience in cell culture techniques to facilitate the translation from macro- to 
microscale. Third, it is indispensable to have a complete background in 
microfluidics and its state of the art in order to properly design these tools for 
the required applications [4][111][124]. 
In conclusion, since culturing and expanding hPSCs at the macroscale is 
considerably expensive compared to other cell types, the miniaturization of 
volumes for culture reagents provided by microfluidic technology can 
guarantee a new system to match the precise requirements of hPSCs in a cost-
effective manner.  
 
 
3.2.1. Facing the soluble control and medium perfusion challenges in 
microfluidic cell cultures 
Although microfluidic posseses several advantages, as described in the 
previous paragraph, translating cell cultures from the macroscale of standard 
dishes, flasks and well-plates to microfluidic devices, requires an adaptation of 
current culture protocols. Microfluidics, compared with standard culture 
systems, is characterized by reduced media volumes and different frequencies 
and methods for medium refresh.  
It is known that PDMS is permeable to gases such as ambient CO2 and O2 , 
allowing to properly buffer the culture medium; however, it is  also permeable 
to water vapour, with subsequent drying problems and significant shift in 
medium osmolarity [134]. In macroscopic cell culture, medium is typically 
stagnant, with excess amounts of nutrients diluted in order to feed cells for 
several days, depending on cell type, cell number and seeding density. On the 
contrary, microfluidic systems enables medium to flow within the 
microchannels to create a more realistic cell microenvironment by continuous 
supply of fresh media with the contemporary removal of waste products [135]. 
However, the microfluidic cultures present their own challenges. 
In vivo cells are continuously subjected to many stimuli coming from 
endogenous soluble paracrine and autocrine factors (EnF) released by 
neighbouring cells and by the cell itself respectively; the exogenous factors 
(ExF) are represented by those delivered with the culture medium. 
Chapter 3 
 
Microfluidic technology for cardiac differentiation of hPSCs 
 
71 
 
Furthermore, cells also require and consume energy sources (glucose, glutamine 
and amino acids) and produce metabolic waste (CO2 and lactate). A typical 
microfluidic channel contains a high number of cells to media volume, to better 
recreate the in vivo cell density. On the contrary, in a conventional Petri dish, 
medium is usually changed every 1-4 days and, for hPSCs culture and expansion, 
it is suggested a daily medium refresh to prevent the accumulation of toxic signals 
and stimulate cells with fresh factors [124]. In fact, deprivation of nutrients and 
accumulation of waste products can elicit cell death or induce unwanted 
differentiation of the stem cell population. This 24 hours cycle in hPSCs medium 
replacement in standard culture is necessary to:  
- provide the necessary volume to cover the entire culture surface;  
- reduce the concentration of medium components due to evaporation at 
37°C; 
- provide a correct supply of nutrients for the high-demanding hPSCs; 
- dilute waste products and debris. 
 
Although microfluidics offers the advantage of delivering, with a homogeneous 
distribution, tiny amounts of media over a cell layer with high spatiotemporal 
control, translating a cell culture in a microfluidic chip, would correspond 
approximately to a total medium exchange frequency every 2-4 hours [124]. For 
this reason, it is mandatory careful validation experiments and feeding schedule 
calibrations for every device and cell type used. In Figure 3.4 is reported a 
schematic of cell niche with the combination of biochemical, physical and 
physicochemical factors (A) and a comparison of cell environment and medium 
usage between conventional dishes and microchannels in emerging microfluidic 
technology (B and C). 
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Figure 3.4: Cell niche and comparison between conventional cell culture environment and a microchannel. A. 
Cell niche is a microenvironment, which regulates cell fate. Intrinsic signals, and extrinsic factors (cells 
interactions, adhesion molecules, extracellular matrix, GFs, cytokines and waste products) and exogenous 
molecules like provided nutrients, interact with cells.  In vivo, chemical signals are in the form of gradient, with 
the characteristics of a laminar flow. B. Longitudinal section of a conventional Petri dish (left) and a channel 
of a microfluidic chip (right). A standard 35-mm-wide Petri dish requires 2ml ( ̴ 2000µm height) while a 
microfluidic chip provides medium exchange into the channels in a range of 100 to 200µm, approximately 1/10 
of the 35-mm-wide Petri dish. C. Magnification of microenvironment recreated in vitro at cell layer level with 
the biochemical signals (cytokines, hormones) and waste products important for cell functions. A correct 
medium replacement frequency is necessary to avoid nutrient depletion and waste accumulation. Excessive 
evaporation of O2, CO2 and H2O must be avoided to maintain the correct osmolarity and cells viability. The 
laminar character of the flow at the microscale generates a precise gradient, supplying fresh nutrients while 
washing out waste products and debris. In standard cultures these events happen with convective and turbulent 
flow, not observed in molecular transport in vivo (modified from [95]) .  
 
 With computational modeling and experimental testing, in our BioERA 
laboratory, Giulitti S. and co-workers in 2013 developed an optimal medium 
replacement strategy for long-term culture of mouse embryonic stem cells 
(mESCs) within microchannels of a PDMS microfluidic device. They tested 
different flow rate, constant, as well as periodic replacement of medium, and 
reported that slow, continuous perfusion produced deleterious effects on cells 
while periodic replacement of 8 hours fast pulses of the same media volumes, 
resulted in uniformly healthy cell growth and survival. This was attributed to 
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the heterogeneous distribution of nutrients (higher concentration upstream) 
versus endogenous factors and waste (higher concentration downstream) in 
slowly perfused culture channels. They concluded that medium delivery strategies 
are extremely relevant for proper maintenance of cell homogeneity, viability and 
behaviour in microfluidic cell culture (Figure 3.5) [136]. 
 
 
Figure 3.5: Effects of two different strategies of medium perfusion on mESCs performed by Giulitti S. et al. A. 
Constant flow rate of fresh medium. B. Periodic medium perfusion in a defined time interval (8 hours). Bright 
field, live green fluorescent protein reporter (GFP) and immunofluorescence (IF) analysis of pluripotency 
markers (NANOG-GFP, SSEA-1). After 6 days of culture, IF analysis for pluripotency markers demonstrated 
that with periodic medium replacement (B), cells maintained pluripotency with a homogeneous distribution of 
compact pluripotent colonies. On the contrary, constant flow rate (A), showed heterogeneous and reduced 
expression of the analysed markers. Scale bars 600µm; (adapted from [136]). 
 
 
3.2.2. Effective Culture Time (ECT) for liquid handling at the microscale 
Since microfluidic channel relies on few microliters of liquid volume and cells 
need fresh nutrients before their depletion and waste products accumulation, new 
fresh culture medium must be supplemented in the chip with a proper refresh rate, 
higher than conventional culture systems with lower surface/medium volume 
ratios. Specifically, the maintenance of cell cultures at the microscale relies on 
media changes at regular time intervals, and failure to do so usually leads to low 
cell viability and poor quality of cultures. A great challenge when culturing cells 
in microchannels is the identification of the ideal time interval for medium refresh. 
To solve this issue Young E.W.K. and Beebe D.J. in 2010 introduced the concept of 
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the Effective Culture Time (ECT) [124], comparing the time scales of standard 
dishes and microfluidic platforms. In a macroscopic culture system, cells grow 
on a surface of area A, in a culture medium with volume V. The medium at the 
air-liquid interface in standard cultures possesses a height on cell layer of 
h=V/A, corresponding to the channel height in confined microchannels. Height 
h represented the characteristic length for microfluidic channels because length 
and width are larger than h, and h represents the limiting dimension for 
diffusion. When the key biochemical factors in the medium become exhausted, 
it is necessary a medium exchange. The time interval between every medium 
refresh is the ECT above mentioned and it depends on: (1) starting nutrients 
concentration C0, (2) cell uptake rate of nutrients Km, (3) nutrients diffusivity D, 
cell density σ, culture area A and medium volume V. These parameters are 
connected by the Damkohler number, here explained: 
𝐷𝑎 =
𝐾𝑚ℎ𝜎
𝐷𝐶0
 
 
Da is a parameter without dimension for the measurement of the ratio 
between reaction and diffusion time scales and can be reformulated as: 
𝐷𝑎 = (
ℎ2
𝐷
)/(
𝐶0ℎ
𝐾𝑚𝜎
) 
Where the numerator indicates time scale for diffusion τd=h2/D, and the 
denominator is the reaction time scale τr. In microfluidics, h is usually one fifth 
to one tenth smaller than standard supports, so Da is up to an order of 
magnitude lower in microchannels. Since τr corresponds to ECT in diffusion-
dominant systems and τr is linearly proportional to h, the ECT is scaled to the 
height of the microchannel. For example, a typical conventional culture Petri 
dish of A ̴  80cm2 has a medium V  ̴  10ml, with a medium height of h ≈ 1,2mm. 
The height of a microfluidic channel is usually h=200µm, as a consequence, the 
ECT is  ̴ 6 fold lowered, suggesting that medium should be replaced every 8h to 
maintain the same culture conditions [124]. This observation is in agreement 
with the experiments conducted by Giulitti S., who optimized medium 
exchange intervals in microchannels, indentifying an ECT of 8 to 12h 
(maximum). See Paragraph 3.2.1 for details [124][136]. 
Depending on cell requirements and microfluidic design, refresh rate of 
culture medium and liquid handling in our laboratory can be performed: 
 automatically, through CAVRO syringe pumps XLP6000 (obtained 
from Tecan) connected via serial ports to a computer and the 
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applications are written in LabVIEW (National Instrument) software 
in order to operate scheduled medium delivery; 
 manually with a pipette, by the same operator, at time interval of 12h 
through the passive pumping. 
 
Syringe pumps are the most common delivery system employed in 
microfluidics: in the BioERA laboratory, CAVRO pumps are integrated with a 
multiport head to make every parallel channel independent. LabVIEW software 
possesses a user-friendly interface to automatically set-up experimental 
parameters such as frequency of medium changes per day. In Figure 3.6 is reported 
an automated PDMS microfluidic device used in the lab. 
 
 
Figure 3.6: Representation of a microfluidic platform in which every independent chennel outlet has a Tygon 
tublings connected to a syringe pump. A LabVIEW interface software developed in the laboratory (left) 
performs periodic perfusion of medium automatically. A complete automatized microfluidic chip is modelled on 
the right (adapted from [136]). 
 
When the number of medium change operations are too frequent, the 
automation of liquid handling is necessary to reduce possible errors by operators 
(e.g. vehicle contamination, removal of chip from the incubator with loss of 
temperature and gases…). 
An alternative and simple method of fluid replacement is passive pumping and 
communicating vessels principle. First developed in 2000by Beebe D. group, it 
relies on the surface tension of different-sized droplets placed at the inlet and 
outlet ports that drive fluid from one port to the other [137]. The difference in 
droplet volumes induces a differential pressure between ports that generates flow 
in the microchannel [124][138]. Figure 3.7 illustrates a schematic of the principle.  
 
Chapter 3 
 
Microfluidic technology for cardiac differentiation of hPSCs 
 
76 
 
 
Figure 3.7: Passive pumping. A smaller droplet with radius Ri at the inlet has an internal pressure Pi  greater 
than one possessed by the larger droplet with radius R the outlet. This phenomenon depends on Laplace’s law 
(∆P=2γ/R.  ∆P pressure difference at the droplet liquid-air interface; γ interface the surface tension; inspired 
from [124]). 
  
The major advantages of passive pumping are the low cost and the 
possibility to be performed without connecting to external pump, eliminating 
the need for tubing and interconnections at the ports. Passive pumping can be 
performed simply manually by pipetting the appropriate volumes.  
 In this PhD work, medium refresh was always performed manually at 
regular time interval of 12h. 
 
 
3.3. Microfluidic platform fabrication  
Microfluidic devices used in this work were fabricated by standard soft-
lithography technique, using the know-how of our BioERA laboratory and well 
described in the work of our colleagues [94][95]; in our laboratory, different 
types of microfluidic platforms are fabricated, with different characteristics, 
depending on the application of every research topic. Soft lithography 
comprises a set of microfabrication techniques for printing and moulding 
elastomeric stamps with the patterns of interest in bas-relief. As a technique for 
fabricating microfluidic devices for cell biology research, soft lithography 
overcomes many limitations of photolithography. In particular, with soft 
lithography it is possible to pattern biological relevant complex molecules, as 
well as cells and to fabricate channel structures suitable for microfluidics. In 
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biology, the production of prototype patterns and structures is convenient, cheap 
and rapid [139]. 
An elastomeric stamp made in polydimethylsiloxane (PDMS) is prepared 
through replica molding by casting a liquid prepolymer and a curing agent 
solution (Sylgard 184 from Dow Corning) onto a premade master with patterned 
relief structure on its surface (Figure 3.8). 
 
 
Figure 3.8: Preparation of polydimethylsiloxane (PDMS) 
microfluidic chip using replica molding and pattern 
transfer by microcontact printing. 
 A. Photoresist exposure to UV light on a silicon wafer (Si-
wafer) support through a photomask or master. Tthe cured 
photoresist remains on the silicon support in a bas-relief 
pattern defined by the master. 
 B. PDMS (Sylgard 184) is used as the elastomer (curing 
is for 2h at 70°C). 
C. After baking, PDMS stamp can be peeled off. 
 
When masters features size is greater than or equal to 20µm, patterns can be 
drawn in AutoCAD® and printed onto polymer sheets, through commercially 
available printers. Photomasks are used for selectively polymerizing UV-sensible 
photoresists, previously spun onto a silicon wafer with defined film-thickness. The 
viscosity of the photoresist as well UV-light intensity and baking time should be 
considered for a selective polymerization of the desired structure. As mentioned 
before in Paragraph 3.2.1, PDMS is chemically inert making microfluidic platform 
employed in this work biocompatible, and is also highly permeable to gasses (O2, 
CO2, N2 diffuse rapidly) but not to fluids, allowing fast equilibration time in 
standard cell culture incubators. It is transparent, for detection analysis 
instruments like fluorescence microscopy, and allows long-term experiments to be 
performed. However, appropriate surface functionalization is required for 
culturing adherent cells such as hPSCs. In fact, PDMS surface properties can be 
rapidly modified by plasma treatment: air or oxygen-based treatments lead to the 
formation of OH-groups, which permit covalent bonding between the stamp and 
glass slides or another PDMS substrate. 
Each microfluidic device contains 10 parallel channels (18mm long, 1,5mm wide 
and 0,2mm high, Table 3.1). Photomask shown in Figure 3.8 and 3.10 (A), was 
designed in AutoCAD® by the engineers of the laboratory (Michielin F., 
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Prevedello L.,  Giulitti S., Zambon A., Gagliano O.), printed onto a transparent 
polymer sheet and photolithographically patterned onto a silicon wafer (Si-
wafer) with SU8-2100 negative photoresist (MicroChem), to obtain a final 
thickness of 200µm, according to manufacturer instructions. The master was 
then treated with hexamethyldisilazane (HDMS) at room temperature for 1 
hour under vacuum, in order to facilitate extraction of PDMS mould from 
silicon wafer. A 10:1 solution of PDMS pre-polymer and curing agent was cast, 
cured and baked in an oven for a precise time interval. In fact, various baking 
times are possible: 15 hours at 45°C,  2 hours at 70°C  or 1 hour and a half at 
85°C. PDMS mold was cut and peeled off from the Si-wafer, punched to obtain 
liquid inlets and outlets with circular steel punches (Small Part Inc.) and finally 
sealed to a previously cleaned glass slide (Menzel-Glaser) by plasma bonding 
with plasma cleaner (Harrick Plasma) for 2 minutes at 30W (Figure 3.9). The 
ionization of gas within the plasma cleaner produces reactive oxygen species 
(ROS) that form oxidized activated species on the exposed surfaces treated. Two 
activated surfaces put in contact lead to the formation of stable chemical bridges 
between glass/PDMS and PDMS/PDMS 
 
 
Figure 3.9:  
Fabrication of a microfluidic device. 
 1. The master mold enables mass-production of microfluidic 
chips.  
2. A 10:1 solution of PDMS pre-polymer (liquid) and a 
crosslinking agent (to cure PDMS) is casted into the mold 
and heated at 70°C for 2h. 
 3. PDMS is peeled off from the mold.  
Microfluidic device completion.  
4. To allow the injection of fluids, the inlets and outlets of the 
microfluidic device are punched with a puncher of the desired 
size.  
5. Plasma treatment of the face of PDMS block with 
microchannels and the glass slide.  
6. The plasma treatment allows PDMS and glass sealing to 
close the microfluidic platform (modified from [140]). 
 
 In Figure 3.10 (A-E) is shown the complete microfluidic platform made of 
PDMS on a glass surface.  
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Figure 3.10: Microfluidic platform for cell cultures integration. A. Photomask with microfluidic channels. B. 
Schematic of microfluidic platform assembly of the three layers: PDMS reservoirs, PDMS channels and glass 
slide. C. Tridimensional representation of completed and assembled microfluidic platform with 10 independent 
channels and medium reservoirs at the outlet of the microchannels with the related dimensions. D. Longitudinal 
section of a microchannel with the geometrical characteristics. E. Picture of completed microfluidic device used 
in this work. 
In Table 3.1 are summarized the geometrical characteristics of the device. 
Table 3.1: geometrical features of microfluidic device. 
Microfluidic channel 
dimensions 
Height 0,2mm 
Width 1,5mm 
Lenght 18mm 
Area 27mm2 
Effective Vol. 5,4µl 
Total Vol. 12µl 
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Before cell culture integration, microfluidic devices were rinsed with 
isopropyl alcohol and sterilized in autoclave, to prevent bacterial 
contaminations. Glass surface has to be opportunely functionalized with 
Matrigel Reduced Factor (MRF) in order to promote cell adhesion, survival and 
growth.   
 
 
3.4. Cell culture integration into microfluidic platform 
As mentioned in previous paragraphs, efficient cell culture integration into 
microfluidic devices can be achieved through proper supply of nutrients along 
time. 
Part of the research conducted during this PhD is focused on optimizing the 
best condition for both hESCs and hiPSCs culture, expansion and 
differentiation into microfluidic device to obtain a robust long-term cell culture 
platform over several days. The cultivation over this timespan will be 
fundamental in order to perform the cardiac differentiation and the cardiac 
programming via transcription factors processes at the microscale; a minimum 
of two weeks for these experiments is required. 
Cell culture in microfluidics is similar to traditional multiwells, concerning 
the type of medium and reagents used; the unique variables are volumes 
handling and procedures. When using microfluidics, any type of liquid could 
be injected or fluxed within the channels. In particular, if the channel is empty, 
the solution is injected directly from channel inlet while, if only liquid refresh 
is required, it’s sufficient to put a droplet of the solution on the inlet and thanks 
to passive pumping and communicating vessels principle, the droplet is 
aspirated through the channel. In the microfluidic platform used in this work, 
the effective channel volume is 5,4µl but it has been always fluxed a total 
volume of 12µl to make sure to perform an extensive medium refreshment and 
waste products removal. 
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To seed cells at a desired cell density, it is sufficient to apply this formula: 
 
𝑉𝑟𝑒𝑠 =
𝑁° 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 ∙ 0,2𝑚𝑚
𝐷𝑒𝑛𝑠𝑖𝑡𝑦 (
𝑐𝑒𝑙𝑙𝑠
𝑚𝑚2
)
 
 
Where:  Vres = Medium volume required for cell resuspension; 
               0,2mm= medium head within the microchannel. 
An early step, before starting the cardiac differentiation-on-chip, was 
performed by integrating hESCs and hiPSCS grown in conventional 6-well-plates 
into the microfluidic device described in Paragraph 3.3. Prior to cell seeding, 
microfluidic channels within the chip were filled with 4°C cold Matrigel Reduced 
Factor® (MRF, BD) 0,5% v/v in DMEM, incubated at room temperature for at least 
1 h and washed with StemMACS™ iPS-Brew XF medium (Miltenyi Biotec). hPSCs 
were then dissociated with 0,5mM EDTA or with Gentle Stem Cell Dissociation 
Reagent (Stem Cell) and injected at high density into the channels in medium 
supplemented with 10µM ROCK inhibitor (Y-27632, CalBiochem) to preserve cell 
viability. Because of the reduced medium volumes in the microchannels, to 
prevent a significant evaporation, the microfluidic platform was placed in a 
100mm Petri dish and maintained in an isotonic bath with PBS for an optimal 
humidity of the chamber. For the first experiment of cell culture integration in the 
microfluidic platform, cells were cultured up to 5 days and then the stemness and 
the homogeneous morphology was verified through immunofluorescence staining 
for pluripotency markers. In these culture conditions both embryonic and induced 
pluripotent stem cells display similar morphology to cells cultured in standard 6-
well-plates (Figure 3.11 A). Moreover cells homogeneously express pluripotency 
markers (OCT4, NANOG and TRA1-60) as revealed by the immunofluorescence 
staining performed both on hESCs and hiPSCs (Figure 3.11 B). 
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Figure 3.11: hPSCs culture in microfluidics. A. hESCs and hiPSCs cultured in microfluidic channels up to 5 
days display normal morphology as in standard 6-well-plates. B. hESCs and hiPSCs cultured in microchannels 
homogeneously express pluripotency markers (OCT4, NANOG and TRA1-60) as revealed by 
immunofluorescence staining. Dotted lines indicate channel outline. 
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3.4.1. Cardiac differentiation on-a-chip with Wnt modulators: optimization of 
the protocol 
The focus of this work was on cardiac cells because they are extremely relevant 
cell candidates for tissue-on-a-chip applications. Cardiac differentiation of human 
pluripotent stem cells was achieved with an initial optimization and adaptation of 
the gold standard monolayer protocol based on Wnt/β-catenin pathway 
perturbations in the microfluidic platform with proper Matrigel Reduced Factor 
(MRF) concentration for the coating of microchannels, creating an ECM to promote 
cardiogenesis, and  frequencies of medium refreshment. 
The optimization of cardiac differentiation protocols reported in literature has 
focused primarily on finding the optimal application, timing and concentration of 
growth factors and small molecules to perturbate specific signaling pathways. 
However, it is well known that cell behavior and stem cell fate decisions 
importantly depend also on extracellular matrix (ECM) interactions that influence 
early cardiac development, starting from events such as gastrulation [97]. From the 
analysis of gene expression profile and activated pathways, it was shown that 
hESCs and hiPSCs are similar to the cells composing the epiblast of the developing 
embryo [141]. At the gastrulation stage, some epiblast cells displayed a transition 
from epithelial to mesenchymal properties (EMT transition) and enter in the 
primitive streak with the subsequent cardiac commitment, leading to the 
formation of the heart [142]. During this process, a proper interaction between 
growth factors, small molecules and ECM becomes necessary [97][143] and ECM 
represents an adhesive substrate important for promoting these cross-talking 
events in a spatio-temporal manner.  
In 2012 Zhang J. and collaborators developed an efficient cardiac differentiation 
protocols for hPSCs by using ECM in combination with growth factors involved 
in cardiogenesis. Briefly, they cultured hPSCs as monolayers on Matrigel, which is 
an ECM preparation, and subsequently overlayed cells with another layer of 
Matrigel (0,5% v/v or 1% v/v concentrated). This assembled matrix sandwich 
promoted the EMT above mentioned, detected by the generation of N-cadherin+ 
mesenchymal cells. From this combination of the matrix sandwich with the 
temporal application of growth factors (Activin A, BMP4 and bFGF) they 
generated CMs with high purity (up to 98%) from multiple hPSC lines [97]. 
In this work, to optimize cardiac differentiation of hPSCs in microfluidics 
different concentrations of Matrigel Reduced Factors (MRF) were used for 
channels coating in combination with different medium refreshment frequencies 
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in order to outline which condition gives a better cell adhesion, proliferation 
and differentiation. Five microfluidic platforms with 10 independent channels 
were coated with two different MRF concentrations: platforms A, B, C and D 
were filled with a solution of 2,5% v/v MRF in DMEM while platform E was 
filled with a solution of 20% v/v MRF. For each microfluidic platform, two cell 
types were seeded: hES Dual Reporter and hiPS mmRNA Clone 7. Four 
different frequencies of medium refreshment were tested: 
1. Platform A and E: medium exchange was performed twice a day, every 12 
hours; 
2. Platform B: medium was refreshed once per day, every 24 hours; 
3. Platform C: medium was exchanged with the same frequencies applied in 
standard culture on 24-well plates; 
4. Platform D: the frequencies of medium exchange were adapted from 
standard culture to microfluidic; when in standard culture medium 
exchange was performed every 24 hours, in microfluidic it was refreshed 
every 12 hours while, when in standard culture medium was exchanged 
every 48 hours, in microfluidic it was exchanged every 24 hours. 
 The details of the experiment are reported in Figure 3.12.  
 
 
Figure 3.12: Schematic of the experimental set-up for the optimization of hPSCs cardiac differentiation on-a-
chip that is the monolayer based differentiation protocol described in Chapter 2 and published by Palecek’s 
group in 2013 based on the temporal modulation of canonical Wnt/β-catenin signaling pathway (adapted from 
[63][64]).  
 
Cardiac differentiation protocol was initiated two days after integrating 
hPSCs into the microfluidic platforms and cardiac differentiation was 
monitored daily to analyze the morphology changes in cells during 
differentiation and to record cell reactions to different medium refreshment 
strategies. Figure 3.13 shows the time-lapse analysis on days 1, 7 and 15 of 
cardiac differentiation of hPSCs on-a-chip. 
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Figure 3.13: Time-lapse analysis on days 1, 7 and 15 of cardiac differentiation using Wnt/β-catenin pathway 
modulators of hES Dual Reporter and hiPS mmRNA Clone 7 seeded in five platform with two different MRF 
coating concentrations and different strategies of medium refreshment. Each picture shows a longitudinal 
section of a microchannel coupled to the related magnification. Note the sequential changes in morphology, 
especially for platform A, C and E marked also by the expression of NKX2.5eGFP in Dual Reporter line, 
indicating the presence of cardiomyocytes. Starting from day 7 of cardiac differentiation, cells seeded in 
platforms B and D showed a decreased viability and epithelioid morphology with no beating cardiomyocytes 
formation (no GFP signal was recorded by Dual Reporter line). Culture conditions in platform B and D were 
then discarded for the following experiments. Scale bar 750µm for the longitudinal section of the microchannel; 
250 µm for the magnification of channel section. 
 
As reported in Figure 3.13, the best conditions for both hESCs and hiPSCs 
cardiac differentiation on-a-chip was achieved in platforms A (2,5% v/v MRF, 
medium refresh every 12h), C (2,5% v/v MRF, medium refresh like in standard 
culture) and E (20%  v/v MRF, medium refresh every 12h). This was confirmed 
by the eGFP signal related to NKX2.5 expression in hES Dual Reporter line used 
to monitor cardiomyocytes formation and only observed in platforms A, C and 
E. NKX2.5 expression started to became evident on day 8/9 of cardiac 
differentiation, while the first contractions appeared on day 12/13 for hES Dual 
Reporter line and 11/12 for hiPS Clone 7. Starting from day 7 of cardiac 
differentiation, cells seeded in platforms B and D showed an epithelioid 
morphology with a decreased viability until the end of the experiment: this was 
probably due to deleterious effects caused by a not optimal medium 
replacement frequency with subsequent nutrients depletion and waste 
products accumulation. For these reasons, strategies applied in platforms B and 
D were discarded for the next experiments.  
At day 15 of differentiation, CMs obtained in Platform A, C and E were 
characterized by immunofluorescence staining against nuclear marker GATA4 
and structural marker troponin T (cTnT) and for hES Dual Reporter line was 
also associated the immunofluorescence against GFP. The immunofluorescence 
NKX2.5-eGFP
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was performed with the classical five step protocol already described in Chapter 
2, Paragraph 2.3. The details of each primary antibody employed are reported in 
Chapter 2, Paragraph 2.5.2, Table 2.3. The primary antibody against GFP was an 
anti-rabbit IgG from Thermo Fisher Scientific (A11122). CMs were then quantified 
by counting the cTnT positive cells from the immunofluorescence, as reported in 
Figure 3.14. 
This experiment allowed the identification of the optimal culture conditions for 
both hESCs and hiPSCs in microfluidics and their differentiation through the 
cardiac lineage. In conclusion, among all the conditions tested, the best results 
were obtained in Platform A in which channels were coated with a solution of 2,5% 
v/v MRF and medium replacement was perform twice a day, with time interval 
of 12h. In fact, as reported in the graph, in Platform A, both hESCs and hiPSCs 
showed a similar behavior in terms of CMs yield. As reported in the 
immunofluorescence pictures of Figure 3.14 C, cells showed expression of specific 
nuclear and structural markers GATA4 and cTnT respectively, with marked 
sarcomeric organization. Moreover, hES Dual Reporter-CMs, stained for both 
cTnT and GFP reporter for TF NKX2.5, showed contemporary overlaid expression 
of both marker, confirming that only GFP+ve cells express cTnT, allowing a clear 
identification of CMs.  
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Figure 3.14: hPSC cardiac differentiation on-a-chip. A. Immunofluorescence staining against cardiac markers 
cTnT in hES Dual Reporter-CMs and hiPS Clone 7-CMs in Platform A, C and E. Nuclei were counterstained 
with Hoechst. Representative immunofluorescence pictures of longitudinal sections of microfluidic channels 
(Scale bar 250µm). B. Quantification of CMs. Percentage of cTnT obtained in Platforms A, C and E. Platform 
A: hES Dual Reporter-CMs (black bars) 74±4%; hiPS Clone 7-CMs (grey bars) 74±12%. Platform C: hES 
Dual Reporter-CMs 65±4%; hiPS Clone 7-CMs 48±3%. Platform E: hES Dual Reporter-CMs 67±5%; hiPS 
Clone 7-CMs 55±9% (n=3; error bars indicate SEM). C. Representative immunofluorescence pictures of 
channel sections; dotted lines represent channel edge (scale bar 250µm):  GATA4 and cTnT for Clone 7-CMs; 
cTnT and GFP reporter associated to NKX2.5 expression in Dual Reporter-CMs (scale bar 250µm). Note the 
remarkable organization of the sarcomere in the associated enlargement of the pictures (scale bar 100µm). 
  
Despite Platform E, characterized by a coating with a solution of 20% v/v 
MRF and the same frequency of medium refresh of Platform A, gave a high 
yield of cTnT+ve cells, this condition was discarded because of the difficulty of 
working with higher MRF concentrations; in fact, at room temperature the 20% 
v/v concentrated matrix gels rapidly and accumulates at channels edge level, 
amassing cells in the center, as reported in Figure 3.15.   
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Figure 3.15: Effect of 20% v/v MRF coating of microchannels in Platform E. When using a higher 
concentration of MRF, the matrix will rapidly gel at room temperature leading to an accumulation of the cells 
in the center of the channel. 
  
These experiments give a proof that a correct matrix concentration for coating 
and medium refreshment frequency can affect stem cell differentiation. Next 
experiments, described in Chapter 4, were performed using the same conditions 
adopted for Platform A with the association of a daily transfection regime using 
synthetic modified mRNAs (mmRNAs) for the main cardiac transcription factors. 
 
 
 
3.5. Conclusions 
In this Chapter an ad hoc microfluidic device containing 10 independent 
channels working in parallel was fabricated using the biotechnological state of the 
art of our BioERA laboratory. 
The gold standard CMs differentiation protocol, based on small molecules that 
modulate Wnt pathway (described in Chapter 2), performed up to now in 
conventional culture, was successfully integrated in the microfluidic device after 
step by step optimization derived by the translation from macro- to microscale. 
Before starting with the cardiac differentiation protocol, the ability of hPSCs to 
maintain their stemness and morphology homogeneity in microfluidics was 
routinely verified, confirmed by the expression of pluripotency markers. 
Next, the best conditions for both hES Dual Reprter and hiPS Clone 7 cardiac 
differentiation were identified, relying on microfluidic channel coating with 2,5% 
v/v MRF and medium refresh twice a day. The first contractions were detected 
500µm
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between 11-13 days and a high yield of CMs was obtained with cells expressing 
typical nuclear and structural cardiac markers. 
In conclusion, the microfluidic chip employed was used in order to obtain 
an easy-to-use platform that allow parallelized experiments and the 
optimization performed enabled a long-term culture over the 15 days required 
for CMs generation. These achievements represent the basis for the association 
of the delivery of synthetic mmRNA encoding cardiac TFs to precisely program 
hPSCs fate and drive cardiac differentiation toward cell maturation.  
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This Chapter introduces the novel non-integrating technology of synthetic 
modified RNA messengers (mmRNA) incorporating specific modifications 
designed to bypass innate immune response from the cells; this novel approach, 
pioneered by Warren L. in 2010, can reprogram cells to pluripotency with 
efficiencies higher than the other reprogramming methodologies [49][50]. Only 
one proof-of-concept study, published by Warren L. himself, demonstrated the 
possibility to use mmRNA to drive hPSCs differentiation toward terminally 
differentiated myogenic cells [49][50]. 
In this thesis, for the first time, specific mmRNA encoding cardiac 
transcription factors (TFs) involved in heart development and function, were 
employed to drive hPSCs cardiac differentiation in our validated microfluidic 
platform. Thanks to the transient nature of mmRNA and to the possibility to 
modulate cellular expression simply by adjusting the payload of mmRNA 
delivery on a daily basis, this novel approach best mimic in vitro the 
developmental signals observed in vivo  [49][50].  
Here, the experimental strategies for TFs delivery were presented, based on 
the association of Wnt pathway modulators with cardiac mmRNA in 
microfluidics to investigate how the delivery of TFs in microscale could 
improve CMs maturation. 
mmRNA is a promising tool to finely control gene expression and, thanks to 
the non-integrating property, to obtain clinical grade CMs that in the next future 
could potentially be a relevant source of autologous cells for cardiac repair and 
regeneration. 
 
 
4.1. Emerging synthetic modified mRNA technology: principle 
of the method 
The possibility to reprogram somatic cells to pluripotency is a powerful tool 
for studying normal development and generating patient-specific hiPSCs that 
could be used as disease models or for next future clinically relevant cell-based 
therapies [49][50].  
As described in Chapter 1 and 2, experiments of induction of pluripotency 
was firstly performed by Yamanaka S. and co-workers via the forced expression 
of 4 transcription factors (TFs), KLF4, c-MYC, OCT4, and SOX2 (KMOS), 
delivered with retroviral vectors [43][44]. However, the use of virus is entailed 
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with the risk of viral integration into the genome, rendering this approach not 
indicated for a clinical use of hiPSCs. Other novel strategies for hiPSCs generation 
with no risk of genetic alterations are represented by:  excisable lentiviral and 
transposon vectors, transient plasmids, episomal and adenoviral vectors 
[51][144][145], and DNA-free methods reling on serial protein transduction [146] 
and transgene delivery with the Sendai virus, characterized by a reproductive cell-
cycle completely RNA-based[50][147].  
Although DNA transfection-based delivery systems are considered safe, a 
minimal risk of genomic recombination or insertional mutagenesis is still present 
while the approaches based on peptide moieties delivery and Sendai virus require 
long purification procedures [49][50][147]. Importantly, all these methods  have 
shown very low iPSC derivation efficiencies, as already described in Chapter 1, 
Paragraph 1.3, Table 1.1 [146][149]. 
In light of these considerations, in 2010 Warren L. and collaborators 
demonstrated the possibility to derive hiPSCs, with efficiencies superior to 
established protcols, through repeated transfections of somatic cells with synthetic 
messenger RNAs incorporating modifications (mmRNA, modified mRNA) 
specifically designed to avoid innate immune responses. These hiPSCs were 
named by the author as RiPSCs (RNA-induced Pluripotent Stem Cells). 
Furthermore, with this simple, nonmutagenic and highly controllable technology, 
Warren himself used mmRNA to direct the myogenic differentiation of RiPSCs 
[49][50]. 
In Figure 4.1 A is reported a table with a list of reprogramming strategies, 
genomic- and non-genomic-based, with their characteristics on the type of the 
effector molecule used and its disposition and the related works published; in B 
the graph simply illustrates the efficiency of each reprogramming methods with 
the associated safety for future clinical applications. 
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Figure 4.1: A. Principal reprogramming methodologies used up to date. Retroviral and lentiviral vectors can 
cause viral integration, with subsequent altered gene function and tumorigenicity when transferred into a host. 
Lentiviral and transposon-based systems with the transgene excision via the Cre-lox system of transposases, 
still retain the risk of  genomic alterations during transgene insertion and/or excision. Safe methods for deriving 
iPSCs involve the use of episomal vectors, recombinant proteins and mmRNAs. B. Efficiency of each 
reprogramming technology versus its safety. mmRNA is the fastest, safest and most efficient method for 
generating integration-free, virus-free clinically relevant human iPS cells with efficiencies higher than the other 
approaches here depicted (modified from [150]).  
In Warren’s work, the author described the production of mmRNA using in 
vitro transcription (IVT) reactions templated by PCR amplicons. Briefly, for an 
efficient translation and for boosting its half-life in the cytoplasm, in every 
mRNA a 5’ guanine cap was incorporated through inclusion of a synthetic cap 
analog in the IVT reactions [49][151]. Within the templates, the gene-specific 
open reading frame (ORF) is flanked by a 5’ untranslated region (UTR) with a 
strong Kozak translational initiation signal and an α-globin 3’ UTR ending with 
an oligo(dT) sequence for templated addition of a polyA tail [49]. 
Cytosolic delivery of mmRNA can be performed with cell electroporation or 
transfection with a lipofectamine-based cationic vehicle to promote endocytosis 
uptake [50][152][153]. The researchers of Warren’s group used a cationic vehicle 
Methods for delivery of iPS cell reprogramming factors
Genomic
Method Effector molecule Effector disposition Citation
Retroviral DNA Integrated Takahashi, K. et al, 2007
Lentiviral DNA Integrated Yu, J. et al, 2007
Lentiviral/cre-lox DNA Excisable Soldner, F. et al, 2009
Transposon DNA Excisable Woltjen, K. et al, 2009
Non-genomic
Method Effector molecule Effector disposition Citation
Episomal vectors Plasmid DNA Degraded/kicked out Yu, J. et al, 2009
Recombinant proteins Proteins Degraded Kim, D. et al, 2009
Sendai virus RNA Degraded/kicked out Fusaki, N. et al, 2009
Synthetic nucleotides mmRNA Degraded/kicked out Warren, L. et al, 2010
Reprogramming Methods
Efficiency
Safety
Adenovirus
Lentiviral/
Retroviral
Sendai
virus
Piggy Bac
Episomal
DNA
Plasmids
rProtein
mmRNAs
A
B
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for repeated transfection, in order to sustain ectopic protein expression over the 
days required for cell reprogramming.  
In mammalian cells, it is known that interferon- and NF-kB-dependent 
pathways antiviral responses are triggered by exogenous single-stranded RNA 
(ssRNA) [49][154][155][156]. Eukaryotic mRNA, in vivo, undergoes post-
transcriptional modifications, thus, having this in mind, Warren’s group 
synthesized mmRNA incorporating specific modifications of nucleobases to 
bypass immune responses mediated by RIG-I (the ssRNA sensor) and the 
inducible endosomal ssRNA sensors TLR7 and TLR8[49][50][157][158]. The 
nucleobases modifications of Warren’s mmRNA are the following: cytidine was 
substituted by 5-methylcytidine (5mC), whereas uridine was substituted by 
pseudouridine (psi). Warren L. and co-workers performed cell viability assays on 
on human neonatal keratinocytes and BJ fibroblasts transfected with unmodified 
mRNA, mmRNA carrying in turn one of the two modifications and mmRNA with 
both 5mC and psi; they also analysed a panel of interferon response genes through 
qRT-PCR and found that the double nucleotide substitution markedly improved 
cell viability, attenuating interferons signaling as reported in Figure 4.2 [49][50].  
 
Figure 4.2: Warren’s group attempt to overcome innate immune responses, incorporating modified nucleobases 
in the mmRNAs.  A. Microscopy images of transfected keratinocytes with 400ng/well of synthetic unmodified 
(No Mods), 5mC modified, psi modified or 5mC+psi mmRNA encoding nGFP. B. Flow cytometry percent 
viability and C. Mean fluorescence intensity of the cells shown in A. D. Quantitative RT-PCR data showing 
expression of 6 interferon-regulated genes in BJ fibroblasts 24 hours after transfection with unmodified (No 
Mods), or modified (5mC+psi) RNA encoding nGFP (1200ng/well) vehicle and untransfected control cells 
(adapted from [49]).   
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Moreover, to further increase cell viability of RNA transfection, Warren L. 
and collaborators used media supplemented with a recombinant version of 
B18R protein, a Vaccinia virus decoy receptor for type I interferons [159]: in fact, 
coupling mmRNA with B18R, enabled a high, dose-dependent levels of protein 
expression with high cell viability[49][50]. In Figure 4.3 is illustrated a schematic 
of mmRNA mechanism of action. 
 
 
Figure 4.3: Synthetic mmRNA bypasses Toll-like receptor-induced apoptosis after transfection. A. The 
exogenous mRNA is detected by Toll-like receptors 7 and 8 (TLR 7 and 8) inducing the expression of innate 
immune respose genes (type I interferons, RIG-I) and cell apoptosis. B. The double nucleobases modification 
(psi and 5-mC) changed the secondary structure of the nucleic acid, bypassing immune recognition and 
mmRNA was then translated. B18R protein addition to the culture medium allowed for high, dose-dependent 
levels of protein expression with high cell viability (adapted from [160][161]). 
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B
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Another important aspect is that this approach is feeder- and xeno-free, 
rendering it suitable for moving hiPSCs from laboratory to clinic [50].  
By combining mmRNA with the soluble interferon inhibitor B18R, it is possible 
to perform a highly efficient reprogramming of somatic cells to pluripotency, as 
demonstrated also by a work published in 2016 by our research group BioERA at 
the University of Padova with the integration of this strategy in micorlfuidics. 
Giulitti S. and collaborators in fact, showed that downscaling mmRNA 
reprogramming strategy to microliter volumes generated a favourable 
environment for the acquisition of pluripotency. With the combination of mmRNA 
and microfluidics, they achieved an average efficiency of over 120 hiPSC colonies 
per 100 seeded cells, 50-fold higher than the current data available in literature 
using conventional multiwells [95].  
To promote the application of hiPSC technology for regenerative medicine or 
disease modeling, it is of paramount importance that the multilineage 
differentiation potential of pluripotent cells can be achieved. Warren himself have 
already demonstrated the abilty to differentiate hiPSCs into terminally 
differentiated myogenic cells using mmRNA, indicating that these modified 
nucleotides could precisely reprogram as well as program cell fate. To derived 
myogenic cells they performed a simple in vitro hiPSCs myogenic differentiation 
protocol (FGF withdrawal and serum additions in gelatin-coated plates) followed 
by 3 days of transfection with a MYOD-encoding mmRNA[49][50]. MYOD was 
considered a “master regulator” for muscle cell fate and several experiments in 
literature reported its ability to induce transdifferentiation of mouse fibroblast into 
myoblasts [162]. At the end of the experiment, Warren’s group obtained large, 
multinucleated myogenin and MyHC (Myosin Heavy Chain) double-positive 
myotubes, with efficiencies ranging from 35-38% using 1800ng of mmRNA to 
transfect 104 and 5x103 cells. Preskey D. and co-workers in 2015, published another 
work, reporting the use of synthetic mmRNA to generate hiPS and to drive the 
transdifferentiation of human fibroblasts into myoblast-like cells. They transfected 
5x104 fibroblasts for 4 days using 200ng and 300ng of mmRNA encoding MYOD1 
but obtained very low efficiencies, 0,04% and 0,8% respectively [163]. 
Finally, the use of mmRNA for cell fate manipulation represent a precious tool 
to modulate cellular expression of specific TFs on daily basis, simply by adjusting 
the quantities of transcripts at every transfection. At the end of each a TFs 
transfection, ectopic expression in the targeted cells stops because of the rapid 
degradation of mRNA in the cytoplasm. 
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In this Chapter, mmRNA technology is combined with microfluidics to 
develop an efficient and robust method for programming cardiac hPSCs fate in 
a high controllable microenvironment that allows cost-effective and 
combinatorial analysis at one time.  
 
 
4.2. Changing cell identity with Transcription Factors - state of 
the art for cardiac regeneration 
As already discussed in the previous paragraph, from the pioneering 
reprogramming experiments performed by Yamanaka, several protocols have 
been developed to program cell fate in order to obtain for example CMs. In 
general these approaches relied on the transdifferentiation of somatic cells by 
forcing the expression of key lineage-specific factors, bypassing the pluripotent 
state. The first experiment was performed almost 30 years ago, when 
overexpression of a single gene, the myogenic TF MyoD, was shown to be able 
to convert fibroblasts into skeletal muscle cells[36][162]. Direct lineage 
conversion experiments have been reported for a plethora of somatic cell types 
[163]: hematopoietic system [164][165][166], pancreatic exocrine cells [167], the 
hepatic system [168] and neuronal lineage [169]. Unfortunately, up to now no 
single TFs has been identified as “master regulator” for CM development, but 
it was hypothesized that a combination of specific TFs can be used to instruct 
the gene expression profile of the transfected cell toward a cardiac fate [36]. 
Pioneering this field, Srivastava D. and Ieda M. group who performed in 
2010 a direct conversion of murine fibroblasts to CMs in vitro and in vivo with a 
specific combination of cardiac TFs. They started by testing 14 different factors 
involved in cardiomygenesis, delivered in mouse post-natal fibroblasts with a 
mixture of retroviruses [48]. Three were identified and considered sufficient for 
cardiac programming: Gata4, Mef2c and Tbx5 (GMT factors). The conversion 
into CMs  was verified by the up-regulation of a cardiac specific reporter gene, 
detected in up to 25% of transfected cells. 1 day after the delivery of GMT, cells 
were transplanted into immunocompromised mouse hearts. However, only 1% 
of these so-called induced CMs (iCMs) displayed in vitro spontaneous 
contractions, indicating an incomplete conversion into fully mature, functional 
CMs. Two later studies delivered the GMT cocktail via a single polycistronic 
vector and observed an enhanced differentiation of iCMs from mouse 
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fibroblasts [170][171]. The second study obtained significantly different results 
from the pioneer experiment performed by Srivastava D. and Ieda M., with cardiac 
gene expression found in all the murine fibroblast lines employed, marginally 
elevated because of GMT transduction, with extremely variable reprogramming 
efficiencies. Moreover, GMT-overexpressing cells showed no spontaneous action 
potential in vitro and, when transplanted into injured mouse hearts, cells were 
characterized by poor survival and minimal activation of cardiac genes. The later 
addition of one more cardiac TF, Hand2, to the reprogramming set (GMTH), lead 
to a low yield of cells positive for both cardiac structural markers αMHC and cTnT 
[172]. 
Since the gene regulatory network that cooperate during human cardiac 
development is more complex than the mouse counterpart, CMs generation from 
human fibroblasts needs more TFs than those applied up to date in murine cells. 
Probably this species-specific requirement is due by differences in gene expression 
and regulation between mouse and human fibroblasts, showing a different 
susceptibility in the activation of lineage-specific genes [36].  
Nam Y.J. in 2013 demonstrated that both GMT and GMTH combinations were 
insufficient and unable to reprogram human fibroblasts: he employed a 
combination of 4 TFs (Gata4, Hand2, Tbx5; Myocd) and 2 miRNAs (miR-1 and miR-
133), to convert human neonatal and adult fibroblasts into CM-like cells 
characterized by the expression of sarcomeric structural features. However, a 
longer time in culture is required for these iCMs to reach a level of maturation, 
compared to murine cells; moreover these human iCMs displayed low-amplitude 
calcium transients after electrical stimulation, extremely rare spontaneous 
contractions and heterogeneity in the cardiac population with different levels of 
cardiac and non-cardiac genes [47].  
Immediately after these first experiments, several groups began to move the 
reprogramming in vivo, by directly injection of cardiac TFs into mouse injured 
hearts. It was found that GMT delivered with retroviruses in a mouse model of 
myocardial infarction (MI) reprogrammed resident fibroblasts into CM-like cells 
[173]. Also in this case, the efficiency was low (  ̴ 15%) but,  in vivo-derived iCMs 
were more fully reprogrammed than in vitro-derived ones, resembling the 
endogenous cardiac cells. These findings indicated that the factors produced 
within the native milieu, absent in the conventional culture system, influenced cell 
fate switch. Importantly, performing the cardiac reprogramming in vivo, allowed 
cells to achieve cardiac functionality features coming from a combination of new 
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muscle formation and environment-dependent effects, such as GFs secretion 
within the ECM. 
Other approaches have been tested, using cell-free methods, taking into 
account the influence of paracrine factors to activate repair mechanisms in 
damaged heart. Selected TFs can be vehiculated into the heart with viral and 
non-viral DNA vectors, small-molecules chemical compounds, recombinant 
proteins or with the novel non-integrating mmRNA technology. These 
strategies have been used especially for transdifferentiate CMs into other CMs 
subtypes, for example to derive conduction system cells using the pacemaker 
cell-related TF TBX3, revolutionizing current clinical treatment based on the 
transplantation of costly electronic pacemakers [174]. Other recent studies 
proposed strategies for First Heart Field (FHF)- and Secondary Heart Field 
(SHF)-derived cardiac progenitor cells (CPCs) and epicardium-derived 
progenitor cells (EPDCs) activation and differentiation. In 2013, Zangi L. and 
colleagues published a work in which they were able to reactivate quiescent 
murine EPDCs with a direct injection of a mmRNA encoding VEGF-A after MI, 
driving them away from the fibroblast, scar-forming fate [161]. Figure 4.4 
summarized the cell-based and cell-free approaches for human cardiac 
regeneration and Table 4.1 reported the studies conducted by several research 
groups. 
 
 
Figure 4.4: Approaches for human cardiac regeneration. Cell-based therapies (left) involve transplantation into 
the damaged heart of in vitro-derived CMs differentiated from hPSCs or from transdifferentiated fibroblasts 
and cardiac progenitor cells (CPC) using specific cardiac TFs. On the right, cell-free therapies rely on the 
administration of chemical compounds or genes (viral vectors, non-viral DNA vectors or mmRNAs) to 
stimulate cardiac regeneration (adapted from [36]). 
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Table 4.1: Strategies for directing cardiac cell fate. 
 
M, mouse; H, human; CFs, cardiac fibroblasts; TTFs, tail tip fibroblasts; MI, myocardial infarction; CPCs, 
cardiac progenitor cells; EPDCs, epicardium-derived progenitor cells; N.D., not determined. 
 
4.3. Unsolved issues of human cardiac regeneration 
As described previously in Paragraph 4.2, despite the encouraging results 
obtained from cell-based and cell-free strategies for cardiac regeneration in animal 
model experiments, much work has still to be done before promoting such 
approaches to the clinical tests. In fact, the following issues will have to be faced: 
- Cell type and scalability: the selection of the ideal cell type is often hard 
because this cell should tolerate autologous transplantation, show a 
rapid in vitro expansion and ability to differentiate into CMs, properly 
electrically coupled with the host cells.  
- Subtype of CMs: as already explained in Chapter 1 and demonstrated in 
Chapter 2 and 3, the direct cardiac differentiation of hPSCs allowed the 
generation of a high yeld of beating CMs; however the resultant 
population is heterogeneous, characterized by a mixture of atrial, 
a) Fibroblasts >> CMs
Reference Species
Recipient cell
type/Organism
TFs/Molecule
Delivery 
method
Experimental read-out Efficiency In vivo
Ieda, M. et al,
2010
M
Post-natal CFs and 
TTFs
Gata4, Mef2c, 
Tbx5
Retrovirus αMHC reporter/cTnT 5-25% -
Chen, J.X. et al, 
2012
M CFs and TTFs
Gata4, Mef2c, 
Tbx5
Lentivirus
αMHC /Nkx2.5/cTnT
reporters
0-35% -
Ingawa, K. et 
al, 2012
M
Adult CFs
Gata4, Mef2c, 
Tbx5
Retrovirus
αMHC reporter 3-7% -
MI model
αMHC reporter and α-
actinin
1% +
Qian, L. et al, 
2012
M MI model
Gata4, Mef2c, 
Tbx5
Retrovirus
Postn/Fsp1 lineage
tracing, α-actinin and 
sarcomeric structure
10-15% +
Nam, Y.J. et al, 
2013
H
Neonatal FFs, adult
CFs and DFs
GATA4, 
HAND2,
TBX5, 
MYOCD, miR-
1, miR-133
Retrovirus cTnT/Tropomyosin 9-45% -
b) CMs >> Conduction system cells - Transdifferentiation
Reference Species Genes/TFs
Delivery 
method
Cell type
obtained
Experimental read-out Efficiency In vivo
Bakker, M.L. et 
al, 2012
M Tbx3
Lentivirus
Pacemaker 
cells
Gene expression, 
electrophysiological
parameters
N.D.
-
Inducible
transgene +
c) CPCs and EPDCs activation
Reference Species TFs/Moleule
Delivery
method
Cell 
activated
Experimental read-out Efficiency In vivo
Zangi, L., et al, 
2013
M VEGF-A mmRNA
EPDCs to 
endothelial/
smooth
muscle cells
Epicardial lineage
tracing with 
bioluminescence assay
N.D.
-
+
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ventricular and conductive cells. In order to achieve better effects on 
cardiac function and prevent arrhythmias after transplantation, it may 
be essential to selectively differentiate the desired cell subtype. 
- Electrical coupling: one major concern is the incomplete electrical 
coupling of the CMs generated, entailing the risk of the development of 
arrhythmias. Transplanted CMs in fact, have to align, engraft and 
couple with host cells in ordered fashion. 
- Teratoma formation: another caveat related to the transplantation of 
hPSC-derived CMs is the presence of residual undifferentiated cells. 
- Issues on using viral vectors: some viral vectors can integrate into the 
host genome, with the subsequent risk of tumorigenity. Thus, it is 
imperative the application of non-integrative methods to efficiently 
drive cell fate conversion without compromising the safety [36][161]. 
Latest experimental and therapeutic tools involving the non-integrating 
mmRNA technology will unveil the mechanisms of human cardiogenesis and 
repair, providing novel alternatives with the ultimate goal of deriving clinical-
grade CMs for cardiac regenerative medicine.  
 
 
4.4. Experimental setup: programming hPSCs with mmRNA 
encoding cardiac TFs in microfluidics 
The experimental procedures above mentioned reinforce the idea that 
guided differentiation of hESCs or hiPSCs into clinically relevant populations 
can be realized in vitro by developmental signals resembling those that instruct 
cells in vivo [21]. The attempt is to trigger hPSCs to mimic the appropriate 
sequential differentiation observed in the embryo via the forced overexpression 
of key TFs as a powerful way for programming cell fate and identity. As a proof-
of-concept, this work aimed at forcing the endogenous protein expression 
through the administration of mmRNA encoding cardiac TFs to drive 
cardiogenesis in vitro toward cell maturation. The cardiac TFs selected to drive 
the cardiac differentiation of hPSCs were MESP1, GATA4, NKX2.5, MEF2C, 
TBX3 and TBX5; this “Cardio mix” will be transfected into cells using a cationic 
vehicle lipofectamine-based, and to monitor the transfection efficiency, an 
mmRNA encoding nGFP will be associated in the TFs mixture. All the mmRNA 
were produced and provided by Miltenyi Biotec (Cologne, Germany). Before 
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describing the experimental set-up it is important to understand cardiac TFs 
activity and timing of expression. 
- MESP1: is regarded as a regulator of the cardiac TFs cascade to direct the 
generation of cardiac mesoderm [175]; 
- GATA4: is essential for proper mammalian cardiac development and for 
survival of the embryo; it works in combination with NKX2.5 and TBX5 
and is expressed in both embryo and adult CMs; promotes cardiac 
morphogenesis, CMs survival and maintains cardiac function in the adult 
heart [176]. 
- NKX2.5: interacts with GATA4 and TBX5 to orchestrate heart 
development, operating in a positive loop to regulate CMs formation; is 
also involved in mechanisms that decide ventricle and atrial cell fate [177]. 
- MEF2C: is involved in cardiac morphogenesis, myogenesis and vascular 
development; regulates the post-natal growth of the myocardium [178]. 
- TBX3: in the developing heart is required for pacemaker and conduction 
system development and is important for functional maturation and post-
natal homeostasis of CMs [175].  
- TBX5: associates with NKX2.5 and synergistically promotes CMs 
differentiation [179]. 
In Table 4.2 are reported the temporal expression windows of cardiac TFs 
observed during studies on human cardiogenesis performed in vitro by Gepstein 
L. and Burridge P.W. in 2001 and 2014 respectively[56][66][21], while Figure 4.5 is 
a schematic of the up and downregulation of these TFs during cardiac 
development. 
 
Table 4.2: Timing of cardiac TFs of cardiogenesis in vitro [56][21]. 
 
Developmental stage Genes Expression window [days] References
Pluripotency OCT4, NANOG Peak D2-3, OFF
- Gepstein, L. et al, 2001
- Burridge, P.W. et al, 2014
Primitive streak Brachyury T Peak D2-3, OFF D5-10
Cardiac mesoderm MESP1 Peak D2-3, OFF
Cardiac TFs
GATA4 Peak D4, ON
MEF2C Peak D6-8, ON
NKX2.5 Peak 7-8, ON
TBX3 Peak D8, ON
TBX5 Peak D8, ON
Structural Genes -
Sarcomere
cTnT (TNNT2) Peak D8, ON
MYH7 (β-MHC) Peak D14, ON
Structural/functional Genes
– Ion channels
SERCA2A Peak D6, ON
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Figure 4.5: Schematic representation of the waves of expression of the principal cardiac TFs during in vitro 
differentiation of pluripotent stem cells. 
 
Taking into account the timing of expression of cardiac TFs and their 
networking activity studied in vitro, an ad hoc experimental strategy was 
designed. Figure 4.6 illustrated a comprehensive scheme of the experimental 
setup.  
 
 
Figure 4.6: Schematic for hPSCs cardiac programming in microfluidics. After expansion in conventional 
culture, hPSCs were seeded in microfluidic device and after 2 days, the cardiac programming was initiated 
associating the Wnt/β-catenin pathway modulation with 6-days of transfection regimen with mmRNA 
encoding cardiac TFs (Cardio mix). After 15 days, cells were characterized for functional assays and gene 
expression pattern analysis. 
 
 hPSCs selected for these experiments are: hiPS mmRNA Clone 7 and hES 
Dual Reporter line for their cardiogenic ability to give a high yield of beating 
CMs in conventional and microfluidic culture, as described in Chapter 2 and 3. 
hPSCs were expanded in 6-well plates for approximately 1 week and, when 
hPSC Cardiac progenitor CM
Mesoderm induction
Cardiac commitment
Cardiac specification
and maturation
D0 D3 D4 D6 D8 D12-14
OCT4
NANOG
BRA-T
MESP1
ISL-1
GATA4
GATA4 NKX2.5 
MEF2C TBX3 
TBX5
cTnT
cTnI
α/β-MHC
SERCA2A
Time [Days]
OUTLET
INLET
Medium
reservoirs
hPSCs expansion hPSCs seeding within microfluidics hPSCs cardiac programming
CMs
Pathway: Wnt/β-catenin
Cardiac TFs mmRNA: 
MESP1, NKX2.5, GATA4, 
MEF2C, TBX3, TBX5
nGFP
Seeding 2 days Programming  15 daysExpansion 7 days Characterization
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they reached confluence, cells were dissociated using standard procedures (details 
in Chapter 2, Paragraph 2.3) and then seeded in the microfluidic device at a density 
of 700cells/mm2 in medium supplemented with 10µM ROCK inhibitor (Y-27632, 
CalBiochem) to preserve cell viability. After 2 days for cell recovery, cardiac 
differentiation using Wnt/β-catenin pathway modulators was initiated and 
associated to cell programming with 6 daily transfections with the Cardio mix. Cell 
were maintained in microfluidic device until day 15 and then, CMs were 
characterized for their structural, functional and maturation features. The 
transfection protocol was optimized and then the approaches designed were 
divided in Part 1 and Part 2 in which two strategies were tested to best mimic the 
TFs action during cardiac differentiation; the details of each strategy will be 
elucidated in the next paragraphs. 
 
 
4.5. Optimization of the transfection with synthetic mmRNA: 
first steps 
In this Paragraph will be elucidated the optimization of the transfection 
procedure before starting with the hPSC programming using cardiac TFs 
mmRNAs. In the transfection strategies presented in this work, the mmRNAs were 
delivered using two transfection kits: StemMacs™ mRNA Transfection Kit (SM; 
Miltenyi Biotec, Cologne, Germany) and Stemfect® mRNA Transfection kit (SF; 
Stemgent, Cambridge, USA). These commercial formulations are lipid-based 
transfection systems, specifically designed for an efficient mmRNA delivery into 
various cells types; they have been selected for these experiments for the minimal 
cytotoxicity and high transfection efficiency reported in each data sheet; they were 
particularly suited for sensitive cell types such as PSCs and complex transfection 
schedules involving repeated transfections over several days.  
For satisfactory transfection results, it is necessary an optimization of the 
protocol. The use of a nuclear eGFP-mmRNA is indicated as an easy read-out for 
transfection efficiency and is recommended as positive control when establishing 
new transfection protocols. Finding the optimal transfection conditions is 
necessary for driving hPSCS differentiation toward cardiac lineage.  
In this experiment, the transfection efficiency of hPSC colonies was evaluated 
comparing standard 24-well plates with the 10-channels microfluidic device. 
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When starting mmRNA transfections, it is necessary to establish the optimal 
cell density to make sure that the majority of the cells will be efficiently 
transfected. In general, in case of a single transfection, it is recommended to 
choose a cell density that bring the culture confluence between 50-90% in 24-48 
hours while, for repeated transfections for several days, a lower cell density is 
indicated. As previously mentioned in Paragraph 4.1, to avoid innate immune 
response, cells were incubated with medium supplemented with B18R 0,2ng/µl 
(1:2500) 4 hours before the transfection. Both the transfection kits used (SM and 
SF) are based on two components: the transfection buffer (TB) and the 
transfection reagent (TR), maintained at +4°C. As reported in Figure 4.7, two 
solutions were prepared in two separate sterile, RNAse-free 0,2ml tubes 
(SARSTEDT, Germany): Solution A was prepared by diluting 5-fold 100ng/µl 
of each mmRNA used in TB; Solution B by adding 10X TR in TB. Solutions A 
an B were then combined in 3:1 (SM) or 2:1 (SF) volume ratio respectively. The 
transfection mix was equilibrated at room temperature for 15 minutes (SM) or 
20 minutes (SF) to allow the formation of the lipid complex incorporating 
mmRNA. The transfection mix was added to the cells and incubated for 4 hours 
at 37°C and 5% CO2.  
 
 
Figure 4.7: Schematic of the mmRNA transfection using lipid-based systems commercially available 
(modified from Clontech website). 
 
The expression of the transfected factor will be detectable 6-24 hours after 
transfection, peaking after 12-18 hours, depending on the transient nature of 
mmRNA and protein stability [49]. After 4 hours, transfection was stopped 
adding new, fresh, prewarmed medium, supplemented with B18R (medium 
with B18R was used until the end of the transfections plus one additional day). 
Solution A:
TRANSFECTION
BUFFER
+ mmRNA
Solution B:
TRANSFECTION
BUFFER
+
TRANSFECTION 
REAGENT
Transfection mix
equilibration Incubation
4h
TRANSFECTION 
EFFICIENCY 
ANALYSIS
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In conventional culture systems, the transfection mix is added dropwise in the 
plate, gently move it back and forth to homogeneously distribute the transfection 
complex while, when using microfluidic device, all the components have to be 
adapted to small volumes. Moreover, in microchannels it is mandatory to dilute 
the transfection mix in an appropriate medium volume. In every channel, 12µl of 
medium were delivered but the effective volume of medium flowing over the cells 
and covering the channel area of 27mm2, is 5,4µl, therefore it is necessary to 
increase the transfection mix/culture medium ratio, compared to conventional 24-
well plates, avoiding a significant reagents loss. These adjustments are necessary 
to increment the transfection efficiency simply by altering the payload of 
transcripts. For the scale down, ratios between mmRNA, TB and TR were 
maintained, while only the proportions of medium used for the delivery of 
transfection mix were reduced.  
In this work, 75%, 50% and 25% of medium were used and tested to dilute the 
transfection mix during cardiac programming in microfluidics, comparing to 
standard transfections performed in conventional cultures and, for convenience, 
these percentages corresponded and were always indicated as low dose, middle 
dose and high dose of transfection mix respectively. These ratios are equal to the 
following absolute quantities of mmRNA/mm2 of microchannels: 150pg 
mmRNA/mm2; 210pg mmRNA/mm2 and 380pg mmRNA/mm2 as reported in 
the Table 4.3. 
 
Table 4.3: quantities of mmRNA used in this work, adapted to microfluidics with the related medium 
volumes. 
Transfection ratios 
Transfection 
mix dose 
Medium 
[%] 
mmRNA[pg/mm2] 
Low 75% 150 
Middle 50% 210 
High 25% 380 
 
The selection of the appropriate concentration of the transfection mix, with the 
related percentage of medium for diluting it, depends on the type of the 
experiment and will be elucidated in the next paragraph. Commercial kits 
recommend to use diluted transfections when performing the delivery of mmRNA 
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for several days, in order to preserve cell viability, since the transfection is a 
stressful event for the cells and a high dose for several days can cause high 
mortality; when it is necessary a single transfection for one day, a higher dose 
can be used for obtaining an immediate gene expression.  
 
 
4.5.1. Transfection efficiency of hPSCs colonies 
 In BioERA laboratory, after reprogramming human fibroblast to hiPSCs 
with high efficiencies, preliminary experiments were performed to study the 
possibility to use mmRNA transfection to direct cell differentiation toward 
desired lineages. Evidences from reprogramming experiments, demonstrated a 
reduced propensity of hiPSC colonies to transfection, until they became 
refractory to the process. This behavior could depend on cell density within the 
pluripotent colony and/or a reduced endocytosis. In the first case, cells are less 
responsive to the transfection because they are closely connected to each other 
through cell adhesion proteins expression, among which E-cadherin plays an 
important role. E cadherin is a calcium-dependent cell-cell adhesion molecule 
involved in epithelial cell behavior, tissue formation, cell survival and 
pluripotency maintenance [180].   
To circumvent these barriers, it was hypothesized that a pre-treatment of 
hPSC colonies with 0,5mM EDTA before the delivery of a nuclear eGFP 
mmRNA for 1 day could help mmRNA up-take. EDTA in fact, is a chelating 
agent that sequesters a variety of polyvalent cations such as Ca2+  necessary for 
E-cadherin, thus allowing a light dissociation of the colony. After this process, 
EDTA was removed adding fresh medium to restore the physiological Ca2+ 
concentration. With this strategy, weakening cell junctions, the cell surface 
accessible to medium carrying the transfection reagent increases, allowing a 
more efficient mmRNA delivery into the cells, as depicted in Figure 4.8.  
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Figure 4.8: Pretreating hiPS colonies with EDTA 0,5mM before the delivery of nGFP mmRNA allows a 
homogeneous transfection. 
 
This experiment was performed comparing the transfection efficiency of hiPS 
Clone 7 in microfluidic platform and conventional 24-well plate. Cells were seeded 
mimicking a possible density obtained from a reprogramming experiment 
established by the expertise in the laboratory: in microfluidics this density 
corresponds to approximately 20 hiPS colonies/channel while in conventional 24-
well is 140 hiPS colonies/well (with  ̴ 460 cells/colony as mean number of cells per 
colony). The mmRNA encoding nGFP was delivered using Stemfect (SF) 
transfection kit. The experiment was divided in two groups:  
1. hiPS colonies pretreated with EDTA 0,5mM for 2-3 minutes in 24-well plate 
and 30-40 seconds in microfluidics; 
2. hiPS colonies not pretreated with EDTA before the delivery of nGFP-
mmRNA, as a control. 
From previous experiments in the laboratory, a high and middle doses of 
transfection mix (75% and 50% respectively) resulted optimal for mmRNA 
delivery. The quantities of mmRNA used were adapted by the reprogramming 
expertise of BioERA lab who calculated the mean cell number within a colony and 
the mean area occupied by the colonies within a channel: high dose 85pg/mm2 of 
hiPS colony, middle dose 48pg mmRNA/mm2 of hiPS colony. In conventional 
culture, additional quantities of mmRNA were tested using higher doses then 
those recommended in SF datasheet, 122pg mmRNA/mm2 of hiPS colony and 
1257pg mmRNA/mm2 of hiPS colony, to make the delivery of nGFP mmRNA 
sufficient for the transfection of all the colonies. 
Transfection efficiency was calculated by counting the nGFP+ve cells versus the 
total cell number. For a better quantification of cells, it is possible to counterstain 
nuclei with live Hoechst (Sigma Aldrich) 0,4ng/µl (1:5000) in culture medium, 
incubated for 10 minutes at 37°C. These data were performed and obtained in 
collaboration with Dr. Torchio E. who earned her master degree in 2014 [181]. 
EDTA
0,5 mM
More efficient
and 
homogeneous
transfection
No EDTA
Only external
cells are 
transfected
Chapter 4 
 
Synthetic mmRNA for programming hPSCs cardiac fate and 
driving CMs maturation on-a-chip 
 
114 
 
As reported in Figure 4.9 A, EDTA increased considerably the transfection 
efficiency in hiPS Clone 7: in fact, without EDTA pretreatment, only the edges 
of the colonies were transfected while colonies pretreated with EDTA showed 
a homogeneous distribution of transfected cells. The percentage of transfection 
efficiency was calculated and showed in the graphs in Figure 4.9 B and C. 
 
 
 
Figure 4.9: Optimization of mmRNA delivery with EDTA 0,5mM pretreatment. A. hiPS Clone 7 colonies 
transfected with nGFP mmRNA  without (CTRL) and with pretreatment with EDTA in 24-well plate and 
microfluidic device. In the right panel it is reported the live Hoechst stain for calculating the transfection 
efficiency. The panels showed cells treated with 85pg mmRNA/mm2 of colony. Scale bar 750µm B. Comparison 
between transfection efficiency of hiPS colonies in conventional 24-well plate and microfluidic device without 
(grey bars) and with EDTA (black bars). C. Transfection efficiency of colonies pretreated with EDTA both in 
conventional culture (cyan bars) and microfluidic device (blue bars). n=3; error bars indicate SEM. Data made 
in collaboration with Dr. Torchio E [181] . 
 
These findings indicate that not only the EDTA pretreatment allowed a more 
homogeneous transfection of hiPS colonies with a diffuse protein expression 
but also the use of the microfluidic platform for mmRNA transfection 
determined an increase in the transfection efficiency when compared with 
conventional cell culture systems, as shown in the graphs of transfection 
efficiency related to the quantity of mmRNA used. Moreover, the same 
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efficiency was reached in microfluidics using approximately 10- fold lower 
amount of mmRNA. 
To describe at best the optimization performed to obtain such results, a list of 
key features are listed: 
 Robust microfluidics for high transfection efficiency; 
 Platform compatibility for mmRNA delivery; 
 Scale down of minimum requirements. 
Thanks to these characteristics, the platform fabricated in our BioERA 
laboratory has the potential to become a tool for programming cardiac hPSCs fate, 
allowing a precise modulation of mmRNA-encoding cardiac TFs delivery to better 
mimic the processes observed in developmental studies on cardiogenesis. The next 
step, in fact, is the cardiac programming of hPSCs via the administration of cardiac 
mmRNAs.  
 
4.6. Part 1: mmRNA-induced overexpression of 
cardiomyogenic TFs.  
Although the mmRNA technology is still in its infancy and very few works are 
reported in literature, the use of mmRNA is endowed with a number of properties. 
These properties include the fact that cellular expression of TFs can be modulated 
on a daily basis, simply by modulating the quantities of mmRNA added to the 
culture medium. In additon, because of multiple different mmRNAs can be 
introduced into cells simultaneously, co-expression of multiple proteins can be 
achieved. Notably, thanks to the transient nature of protein expression mediated 
by mmRNA it will be possible to activate specific developmental programs[49]. 
In this thesis, the cardiac programming of hPSCs fate was divided in 2 parts, 
each one carried out by testing two strategies in parallel. The Part 1, with the 
related strategies, is illustrated in Figure 4.10 A-C. Control cells were represented 
by CMs differentiated with the gold standard protocol (described in Chapter 2) 
based on Wnt pathway modulators, without mmRNA (Figure 4.10 A). The first 
strategy (Figure 4.10 B) relied on the complete Wnt/β-catenin pathway 
perturbation with the timed application of CHIR99021 (indicated in the green box) 
and IWP4 (indicated in the red box) on day 0 and 3 respectively, coupled to 6 days 
of transfection with the 6 cardiac TFs mmRNAs, while the second one (Figure 4.10 
C) was based on the only CHIR99021 administration coupled to mmRNA 
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transfection, to test the ability of mmRNA to influence CMs formation. The 
unique variable was the presence or absence of IWP4 molecule; for convenience, 
the first strategy was named WNT OFF+mmRNA, whereas the second one 
WNT ON+mmRNA.  
 
A 
 
B 
 
C 
 
Figure 4.10: Schematic representation of the two strategies applied in parallel. A. Control platform in which 
cells were differentiated with the only gold standard protocol with small molecules modulating Wnt/β-catenin 
pathway. B. Strategy WNT OFF+mmRNA in which the complete Wnt/β-catenin pathway perturbation with 
CHIR99021 and IWP4 was coupled to mmRNA transfections for 6 days. C. Strategy WNT ON+mmRNA in 
which only CHIR99021 was administered, in combination with Cardio mix transfections for 6 days. 
 
For a better understanding, the details of each condition tested with the 
related acronyms, are reported in Table 4.4. 
Table 4.4: Part 1 experimental conditions 
CTRL WNT OFF mmRNA WNT ON mmRNA 
Complete Wnt pathway 
perturbation 
(CHIR99021+IWP4) 
Complete Wnt pathway 
perturbation 
(CHIR99021+IWP4) 
associated to mmRNA 
Only Wnt activation 
(CHIR99021) associated to 
mmRNA 
 
Cell seeding
-2 0 1 2 3 5 7 154
hPSC medium WNT ON Basal medium WNT OFF Basal medium
Time line [days]
Pathway modulators
Cell seeding
-2 0 1 2 3 5 7 154
hPSC medium WNT ON Basal medium WNT OFF Basal medium
MESP1,GATA4,NKX2.5,MEF2C,TBX3,TBX5, nGFP
Time line [days]
Pathway modulators
Transcription Factors
mmRNA
Cell seeding
-2 0 1 2 3 5 7 154
hPSC medium WNT ON Basal medium
MESP1,GATA4,NKX2.5,MEF2C,TBX3,TBX5 nGFP
Time line [days]
Pathway modulators
Transcription Factors
mmRNA
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For the delivery of cardiac mmRNAs, 2 commercial transfection kits were used, 
StemMacs™ (Miltenyi) and Stemfect® (Stemgent), as already mentioned in 
Paragraph 4.5. The 6 mmRNAs encoding cardiac TFs were manufactured and 
provided by Miltenyi Biotec (Germany); as indicated by the datasheet, each 
mmRNA was diluted at a final concentration of 100ng/µl in RNAse free water 
(Miltenyi Biotec). When preparing the Cardio mix, the equimolar ratios of MESP1, 
GATA4, NKX2.5, MEF2C, TBX3, TBX5 and nGFP were 1 : 2 : 1,5 : 1,5 : 2 : 1 
respectively. The medium used during the cardiac programming of hPSCs was 
RPMI with (until day 7) and without insulin (until day 15), supplemented with 
B18R 4 hours prior to transfections and added fresh every day throughout the 
experiment. Regarding the experimental procedure, hES Dual reporter line and 
hiPS Clone 7 were expanded in conventional 6-well plates and then seeded in the 
microfluidic platform at a density of 700cells/mm2. Notably, a high seeding 
density was used since the switch from hPSC medium to RPMI and the exposure 
to CHIR99021 (10µM) for 24h can cause cell death and/or detachment, as 
suggested by Lian X. and co-workers in 2012 [63][64]. Preliminary experiments 
were performed associating simultaneously the application of CHIR99021 with the 
transfection regimen; however this approach was withdrawn because determined 
a high mortality of cells. Moreover, since the early cardiac gene MESP1 peaks on 
day 2-3, activating the cascade of the other TFs, the mmRNAs delivery was 
initiated on day 2. To avoid stressful events for the cells, a transfection dose 
ramping of medium for the dilution of the transfection mix was always performed, 
as reported in the Table 4.5: 
Table 4.5: Transfection dose ramping. 
Transfection dose-ramp 
Transfection 
days 
Medium/Cardio Mix [%] 
Day 1 Middle dose (50/50%) 
Day 2 
High dose (25/75%) 
Day 3 
Day 4 
Day 5 
Day 6 Middle dose (50/50%) 
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Cells were transfected for 6 consecutive days for 4 hours, in accord with the 
datasheet, until day 7 of cardiac differentiation. The cardiac differentiation was 
monitored daily and the transfection efficiency was assayed through the 
reporter mmRNA for nGFP. Cells were then maintained in basal medium 
supplemented with insulin and finally, on day 15 they were characterized by 
functional and molecular assays. 
 
 
4.7. Part 1: analysis of the transfection efficiency and CMs 
characterization 
As explained in the previous paragraph, the transfections started on day 2 of 
cardiac differentiation. During the entire experiment, the change of cell 
morphology and the transfection time course  were monitored and recorded 
daily and a summarizing panel is reported in Figure 4.11. 
For the sake of simplicity, since the unique difference between the two 
strategies tested is the presence or absence of Wnt OFF (IWP4), the inscription 
“WNT OFF + “is adopted for the complete Wnt/β-catenin pathway 
perturbation associated to mmRNA transfections whereas “WNT OFF – “ is 
indicated for the only CHIR99021 administration coupled to mmRNAs delivery 
in all the pictures and graphs presented.  
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Figure 4.11: hPSCs programming with mmRNA Cardio mix TFs. The transfection time course was monitored 
through the expression of nGFP mmRNA in cells seeded at a density of 700cells/mm2. A, B and C represent 
the transfection monitoring on day 1, 3 and 6 respectively, comparing the two transfection kits, StemMacs™ 
(SM) and Stemfect® (SF) and the two strategies WNT OFF (+) and WNT ON (-)  coupled to mmRNA 
delivery. 
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The efficiency of transfection was then calculated and the results are 
reported in the graphs of Figure 4.12. 
 
 
 
Figure 4.12: Percentage of transfection efficiency on day 1, 3 and 6 of hES Dual reporter (A) and hiPS Clone 
7 (B) transfected with SM (blue bars) and SF (red bars) and differentiated with the association of WNT OFF 
and WNT ON. (n=3; error bars indicate SEM). 
 
From the pictures of the time lapse in Figure 4.11, it is evident that the nGFP 
signal was more intense when using SM transfection kit. As shown in the 
graphs of Figure 4.12, SF presented a slightly higher efficiency than SM but 
these results indicate that both the transfection kits were suitable for repeated 
mmRNAs delivery in hPSCs showing an increasing in the number of 
transfected cells. Moreover, to verify a possible toxic effect due to transfection 
kit and/or to the transfection itself, a LIVE & DEAD cell viability assay (L&D; 
Invitrogen) was performed after the first transfection. This kit quickly 
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discriminates live from dead cells by simultaneously staining with green-
fluorescent calcein-AM, to indicate intracellular esterase activity, and red-
fluorescent ethidium homodimer-1, to identify loss of plasma membrane; Figure 
4.13 showed the results obtained from both SM and SF. As demonstrated by this 
viability assay, no cell mortality nor toxicity were observed. In fact, only few cells 
were positive to ethidium while the red signals detected were predominantly cell 
debris. 
 
A
 
B 
 
Figure 4.13: A. Representative picture of L&D cell viability assay on hES Dual Reporter and hiPS Clone 7 
after the first transfection, comparing SM and SF transfection kit. Green-fluorescent calcein represents alive 
cells while red-fluorescent ethidium represents dead cells. B. Mortality quantification by count of ethidium 
bromide stained nuclei (n=3; error bars indicate SEM). 
 
During the cardiac differentiation, the temporal expression of MESP1 and 
NKX2.5 in hES Dual Reporter line was monitored and in transfected cells 
Hoechst MergeEthidiumCalcein
StemMacs™
Calcein Ethidium Hoechst Merge
Stemfect®
A
li
v
e
D
e
a
d
N
u
cl
e
i
40%
50%
60%
70%
80%
90%
100%
hES Dual Reporter hiPS Clone 7
V
ia
b
le
 c
e
ll
s 
[%
]
StemMacs™
Stemfect®
Chapter 4 
 
Synthetic mmRNA for programming hPSCs cardiac fate and 
driving CMs maturation on-a-chip 
 
124 
 
MESP1mCherry was detectable on day 2-3 while in non-transfected control cells it 
appeared one day later, on day 3. NKX2.5eGFP signal, as already reported in the 
transfection time course of the panel in Figure 4.11, started on day 5-6 whereas 
in control cells it was observed only on day 8-9, as previously demonstrated in 
Chapter 3. In Figure 4.14 is reported the expression monitoring of the two 
cardiac TFs in control cells and transfected hES Dual Reporter, together with 
the negative control for the GFP signal in hiPS Clone 7 (A-C); the contraction 
detection in hiPS Clone 7 is reported in D.  
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D 
 
Figure 4.14: hES Dual Reporter TFs expression monitoring. A. Exemplificative pictures of MESP1mCherry 
expression recorded on day 3 and NKX2.5eGF (video frame shot) expression on day 8-9 in control (CTRL) non-
transfected cells. B.  MESP1mCherry expression on day 2-3 and NKX2.5eGFP expression (video frame shot) on day 
5-6 in transfected cells (mmRNA). C. Negative control for GFP signal in hiPS Clone 7 to compare the GFP 
signal associated to NKX2.5 expression in the hES Dual Reporter. D. Video frame shots of the central section 
of microfluidic channel of contracting hiPS Clone 7 (control CTRL, and transfected mmRNA); dotted lines 
represent channel edges.  
 
The first contractions started to became evident 3 days earlier in transfected 
cells, approximately on day 8-9 while in non transfected control cells they were 
recorded only on day 10-11, both in hES Dual Reporter and hiPS Clone 7 (Figure 
4.14). These findings indicated a possible role of cardiac mmRNA on protein 
expression. 
CMs obtained from both cell types were characterized for nuclear and 
structural cardiac markers through classical immunofluorescence protocol (the 
panels are reported in Paragraph 4.11.1, Figure 4.25) and were also quantified 
by counting the cTnT+ve cells in every microchannel. Figure 4.15 shows the tile 
scan immunofluorescence staining against cTnT in microfluidic channels while 
the results from the quantification of troponin T positive cells are summarized 
in the graphs of Figure 4.16 with the related tables reporting the percentage of 
CMs obtained from every tested condition. 
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Figure 4.15: Immunofluorescence staining for cTnT (green) in CMs obtained from hES Dual Reporter (upper 
panel) and hiPS Clone 7 (lower panel) differentiated in the microfluidic platform. Nuclei were counterstained 
with Hoechst. The differentiation conditions are reported to the right while to the left are indicated the control 
cells (CTRL) and the transfection kit tested (SM, StemMacs™; SF, Stemfect®). Scale bar=100µm. 
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B   
 
 
Figure 4.16: Percentage of cTnT positive CMs obtained with Wnt/β-catenin pathway modulators and cardiac 
mmRNA delivered with SM (blue bars) and SF (red bars) compared with control CMs obtained with Wnt 
modulators alone (black bars); n=3; error bars indicate SEM. 
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From immunofluorescence panels of Figure 4.15, it is evident that, in some 
cases, both in transfected as well in non-transfected control cells there is a gradient-
like distribution of CMs within the channels, especially concentrated close to 
channel outlet; this was probably due to medium flow, nutrients and reagents 
concentration at this level, stagnant in medium reservoirs with subsequent 
incomplete medium refresh. In the following experiments, this issue was solved 
by leaving the medium reservoirs empty after every medium replacement.  
Furthermore, the cTnT quantification revealed that cardiac mmRNAs coupled 
to Wnt perturbation (WNT OFF with mmRNAs) lead approximately to the same 
CMs yield of control non-transfected cells whereas in cells transfected with 
mmRNAs coupled to the only CHIR99021 administration (WNT ON with 
mmRNAs), the cTnT+ve cells were significantly lower. These findings indicate that 
cardiac mmRNAs alone, cannot replace Wnt modulators in terms of CMs yield but 
the major goal of this work is to drive cardiac differentiation of hPSCs toward cell 
maturation. In the Part 2, described in the following Paragraph, a new approach is 
proposed with a further optimization of the transfection with a more precise 
adjustment on TFs delivery.  Moreover, thanks to the more intense nGFP signal 
observed when transfecting cells with SM, this transfection kit was adopted for the 
following experiments. 
 
 
4.8. Part 2: optimization of cardiac TFs delivery to best mimic 
cardiac development in vitro 
From the preliminary data obtained in Part 1, the transfection was further 
optimized and, taking into account the temporal developmental expression of TFs 
from studies on cardiogenesis in vitro (see Figure 4.5, relying on cardiac TFs waves 
of expression), a new approach was designed and the set-up is illustrated in Figure 
4.17 (A-D).  
The complete Wnt/β-catenin perturbation (WNT OFF) and the only CHIR99021 
administration (WNT ON) were maintained but the transfection regimen was 
divided in two stages: the first one was defined the “early stage”in which only 
MESP1 and GATA4 were administered for the first 3 days; during the second “late 
stage”, for the last 3 days of transfection, all the other cardiac TFs were added with 
the exception of MESP1 because its expression window lasts only 2-3 days. Also in 
this case, the transfection dose ramp of medium dilution for the Cardio mix was 
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performed, with the same scheme adopted for the experiments of Part 1: a 
middle dose was used on day 1 and 6 of transfection while, from day 2 to day 5 
a high dose of cardiac TFs was employed to strongly force endogenous protein 
expression. Two controls were used to compare the effects of mmRNA delivery: 
the first control was represented by CMs differentiated with the complete 
Wnt/β-catenin pathway perturbation (WNT OFF) and the second control relied 
on the only CHIR99021 application (WNT ON). Cells were always seeded at a 
density of 700cells/mm2 and the experimental procedure was the same as Part 
1. 
A  
 
B 
 
C  
 
D 
 
Figure 4.17: Schematic representation of the optimized delivery of cardiac TFs. A and B: Control platforms in 
which cells were differentiated with the gold standard protocol relying on the complete Wnt perturbation (A) 
or only CHIR99021 administration (B). C and D. The two strategies tested in parallel in which early stage 
(MESP1 and GATA4 for the first 3 days) and late stage (GATA4, NKX2.5, MEF2C, TBX3 and 5 for the last 
3 days) were associated to complete Wnt perturbation (C) or to CHIR99021 administration (D). 
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The details of each condition tested with the related acronyms are indicated in 
the Table 4.6. 
Table 4.6: Part 2 experimental conditions. 
CTRL WNT OFF CTRL WNT ON 
WNT OFF 
mmRNA 
WNT ON 
mmRNA 
Complete Wnt 
pathway 
perturbation 
(CHIR99021+IWP4) 
Only Wnt 
activation 
(CHIR99021) 
Complete Wnt 
pathway 
perturbation 
(CHIR99021+IWP4) 
associated to 
mmRNA 
Only Wnt 
activation 
(CHIR99021) 
associated to 
mmRNA 
 
As already mentioned, for the delivery of cardiac mmRNAs, only StemMacs™ 
transfection kit was used. At the end of the transfections, cells were maintained in 
basal medium until day 15 and then, CMs were characterized by functional and 
molecular assays.  
4.9. Part 2: analysis of the transfection efficiency   
Since the high transfection efficiency reached with SM transfection kit was 
already demonstrated in Paragraph 4.7, for convenience, only the pictures of 
transfection day 6 were reported in Figure 4.18, showing an homogeneous 
transfection with intense nGFP signal in both hPSCs; in addition, NKX2.5 signal 
associated to eGFP expression in hES Dual Reporter line was detectable between 
day 5 and 6, 2-3 day earlier than control cells (Figure 4.20).  
 
Figure 4.18: hPSCs programming with early and late stage of cardiac mmRNA delivery using SM transfection 
kit. Panel of transfection day 6 comparing the two strategies in parallel, WNT OFF (+) and WNT ON (-) 
coupled to mmRNA transfections. 
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Notably, from this panel, also hES Dual Reporter, differentiated with 
CHIR99021 associated to mmRNA delivery (WNT ON) showed a wide 
NKX2.5eGFP signal, compared with the panels of Part 1. The percentage of 
transfection efficiency was reported in the graphs of Figure 4.19. 
 
A 
 
B
 
Figure 4.19: Percentage of transfection efficiency on day 1, 3 and 6 of hES Dual Reporter line (A) and hiPS 
Clone 7 (B) transfected with SM. Light blue bars indicate  WNT OFF (+) coupled to mmRNA delivery  while 
dark blue bars indicate WNT ON (-) with mmRNAs; n=3; error bars indicate SEM. 
 
From these graphs, a high transfection efficiency was reached, increasing 
day by day, in both hES Dual Reporter and hiPS Clone 7. Also in this case the 
mCherry signal associated to MESP1 expression in hES Dual Reporter line was 
monitored and a peak of expression was detected on day 2-3 in transfected cells 
whereas in control cells it appeared slightly later, on day 3. Representative 
pictures of MESP1 and NKX2.5 expressing cells together with the negative 
control for the GFP signal are reported in Figure 4.20 (A-C), with video frame 
shots of contraction detection in hiPS Clone 7 (D). 
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C 
 
 
D 
 
Figure 4.20: Cardiac differentiation monitoring through the recording of MESP1mCherry and NKX2.5eGFP in 
control (CTRL) and transfected (mmRNA) hES Dual Reporter-CMs with the negative control for GFP signal 
in hiPS Clone 7 (A-C) and contraction detection in control and transfected hiPS Clone 7 (D). hES Dual 
Reporter NKX2.5 and hiPS Clone 7  pictures are a video frame shots of a central section of microchannel with 
beating CMs. Dotted lines represent channel edges. 
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In Figure 4.21 is reported the tile scan immunofluorescence staining against 
cTnT performed in the microchannels.  
 
 
Figure 4.21: Immunofluorescence staining for cTnT (green) in CMs obtained from hES Dual Reporter (upper 
panel) and hiPS Clone 7 (lower panel) differentiated in the microfluidic platform. Nuclei were counterstained 
with Hoechst. The differentiation conditions are reported to the right while to the left are indicated the control 
cells (CTRL) and the transfection kit tested (StemMacs™). Scale bar=100µm. 
 
The quantification of cTnT positive cells was reported in Figure 4.22 with the 
related table summarizing each percentage obtained from every condition tested. 
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A 
 
B 
 
 
C 
 
Figure 4.22: Percentage of cTnT+ve  cells obtained combining Wnt pathway modulators with early and late 
cardiac mmRNA delivery (A. hES Dual Reporter-CMs: light blue bars for WNT OFF mmRNA, dark blue bars 
for WNT ON mmRNA; B. hiPS Clone 7-CMs: light green bars for WNT OFF mmRNA, dark green bars for 
WNT ON mmRNA) with StemMacs (SM) compared with control CMs obtained with the only WNT OFF 
(black bars) or WNT ON (grey bars). In C is reported a summarizing table of cTnT percentages; n=3; error 
bars indicate SEM. 
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experiment gave a high yield of CMs in cells transfected with the optimized 
delivery of mmRNA with early and late cardiac TFs, both in presence or absence 
of Wnt inhibitor (WNT OFF and WNT ON) while, in control cells, the cTnT+ve 
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obtained in Part 1 are encouraging because with this TFs modulation it was 
possible to increase the number of CMs obtained by a partial modulation of Wnt 
pathway, indicating a clear effect of mmRNAs on protein expression. These 
findings give hope for further optimization of cardiac TFs delivery for 
cardiomyocytes generation from hPSCs without small molecules. 
 
 
4.10. Calcium handling regulation in hPSC-derived CMs 
4.10.1. Functional characterization of calcium handling in mmRNA-
derived CMs 
Although the discovery of hiPS derivation technology pioneered by Takahashi 
and Yamanaka in 2006 and 2007[43][44] lead to the development of a wide variety 
of cardiac differentiation procedures (as described in Chapter1 and 2), few works 
reported the description of the functional hPSC-CMs properties with information 
about their excitation-contraction (E-C) coupling and Ca2+ handling properties 
[182][183]. For this reason, a characterization of the functional nature of CMs 
obtained from both hES and hiPS is necessary to understand the degree of 
maturity, before the employment of hPSC-CMs in the emerging field of 
regenerative medicine. This depends in part on the status of the CMs contractile 
features and their Ca2+ handling dynamics. As already explained in Paragraph 1.1 
of Chapter 1, intracellular calcium transients, the cyclic variations in the 
concentration of cytosolic Ca2+, play a crucial role in the Excitation-Contrction (E-
C) coupling, as a result of a spatio-temporal balance between cytosolic Ca2+ 
increase and Ca2+ re-uptake by the sarcoplasmic reticulum (SR). In adult CMs, the 
Ca2+-induced Ca2+release (CICR), starts with a relative small Ca2+ influx through 
the sarcolemmal L-type Ca2+ channels that triggers a higer Ca2+  release from SR via 
type-2 ryanodine receptor (RyR2). Once recycling the majority of cytosolic Ca2+ 
back to the SR by the SR Ca2+-pump ATPase (SERCA2a) and a small portion of 
cytosolic Ca2+ extruded from the sarcolemma by Na2+- Ca2+ exchabger (NCX), a 
decrease of intracellular [Ca2+] occurs, determining the subsequent myocardial 
relaxation [183]. However, in literature it has been reported that both hES and 
hiPS-derived CMs exhibit a fetal and immature calcium dynamics due the 
underdeveloped SR and the immature expression profiles of proteins involved in 
calcium handling machinery. Such immature status represents the major concern 
for the clinical application of these CMs and can leads not only in poor host-graft 
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electromechanical integration when transplanted, but also leads to lethal 
arrhythmias [184]. 
In light of these considerations, at Venetian Institute of Molecular Medicine 
(VIMM) of Padova, the intracellular calcium pattern dynamics were 
investigated and recorded under confocal microscope, using a specific Ca2+ 
probe, to investigate an improvement in organization of cardiac structural, 
functional and maturation features in 15 days mmRNA-derived CMs from hES 
Dual Reporter line, obtained with the optimized delivery of cardiac TFs 
described in Part 2. This experiment was performed in collaboration and 
according with the protocol described by our colleague of BioERA laboratory, 
Martewics S. who published a work in 2012 regarding the study of CMs calcium 
dynamics [185]. 
Briefly, confocal calcium measurements were performed by loading CMs in 
serum-free 25mM HEPES D-MEM (Life Technologies), supplemented with 
2,5µM fluorescent calcium binding dye Fluo-4 AM (Life Technologies). To 
increase its liposolubility and facilitate the crossing of cell membrane, Fluo-4 
was loaded as an acetyl-methyl ester, in presence of 2µM Pluronic F-127 
(Invitrogen) as a mild detergent, for 20 minutes at 37°C. Cells were then 
incubated for additional 10 minutes at 37°C without Fluo-4 for a complete de-
esterification of the dye. 20 µM of the anionic transporter inhibitor 
sulphinpyrazone (Sigma Aldrich) was added in all the media used to limit the 
dye active extrusion from the cells. As red cell membrane counterstain, 0,2 µM 
di-8-ANEPPS (Invitrogen) was used in order to distinguish separate cells. 
Calcium dynamics were acquired in recording solution containing: NaCl 
125mM; KCl 5mM; Na3PO4 1mM; MgSO4 1mM; HEPES 20mM; CaCl2 2mM; 
glucose 5,5mM, adjusted to pH 7,4 with NaOH (all from Sigma Aldrich). Line 
scans were acquired with a Leica TCS SP5 confocal microscope equipped with 
a 63X, 1,4 NA oil immersion objective, with 488nm Ar laser line as an excitation 
source, 400Hz frequency. To avoid or reduce dye photo-bleaching and 
phototoxic effects on CMs, the laser power was set at minimum possible. All 
the experiments were conducted at room temperature within 20-30 minutes 
from the end of the loading procedures described previously. With this 
configuration, when Ca2+ concentration increases inside the cell, Fluo-4 
molecules bind to the ion and emit a fluorescent signal. The increasing (calcium 
release phase) and decreasing (calcium re-uptake phase) fluorescent signal 
emitted by the analyzed CMs was recorded for few seconds. Figure 4.23, shows 
a representative plot of the variation of the intensity signal along time, 
Chapter 4 
 
Synthetic mmRNA for programming hPSCs cardiac fate and 
driving CMs maturation on-a-chip 
 
139 
 
providing the shape of the calcium transient from which it is possible to determine 
these parameters: for the calcium release phase, the time to peak (TTP) value was 
calculated considering the time that the transient takes to go from the baseline 
value to the peak of fluorescence intensity; for the evaluation of the calcium re-
uptake rate, the half-life of calcium decay rate was used indicating the time that 
the descending part of the transient takes to go from the peak of fluorescence to a 
value of 50% of the peak. In the same figure are reported the data acquired from 
CMs obtained from the hES Dual Reporter line displaying cardiac-like calcium 
transient. To perform such analysis, cells were differentiated in a microfluidic 
device containing only 3 or 4 channels in a glass slide of 0,1mm thickness, 
compatible with confocal microscope equipment. All data handling and 
computation was performed with Origin 8.1 software. 
Intriguingly, as shown in the graphs of Figure 4.23 C, calcium transients 
significantly shortened (P<0,001 and P<0,01) in cells differentiated with Wnt 
modulators (WNT OFF) associated with the optimized delivery of cardiac 
mmRNA using StemMacs™ transfection kit compared with control cells 
differentiated with the only application of Wnt modulators. Also in CMs obtained 
with the WNT ON approach and transfected with cardiac mmRNA the transient 
is shorter but no significant difference was observed, compared with control cells. 
These findings clearly demonstrate that the combination of Wnt modulators with 
the optimized delivery of cardiac mmRNA, that more closely recapitulate the 
temporal TFs expression observed during cardiac development, can influence 
CMs intracellular calcium patterns, indicating an improvement in cardiac 
functional and maturation features. 
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Figure 4.23: Calcium handling in hES Dual Reporter. A. Representative Ca2+ transient profile reporting the 
fluorescence ratio (F/F0) versus time (s) with the line scan acquisition of the variation of Fluo-4 intentsity due 
to cell contraction and relaxation along time (left panel with the plot at the bottom). Representative picture of 
CMs loaded with Ca2+ Fluo-4 (green) allowing the detection of intracellular calcium and cell membranes 
counterstain with di-8-ANEPPS (red) to distinguish, in this case (dotted lines), 5 separate cells. B. From such 
curves it is possible to evaluate the time to peak (TTP) and half-life of calcium decay. C. Time to peak (TTP) 
estimates (left graph) and evaluation of the calcium re-uptake by the half-life of Ca2+ decay (right graph) in hES 
Dual Reporter-CMs differentiated with the association of complete (WNT OFF) or partial (WNT ON) Wnt 
perturbation with the optimized delivery of cardiac mmRNAs with StemMacs™ (SM, blue bars) compared to 
control CMs obtained only with the complete Wnt perturbation (black bars).  Abbreviations: F/F0 fluorescence 
(F) normalized to baseline fluorescence (F0). Data are presented as mean and error bars represent SEM. Data 
pairs were compared by Student’s t-test. Student’s t-test p-values: P<0,001 (***) and P<0,01 (**). 
 
This increased calcium handling ability, with calcium transient lasting less 
than 1 second, typical of calcium cycling during contraction, is consistent with 
maturing CMs features. Moreover, as reported in literature [185][186], the Ca2+ 
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cycling is orchestrated by several molecular components that cooperate for the 
generation of the Ca2+ transient profile. A key element of calcium handling 
machinery, responsible of the Ca2+ re-uptake phase is the cardiac-specific 
sarcoendoplasmic reticulum calcium ATPase SERCA2. Starting from these 
observations, CMs obtained by combining Wnt modulators with the optimized 
delivery of cardiac mmRNA were characterized by immunofluorescence staining 
to investigate the expression of SERCA2 and a representative picture is reported 
in Figure 4.24, in association with a co-staining against cTnT showing the 
sarcomeric organization in the contractile apparatus.  
 
 
Figure 4.24: hES Dual Reorter-CMs on day 15. Immunofluorescence staining for Ca2+ pump SERCA2a 
responsible for Ca2+ re-uptake showing a spreading localization in the whole cell volume in association with 
immunofluorescence staining against cTnT demonstrating  sarcomeric organization. In the lower panel is 
reported a magnification of the area selected with dotted line. Upper panel scale bar: 25µm; magnification scale 
bar: 15µm. 
 
As observed, the calcium transient shortening in CMs-mmRNA derived is 
accompanied by the expression of SERCA2a spread in the cytosol indicating an 
improvement in maturation features of the cells. 
 
  
SERCA2a cTnT Hoechst Merge
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4.11. Qualitative and quantitative characterization of Part 1 
and Part 2 mmRNA-derived CMs 
4.11.1. Qualitative characterization: immunofluorescence staining for 
cardiac markers 
The expression of typical cardiac markers was routinely assessed by 
immunofluorescence staining in 15 days CMs obtained from both hES Dual 
Reporter and hiPS Clone 7 from experiments presented in Part 1 and Part 2, as 
shown in the panel of Figure 4.25, in which nuclear markers GATA4 and 
NKX2.5 and structural markers cTnT, α-Actinin and MYH7 (Myosin Heavy 
Chain or BA-D5, kindly given by Professor Schiaffino S., University of Padova) 
were analyzed. Cells from both Part1 and Part2 exhibited a remarkable 
expression of typical cardiac markers.  
 
 
Figure 4.25: Representative immunofluorescence pictures of 15 days CMs mmRNA-derived expressing 
nuclear and structural cardiac-specific proteins. Note the sarcomeric organization of the contractile proteins in 
the related magnification. Dotted lines represent channel edge. 
 
HoechstcTnTGATA4
Hoechstα-Actinin HoechstMyosinHeavyChain
HoechstcTnTNKX2.5
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4.11.2. Quantitative characterization: gene expression pattern analysis 
For gene expression analysis, total RNA from 15 days cells in the microfluidic 
platform was extracted using iScript (BioRAD), a sample preparation buffer 
designed to efficiently degrade the cytoplasmic membrane while leaving intact the 
nuclear membrane; thus only the cytoplasmic RNA was extracted, whereas the 
genomic DNA remains confined within the nuclei, allowing a sensitive 
quantitative gene expression analysis. This novel reagent accelerates and 
streamlines quantitative real-time PCR (qRT-PCR) by eliminating the need for 
lengthy RNA purification. Briefly, microfluidic channels were perfused with D-
PBS prior to 10µl of iScript injection and solution was then collected after 1 minute 
of incubation at room temperature. RNA (0,1µg) was reverse transcribed into 
cDNA by Reverse Transcription (RT, Life Technologies), according to 
manufacturer’s instructions. 
To conclude the characterization of CMs mmRNA-derived, the expression of 
cardiac TFs involved in cardiogenesis was assessed with quantitative real-time 
PCR (qRT-PCR) analysis using TaqMan® gene expression assay probes 
(Invitrogen), accordingly to manufacturer’s instructions. The expression of these 
genes was investigated: the early cardiac markers GATA4 and NKX2.5 and late 
structural, functional and maturation markers cTnT, MYH7 and SERCA2a, all 
labeled with FAM™ dye on the 5’ end, designed and provided by BioERA lab in 
Shanghai, ShanghaiTech University. The expression levels of each gene analyzed 
were normalized to GAPDH, an housekeeping glycolytic enzyme (glyceraldehyde 
3-phosphate dehydrogenase), which primer is conjugated with a VIC™ dye on the 
5’ end, whereas the results were normalized comparing the transcripts with 
control CMs differentiated with the only WNT OFF and WNT ON approaches. 
Reaction was done on ABI Prism 7000 SDS, Sequence-Detection-System (Applied 
Biosystems) machine and results were analyzed with ABI Prism 7000 SDS 
Software. Data obtained are shown as relative expression fold change of mmRNA-
derived CMs compared with control CMs (WNT OFF or WNT ON) and are 
reported in Figure 4.26 (A-D). 
As reported in the graphs, with TaqMan® gene expression assay it was possible 
to perform an accurate quantitative analysis of multiple early and late cardiac 
genes at the same time, giving a complete portrait of the CMs-mmRNA derived. 
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Figure 4.26: The qRT-PCR analysis (gene expression normalized to GAPDH) of GATA4, NKX2.5, cTnT, 
MYH7 and SERCA2a in CMs-mmRNA derived obtained from hES Dual Reporter line and hiPS Clone 7 from  
Part 1 experiments (panels A and C) in which the TFs were delivered all together in the Cardio mix and the 
control was represented only by the WNT OFF approach, and  Part 2 (panels B and D) in which the transfection 
was divided into early and late stage of TFs delivery and the further control of WNT ON was added. Every 
transcript was compared with control cells (black bars) differentiated with WNT OFF and WNT ON approach. 
Histograms are based on 3 replicates in the same condition. Data are shown as mean, error bars indicate SEM. 
Stundent’s t-test p-values P<0,05 (*); P<0,01 (**); n.s, non significant. 
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This gene expression pattern analysis confirmed that the CMs-mmRNA 
derived from both Part 1 and Part 2 experiments, expressed significantly higher 
amounts of cardiac TFs compared with the controls, especially those involved 
in structure, functionality and maturation and especially when CMs were 
derived with the mmRNA transfection divided into early and late stages (Part 
2 experiments) and associated with the complete Wnt perturbation (WNT OFF). 
Intriguingly, significantly higher amounts of transcripts were observed also in 
the majority of CMs differentiated with the partial Wnt perturbation (WNT ON) 
and mmRNAs, compared with both control cells (WNT OFF and WNT ON), 
indicating the effect of mmRNA on protein expression. 
 
4.12. Conclusions 
In this Chapter was reported, for the first time, the cardiac programming of 
hPSCs fate with the novel mmRNA technology in microfluidics to generate 
clinically relevant CMs.  
Six cardiac TFs were selected, taking into account their networking 
cooperation coming from developmental studies on cardiogenesis in vivo. The 
association of this novel strategy with our microfluidic platform, allowed a 
precise and tiny control and manipulation of mmRNAs and reagents in both 
space and time. 
Before starting the hPSC programming with the mmRNA “Cardio mix”, the 
mmRNA transfection protocol was deeply studied and optimized using only a 
GFP-encoding mmRNA. It was demonstrated that the integration of the 
experiments into the microfluidic device, thanks to its high surface/volume 
ratio, determined an increase in the transfection efficiency using 10-fold lower 
amounts of mmRNA and reagents compared with standard 24-well plates. 
Cells were efficiently transfected using two commercial transfection kits based 
on lipid vehicles and StemMacs™ was identified as the optimal for TFs 
delivery. 
The experimental set-up was developed in 2 parts in which ad hoc strategies 
for the mmRNA Cardio mix delivery were designed and optimized, aiming at 
recapitulating more closely the cardiac developmental stages observed in the 
embryo, reflecting the temporal expression windows of each TFs. In particular, 
by dividing the transfection regimen into an early and a late stage, it was 
possible to obtain CMs-mmRNA derived with efficiencies that surpass those 
obtained in control cells differentiated with the only application of small 
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molecules. CMs-mmRNA derived expressed typical cardiac markers and, 
importantly, they showed significantly shorter calcium transients, indicating an 
improvement in cell organization, structure and function toward cell maturation. 
These results were also confirmed by the analysis of gene expression pattern with 
qRT-PCR, which showed significantly higher amounts of transcripts than cells 
differentiated with only Wnt modulators. 
Taken together, these experiments provide proof-of-principle that it is possible 
to program hPSCs fate toward cardiac lineage by combining the novel technology 
of synthetic mmRNA with microfluidics for precise delivery of specific TFs to 
obtain clinical-grade cells in a cost-effective manner.  
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Chapter 5. Conclusions and 
Future Perspectives
5.1. Conclusions 
Cardiovascular disease (CVD) is still one of the main causes of death worldwide 
and the high burden of the disease, associated with the high costs for the healthcare 
systems, claim for the development of novel therapeutic strategies [16]. The main 
issue of current pharmacological or interventional therapies is their inability to 
compensate the irreversible loss of functional CMs [187]. Because of the limited 
regenerative capacity of post-natal CMs, and the difficulties to isolate cardiac 
bioptic tissue and maintain human adult CMs, very limited supplies of these cells 
are available at present. Furthermore, animal models are surely one of the best tool 
for in vivo heart study of physiology and pathophysiology in the context of a whole 
complex organism, but they are not fully representative of the human counterpart 
[41]; from an economic point of view, animals maintenance and experimentations 
required elevated costs [40]. 
In this scenario, hPSCs, including hESCs and hiPSCs possess a high potential 
for cardiovascular research. Thanks to the possibility to be expanded in culture 
indefinitely while still maintaining their stemness and potency properties, they 
represent a virtually inexhaustible source of cell from the three germ layers, such 
as CMs [42]. Moreover, the discovery of hiPSCs first in mouse [43] and then in 
human [44] by 2012 Nobel Prize Shinya Yamanaka, represents an important 
breakthrough in science thanks to the fact that these cells can be derived by the 
reprogramming of adult somatic cell types, bypassing much of the ethical and 
political debate surrounding hESCs derivation [83]. One exciting advance is the 
ability to generate patient-specific hiPSCs as an unprecedented opportunity to 
study disease-specific differences between patients and evaluate novel therapeutic 
routes. 
Substantial efforts has been made by the investigators to develop strategies that 
efficiently direct the cardiac differentiation of hPSCs, finally aiming at producing 
clinically relevant cell source [21]. 
Existing methods for deriving CMs from hPSCs involve stage-specific 
perturbation of different signaling pathways recapitulating key steps in cardiac 
development. However, these techniques present the following limitations: high 
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intra- and inter-experimental variability, low efficiencies, presence of xeno-
contaminants, undefined medium components and differences in the 
expression levels of cytokines of endogenous signalling pathways [63]. 
Furthermore, new studies have been published, based on the direct lineage 
conversion of somatic cells through the overexpression of specific cardiac TFs, 
delivered with integrating and non-integrating vectors, but also these 
approaches suffered low efficiencies, risk of genomic integration and 
insertional mutagenesis (integrating vectors) and require stringent steps of 
purification (non-integrating vectors) [48][51]. In general, the major critical 
point of CMs produced to date with these protocols, is their early and immature 
phenotype, most analogous to fetal developing cardiac cells, thus representing 
an obstacle for future clinical applications [69]. 
In 2010, Warren L. pioneered a novel, non-integrating strategy based on 
repeated transfections with cationic vehicles of synthetically modified mRNA 
(mmRNA), specifically designed to avoid cell innate immune response. He 
demonstrated the possibility to both reprogram somatic cells to pluripotency 
with efficiencies significantly higher than established protocols, and to program 
hiPS differentiation by using a MYO-D encoding mmRNA to derive terminally 
differentiated myogenic cells [49][50]. 
In light of these considerations, this PhD thesis focused on the development 
of an efficient and robust method for cardiac differentiation of hPSCs in 
microfluidics through the overexpression of a defined set of cardiomyogenic 
TFs. To this end, the endogenous protein expression was forced by repeated 
mmRNA transfections to finely drive cardiac differentiation toward cell 
maturation. In order to improve the delivery of mmRNAs, the microfluidic 
technology was exploited to perform an efficient hPSCs cardiac differentiation 
in a high controllable microenvironment that allowed combinatorial, 
parallelized, multi-parametric analysis at one time in a cost-effective manner.  
The work started with the culture, maintenance and expansion of different 
hESC lines and hiPSC clones that were successfully characterized, 
demonstrating that all the cells employed were bona fide plutipotent stem cells. 
Among the current strategies available, the differentiation of both hESCs and 
hiPSCs was achieved firstly by the application, in standard culture systems, of 
the protocol that to date it is considered the gold standard for simple and fast 
(  ̴ 15 days) hPSCs differentiation into CMs with variability lower than that 
observed with the other approaches described (Chapter 1 and 2). This 
monolayer-based method relies on the administration of small molecules, 
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CHIR99021 and IWP4 that, in turn, activate and inhibit the canonical Wnt/β-
catenin pathway [63][64]. To precisely monitor the progression of cardiac 
differentiation, a hESC line, Dual Reporter for this two cardiac TFs, MESP1 and 
NKX2.5 was always used in parallel with hiPS clones. The experimental conditions 
were optimized, adjusting CHIR99021 concentrations, to perform an optimal Wnt 
modulation and two hPSCs emerged for their cardiogeneic ability to give the 
highest yield of CMs. A deep characterization of CMs was performed, from 
immunofluorescence staining and flow cytometry to double-whole cell-voltage 
patch clamp; cells showed a remarkable organization of the sarcomeric contractile 
apparatus, with self contraction capacity and ability to correctly respond to 
functional test demonstrated by the presence of junctional current, sensitive to 
external stimuli. However, a first attempt to investigate the degree of maturity of 
CMs derived with this strategy was performed with an immunofluorescence 
staining against an embryo/fetal isoform and an adult isoform of cTnT and cTnI 
respectively, which revealed that a great portion of cardiac cells expressed the 
embryo/fetal troponin T, indicating their early and immature phenotype. These 
findings proved also the heterogeneity of CMs obtained, with differentiation 
toward random subpopulations, leaving room for improvement regarding the 
ability to homogeneously differentiate and mature cells to obtain completely 
functional CMs. 
As described in Chapter 3, this problem is enhanced in standard culture systems 
because of the impossibility to precisely monitor and properly mimic cell 
microenvironment. Microfluidics, with its ability to managed small amounts of 
fluids in microchannels [3], can help overcome this issue. For this reason, hPSCs 
culture and expansion and the gold standard protocol for cardiac differentiation 
were successfully integrated into a microfluidic device fabricated in our BioERA 
laboratory that allowed parallelized experiments at one time with a precise control 
of the differentiation process. When translating the gold standard cardiac 
differentiation protocol from the macro-scale of conventional multiwells to the 
microscale of the microfluidic platform, a step by step optimization was done, 
demonstrating how the identification of the correct medium refresh frequency and 
the optimal MRF concentration for channel coating are essential in directing hPSCs 
CMs generation. 
These achievements represented the basis for the following step of this PhD 
work, presented in Chapter 4, and describing the association of the delivery of 
mmRNA encoding 6 cardiac TFs with Wnt modulators in microfluidics. Thanks to 
the properties of the microfluidic chip, coupled with the transient nature of 
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mmRNA, with the possibility to modulate cellular expression by daily 
adjustment of the payload of TFs transfected, a precise spatiotemporal control 
of the experimental conditions was possible. Also in this case, a first 
optimization of the transfection process was necessary to study the possibility 
to integrate mmRNA in microfluidics and was carried out with the initial 
delivery of a single mmRNA encoding for nGFP. The results obtained 
demonstrated that the integration of mmRNA technology into microfluidics, 
thanks to the high surface/voulme ratio, determined an increase in the 
transfection efficiency compared with standard multiwells, using significantly 
lower amounts of mmRNA and reagents.  
Then, ad hoc strategies of mmRNA delivery associated with the complete or 
partial Wnt perturbation with small molecules, were developed, in order to 
recapitulate more closely the cardiac developmental stages observed in the 
embyo, reflecting the temporal expression window of each cardiac TFs. The use 
of mmRNA to drive the cardiac differentiation of hPSCs allowed the generation 
of CMs that contract 2-3 days earlier than control cells differentiated with the 
only application of small molecules. Moreover, with the final approach 
adopted, based on the division of the transfection regimen into an early and a 
late stage that better recapitulates TFs expression studied in vivo, CMs-mmRNA 
derived responded to functional test, showing proper calcium dynamics with 
significantly shorter calcium transients than control cells. These data were also 
confirmed by the gene expression pattern analysis revealing a significantly 
higher amount of cardiac transcripts, especially those related to late, structural, 
functional and maturation genes, indicating a clear effect of mmRNA on cell 
transcriptome.  
In conclusion, the research conducted in this PhD, provide proof-of-principle 
that it is possible to program hPSCs fate toward cardiac lineage and CMs 
maturation by combining the emerging mmRNA technology with 
microfluidics; furthermore the strategies developed allowed the generation of 
clinical-grade CMs holding great promise for regenerative medicine research 
and disease modelling.  
The results obtained are encouraging compared to the few data available in 
literature regarding the use of mmRNA. In fact there are only 2 works reporting 
the generation, in conventional culture systems, of myoblast-like cells, not CMs. 
The first, published by Warren L. in 2010 demonstrated the ability to direct 
hPSCs fate to myogenic cells [49][50] while the second one, published by 
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Preskey D. in 2015 reported the transdifferentiation of fibroblasts to myoblast 
[163].  
In this PhD thesis, having associated the mmRNA with microfluidics allowed a 
precise and high efficient generation of functional CMs. Moreover, the 
microfluidic device, fabricated in our laboratory, allowed reproducibility of the 
experiments, is completely customizable, cost-effective and versatile for a wide 
range of tests. In fact, the miniaturization can attract the pharmaceutical industry 
as a tool for the discovery and development of new drugs with more economic 
procedures, avoiding the non fully predictive animal tests before clinical trials.  
 
 
5.2. Future Perspectives 
Further investigations  have still to be done in order to obtain clinically relevant 
CMs, starting from the optimization of the culture conditions. In all the 
experiments described in this thesis and, in general in the majority of published 
works, feeder-free cultures are employed, with cells maintained on Matrigel 
Reduced growth Factors (MRF) that is an extracellular matrix (ECM) preparation 
isolated from mouse sarcoma. However, this undefined ECM preparation, based 
on animal glycoproteins and Growth Factors (GFs) is not ideal for hPSCs culture 
and subsequent differentiation because of its lot-to-lot variability and the possible 
introduction of unwanted xenogenic contaminants; these issues are not indicated, 
especially when the primary objective is to culture these cells for eventual human 
clinical applications. 
A specialized ECM structure, basement membrane, consists of indispensable 
protein and carbohydrate macromolecules secreted by cells, for mechanical 
support as well as tissue homeostasis maintenance [188]. Among these biologically 
active proteins, liminins (lm) play the major role. To this end, for future 
experiments, feeder-free and xeno-free culture matrices can be adopted, such as 
those based on recombinant human ECM preparations composed of collagen, 
fibronectin, laminin or vitronectin, or synthetic commercial reconstituted ECM. 
Furthermore, the association of a complete chemically defined medium, in which 
all the constituents are well known, free of animal products (e.g. bovine serum 
albumin, BSA, MRF or B27 supplement), becomes necessary. 
As described in Chapter 2, the gold standard protocol relies on the basal 
medium RPMI 1640 (which is chemically defined), supplemented with B27, that is 
a complex mixture of 21 components (many of animal origin) and remains still 
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unknown the influence exerted by these compounds on hPSCs differentiation. 
A valuable alternative to circumvent the issue of xeno-contaminants is 
described by Burridge P.W. in 2014. Burridge’s research group developed a 
cardiac differentiation strategy of hPSCs employing a chemically defined 
medium ,named “CDM3”, prepared with 3 components: the basal medium 
RPMI 1640, L-ascorbic acid 2-phosphate as an antioxidant, and rice-derived 
recombinant human albumin as a detoxifier, buffer and ROX binding protein, 
with cells seeded on a matrix composed of synthesized vitronectin peptide 
substrate [66].  
With these culture conditions, it will be possible to test and compare the 
ability of cardiac mmRNA to program hPSCs fate toward cardiac lineage alone, 
without the association of the small molecules CHIR99021 and IWP4, employed 
up to now. 
In addition, current differentiation protocols generated a variable mixture of 
atrial and ventricular CMs, with small percentages of nodal and conduction 
system cells [189]. As demonstrated in this PhD work, the forced 
overexpression of specific cardiac TFs via mmRNA delivery can efficiently 
direct hPSCs fate to beating CMs, which showed an improvement in cell 
organization, function, structure, and maturation features. Having this in mind 
and taking into account the possibility to deliver simultaneously several 
combinations of cardiac TFs-mmRNA, future experiments will address the 
subtype specification toward different CMs phenotypes such as atrial and 
ventricular CMs, conduction and endocardial cells, as illustrated in  Figure 5.1.  
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Figure 5.1: Cardiac cell types derived from multipotent progenitors with the related TFs. Differentiated cardiac 
cell types are characterized by the expression of specific genes (green). Recently, several works published in 
literature have identified and studied the delivery of TFs combinations for cardiac transdifferentiation of 
fibroblasts (red) (adapted from [190]). 
 
The possibility to modulate hPSCs programming via specific mmRNA 
administration can provide a more homogeneous population of clinical-grade 
CMs subtypes suitable for future clinical applications and disease modeling with 
the appropriate cardiac phenotype generated from patient hiPSCs, allowing a 
more accurate therapy assessment and therapeutic drug discovery.  
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